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Metabolism  is  the  set  of  chemical  reactions  that  allow  an  organism  to maintain  its  functions, whereas 
metabolites are its intermediates and products. The complete set of small molecule metabolites is referred 




the  so‐called endocrine disrupters which mimic natural endogenous hormones  and  are  suspected  to be 





technique  suited  to handle a wide  range of metabolites  in  the plasma metabolome was developed. The 
technique  included  sub‐fractionation  by  solid  phase  extraction  into  three  sub‐samples.  The  resulting 





fluids;  however,  the  consequences  of  low  dose  exposure  to  complex mixtures  of  chemicals  are  poorly 
understood. By use of two omics approaches, metabolomics and transcriptomics, the effects on rats caused 
by exposure  to  a 14‐compound mixture  (Mix)  ± PFNA were profiled.  The  applied  technologies provided 
complementary information allowing for a detailed analysis of the affected signalling pathways. Mix alone 
caused reduced lipid concentration evident in plasma. The hepatic effects on lipid metabolism were mainly 
driven by PFNA by activation of  the PPAR  receptors. This  study verifies  that a chemical mixture given at 
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high‐end human exposure  levels can affect  lipid homeostasis.    In a  follow‐up study on the  importance of 
exposure  to  complex  real‐world mixtures,  data  suggested  that mixtures  of  environmental  chemicals  at 








and  a  polar  fraction  and  reveals  changes  in  the metabolome  that  could  not  be  foreseen  using  regular 










Mennesket  er  eksponeret  for  kemikalier  fra mange  forskellige  kilder, blandt  andet mad, medikamenter, 
kosmetik  og  atmosfærisk  luft  (Monosson  2005).  Mange  af  disse  kemikalier  kan  påvirke  menneskets 
helbred,  i  nogle  tilfælde  påføre  store  skader  og  i  værste  fald  slå  folk  ihjel  (Nielsen  et  al  2010a). 
Toksikologien  er den  videnskab der  beskæftiger  sig med  studiet  af  kemikaliers  toksiske  effekter  på den 
levende  organisme.  Den  er  også  associeret  til  spørgsmål  relateret  til  giftstoffer,  vedrørende  kliniske, 
industrielle eller juridiske problemer. 
Metabolisme er det sæt af kemiske reaktioner som er essentielle for at opretholde organismens funktioner, 
mens metaboliter  er dens  intermediater og produkter. Den  samlede mængde  af metaboliter benævnes 
metabolomet og den omfattende og kvantitative analyse af alle metaboliter kaldes metabolomics  (Fiehn 
2001). Ændringer  forårsaget  af  stoffer  der  fysiologisk  eller  kemisk  påvirker  den menneskelige  krop  kan 
observeres i plasma metabolomet.  
Stoffer, der påvirker hormonreguleringen, har  fået stor opmærksomhed  i  toksikologien.     Disse stoffer er 
såkaldte hormonforstyrrende stoffer, som efterligner de naturlige hormoner. I Danmark er der observeret 
en  nedsat  fertilitet  over  de  sidste  to  årtier,  og  det menes  at  de  hormonforstyrrende  stoffer  kan  være 
medvirkende til denne nedgang. Eftersom de hormonforstyrrende stoffer har effekt på mennesket ved lav 










der  er mangel  på  forståelse  for,  hvordan  komplekse  blandinger  af  disse  stoffer  vil  påvirke  os.  For  at 
undersøge dette brugte vi en dels metabolomics og dels transcriptomics tilgang for at undersøge effekten 
af PFNA med og uden en mix af 14 relevante kemikalier. Disse to fremgangsmåder blev brugt i kombination 
til  at  analysere  en  mulig  påvirkning  af  biologiske  pathways.  Blandingen  viste  effekt  på  fedtstofskiftet 
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udtrykt  ved  en  nedgang  i  plasma  fedtstofferne, mens  effekterne  på  leveren  primært  var  fra  PFNA  ved 
aktivering  af  PPAR  receptorerne.  Studiet  viste  således  at  kemikalieeksponering,  ved  koncentrationer 
relevante  for mennesker,  kan  påvirke  fedtstofmetabolismen.  Derudover  viste  forsøget  at  lav  dosis  kan 
påvirke hormonniveauerne  i blodet hos mennesket, ved en  forøget corticosterone plasma koncentration, 
samt reguleringen af disse.   





en  polær  fraktion.  Platformen  viste ændringer  som  ikke  ville  være  fundet  ved  regulære  toksikologiske 
studier.  Studierne  i denne  afhandling præsenterer  en ny  strategi  til  at  evaluere biokemiske ændringer  i 
rotter  efter  toksisk  eksponering.  Data  fra  dette  studie  viser,  at  det  ikke  kun  er  muligt  at  påvise 

































































carried out  in  the Division of Toxicology and Risk Assessment, DTU Food and  the metabolic profiling was 
performed  in  Division  of  Food  Chemistry,  DTU  Food.  The  NMR  experiments  have  been  carried  out  in 
Canada, in the Wishart Group at University of Alberta, Edmonton, Alberta, Canada.  
This  project  would  not  have  been  possible without  the many  people who  contributed  their  time  and 
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affected  by  exposure  to  chemicals  and  poisons,  also  extending  to  associated  problems  such  as  clinical, 
industrial, or  legal aspects. The prediction of toxic effects and pre‐disease determinations are challenging 
and  often  time‐  and  resource‐consuming.  Therefore  new  and  more  efficient  techniques  than  what  is 
presently available are needed.  




and  implicated as  causative of a broad  range of  reproductive dysfunction phenotypes  (Skakkebaek et al 
2006). As EDCs can have effects on humans at low concentrations, a particular challenge in toxicology is to 
develop methods  to detect more  subtle  effects, both  at  the molecular  and  physiological  levels.  In  fact, 
effects  of  low  dose  exposure  can  be  difficult  to  establish,  as  it  causes  changes  to  hormone  levels  and 
metabolism only observed at the metabolite level and not detectable by traditional toxicological endpoints. 
Therefore,  to  better  understand  the  real  consequences  of  EDCs,  also  taking  into  account  less  adverse 
effects  that  can  later  contribute  towards  adverse  health  effects,  new  and  improved  technologies  are 
necessary to monitor toxic chemicals. 
Significant advances in systems biology over the last couple of decades offer unparalleled opportunities to 
unravel  some  of  the  complex mechanisms  behind  the  toxic  effects  caused  by  chemical  exposure.  The 
‘omics’  strategies,  including  genomics,  transcriptomics,  proteomics,  metabolomics,  are  now  routinely 
applied across biological disciplines, with  the  combination of  two or more  ‘omics’ approaches becoming 
increasingly more popular.  
The metabolism  is  the  set  of  chemical  reactions  that  allow  an  organism  to maintain  its  functions  and 
metabolites  being  its  intermediates  and  products.  The  complete  set  of  small molecule metabolites  is 





biological system,  including  the human body. High  resolution mass spectrometry has become  the  tool of 
choice  to  study metabolism  and metabolites,  not  least  due  to  its  very  high  sensitivity  and  potential  to 
detect  a  spectrum  of metabolites,  but  also  its  ability  to  scrutinize  the  impact  of  toxic  compounds  on 
metabolites, allowing for determination of interaction.  
During  the  last  two  decades  the  application  of metabolomics  has  significantly  changed  the  strategy  of 
metabolic  studies.  This  change  has  been  very much  driven  by  developments  in mass  spectrometry,  in 
particular electrospray ionization MS and affordable high resolution mass analyzers. Today the methods of 
choice  are  liquid  chromatography mass  spectrometry  (LC‐MS),  gas  chromatography mass  spectrometry 
(GC‐MS) and nuclear magnetic resonance (NMR) (Robertson et al 2011). Using metabolomics to study the 
effects on metabolism by disease or external (environmental) factors has given new  insights  into diseases 
and effects of  toxic exposures  in humans  (Souverain et al 2004; Psychogios et al 2011). Combined with 
other strategies such as transcriptomics, genomics and proteomics, metabolomics has proven a powerful 
strategy to discover modes‐ and mechanisms‐of‐action underpinning various pathologies. Metabolomics is 






compared  to  conventional  techniques.  Also,  the  metabolomics  approach  was  compared  to  a  more 
traditional  toxicology  approach  in  order  to  evaluate whether  the  new  approach  performed  better  than 
traditional  toxicology protocols. Furthermore, a hypothesis  that  the metabolomics approach could reveal 
better mechanistic insights, and thus a better understanding of low‐dose exposure effects, a lower dose of 
exposure than traditional protocols was tested. For one study the systemic change caused by exposure to a 





was  capable of determining metabolic  changes  following  low‐dose mixture effects  in  rats. Animals were 




revealed similar  results. Changes  in plasma hormone  levels were observed by  the classical approach and 
also  corroborated  by  the  metabolomics  analysis  of  the  blood  plasma.  Furthermore,  the  highest 
concentration  of  PFNA‐exposure  caused  hepatic  steatosis,  which  could  also  be  predicted  from  the 
metabolomics and transcriptomics data, but with the latter approach also revealing additional insights into 
affected  regulatory  pathways.  To  further  challenge  the  new  strategy,  two  more  low‐dose  exposure 
experiments  (mothers  and pups  exposed  to  a  low dose of bisphenol A  (BPA)) were  analyzed. Here, we 
found  changes  in  both  the mother  animals  exposed  directly  to  BPA  and  in  the  pups  exposed  via  the 
placenta  and  the  mother  milk.  Thus  low‐dose  exposure  could  indeed  be  detected  in  the  plasma 
metabolome and hence be used to reveal additional information regarding effects of toxic exposures.    
Before discussing the results of the individual studies undertaken during this project, a further overview of 

















doses  to  detect  possible  adverse  effects  in  an  organism  (Monosson  2005). Within  toxicology  the  “No 
Observed Adverse Effect Level”  (NOAEL:  the highest concentration of compound with no adverse effect) 




profiles  of  chemical  substances  are  usually  obtained  through  in  vivo  studies  and  these  often  are 











Recently,  it has been  suggested  that  toxic compounds might  interact. Figure 1  shows an example of  the 
effect of mixtures of  toxic compounds which cause an effect different  from  that observed  from a  single 
compound. Three main mechanisms of  interaction have been  suggested, namely  synergism, antagonism 
and  addition  (Crofton  et  al  2005; Moser  et  al  2006;  Frische  et  al  2009;  Christiansen  et  al  2009).   With 





As mentioned  above,  sources  of  toxic  chemicals  are  numerous,  for  instance  air  pollution,  occupational 
exposure  and  food.  Chemicals may  include  pesticides, medical  residues,  cardboard materials,  thermal 
printings, plastics, surfactants and many more (Monosson 2005; Crofton et al 2005; Lau 2012). The effect 
exerted by these compounds can differ significantly between species, sex,  doses, time of exposure, and a 
variety of other  factors  (Colborn  et  al  1993;  Evans  et  al  2004).  Furthermore,  two  individuals may  react 
differently to the same toxic chemical due to genetic polymorphisms. 
 A  particular  group  of  compounds which  has  received much  attention  is  EDCs  (Kozlowska‐Tylingo  et  al 
2010). They are compounds that can mimic  endogenous steroid hormones (Connolly et al 2011). There is 
evidence  suggesting  that  EDCs  affect  wildlife  and  humans  by  causing  reproductive,  developmental,  or 
metabolic disorders (Colborn et al 1993; Evans et al 2004; Nicolucci et al 2011; Tse et al 2013). An EDC was 
defined  by  the  U.S.  Environmental  Protection  Agency  as  “an  exogenous  agent  that  interferes  with 
synthesis,  secretion,  transport,  metabolism,  binding  action,  or  elimination  of  natural  blood‐borne 



















effects  are often only detected  at  the higher doses. Below  the NOAEL, no  effects  are  seen. Herein, we 
applied  a  metabolomics  approach  to  study  EDCs  in  order  to  investigate  whether  changes  to  the 
metabolome could be detected at lower doses than those causing toxic effects. Therefore, metabolism and 









1000 metabolites  in  E.  coli  (Bajad  et  al  2006).  In  humans,  the  number  of  endogenous metabolites  are 





The  non‐polar  compounds  are  digested  and  converted  into  chylomicrons  and  transported  through  the 
lymphatic system to the liver from where it is distributed throughout the body (Berg et al 2006). The polar 





of  food and energy  levels are  regulated by enzymes. The  concentrations of metabolites  in  the body are 
closely  regulated e.g. by  enzymatic  reactions.    The  regulation of  transcription  is partly  regulated by  the 
concentration of metabolites, as depicted in Figure 2.  
At the cellular  level two types of metabolic reactions take place: anabolism (‘building up’) and catabolism 









high ADP concentration will  therefore  induce energy production  in  the TCA cycle while an  increased ATP 
concentration will inhibit multiple enzymes leading to a reduction in ATP production.  
1.3	Systems	biology	














The  relationship between  the  ‘omics’  strategies  is  that DNA  is  transcribed  into mRNA  (transcriptomics), 
which  is  translated  into  proteins  (proteomics), which  is  involved  in  the  regulation  of  the metabolome 
(metabolomics). Concentrations of metabolites are  involved  in the control of enzymatic activity and verse 
visa.  Furthermore, metabolites  are  involved  in  the  regulation  of  transcription  as well  as  translation  of 
mRNA. Determination of all parts of the central dogma could reveal a full picture of how the body reacts at 






later,  Oliver  Fiehn  introduced  the  term  metabolomics  and    defined  it  as  ”the  comprehensive  and 
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quantitative  analysis  of  all  metabolites”  (Fiehn  2001).  An  additional  term,  metabolic  profiling,  is  also 
occasionally  used  as  a  name  for  the  strategy  of  analyzing  the  metabolome.  However,  the  term 






of  analytical  strategies  are  used,  including  metabolite  profiling  and  target  analysis.  While  the  term 
metabolomics is relatively new, the concept of metabolomics has been around for at least 2000 years as it 
was   believed  in ancient China  that  there was a  correlation between health and body  fluids and    in  the 
middle age ”urine charts” were used to diagnose health conditions (Lindon and Nicholson 2008). The main 
indicators in these old “metabolic” studies was color, taste and smell of urine (Lindon and Nicholson 2008).  
Mass  spectrometry  is  the  technique  of  choice  for  high  throughput  metabolomics  (Feng  et  al  2008). 
Although,  as mentioned  above  it  is  not  yet  possible  to measure  every  single metabolite with  a  single 
analytical method (Shulaev 2006; Callahan et al 2009). A high throughput method for metabolome analysis 
can reveal information not obtained by the other “omics” approaches  and could very easily be applied due 
to  low  cost  (Gomase  et  al  2008).  Furthermore,  data  obtained  from metabolomics  analyses  are more 
phenotypic  (Gomase et al 2008)  compared  to  transcriptomics and proteomics. The  combination of DNA 
sequencing,  gene  expression  analysis,  protein  analysis  and  metabolite  analysis  could  improve  our 
understanding of complex systems, much more  than  the application of single method only. Analysing all 
parts  simultaneously  would  possibly  reveal  a  systemic  change  not  observed  using  a  single  analytical 
method, ultimately  increasing  the  likelihood of determining mode of action of  toxic chemicals. However, 
many of  these  technologies are  still very costly, at  least  if  several are  to be employed at  the  same  time 
(Ramirez et al 2013). Also, current available technologies for metabolomics does not allow for an analysis of 
the complete metabolome.    









a  compound. Concepts  such as  transcriptomics, proteomics and metabolomics are applied  to  clarify  the 
mode of action of toxic chemicals  (Monosson 2005).    In toxicology, metabolomics approaches have been 
used  over  the  last  15  years  (Robertson  et  al  2011).  The  observation  of  metabolic  changes  can  help 







primary  interest  is blood and urine  (Robosky et al 2002).   Examples  include  the   determination of blood 
parameters such as changes in cholesterol levels, low‐density and high‐density lipoprotein levels (Seidlová‐
Wuttke et al 2005; Hu et al 2010).  




metabolic consequences of external stimuli such as  the onset and  regression of  toxicity can be obtained 
from a  single animal”  (Robosky et al 2002). Metabolomics approaches have been used  in  the  toxicology 
community  to determine biomarkers of both  renal  (Sieber et al 2009) and hepatic  toxicity  (Antoine et al 
2009; McBurney et al 2009). Furthermore, metabolomics approaches show great perspectives for analysis 
of  low‐dose exposure  to  toxic chemicals  (Ramirez et al 2013). Hence,  low‐dose exposure  to a compound 
such as BPA has been shown to induce changes of the polar fraction of compounds in the plasma (Zeng et 







As  discussed  in  section  1.4,  metabolomics  is  a  strategy  used  to  determine  the  metabolome:  all  low 
molecular weight metabolites  in  a  given  sample  at  a  specific  time  point  (Fiehn  et  al  2007).  This  is  an 




stop  all biochemical processes  (if needed)  and preparation of  sample  to match  the  subsequent  analysis 






Figure  4  The  paradigm  in  metabolomics.  Samples  representing  the  specific  study  are  collected,  quenched  and  prepared. 




To  create  a  platform  for  analysis  of  the metabolome, many  aspects  have  to  be  considered.  A  general 
outline of the platform  is  illustrated  in Figure 4. Urine or blood would be biological samples of choice, as 












including  temporal  insight  into  the dynamic process of metabolism. On  the analytical end, blood    is also 
slightly more complex due to the large number of metabolites present, blood cells and proteins, as well as 





that  the enzymatic  systems need  to be  stopped  to  achieve  a  snapshot picture of  the metabolome. The 
process employed to ‘freeze’ metabolism in time is referred to as quenching. For microorganisms it is very 
important  to quench metabolism, as  they are very easily stressed and  the metabolitic concentration can 
change  rapidly upon  stress  (Villas‐Bôas et al 2005). For plasma  samples,  storage at  ‐80OC will arrest  the 
enzymatic reactions, whereas protein precipitation will denature the enzymes.    
2.3	Plasma	analysis	
Blood  is  the main  transport medium of metabolites  in  the body. Hence,  the  plasma metabolome holds 
comprehensive information about the status of the various organs, cells and their regulation (Psychogios et 
al  2011).  Plasma  is  obtained  from  blood  samples  by  addition  of  anti‐coagulants,  followed  by  simple 
centrifugation  and  removing  or  decanting  of  the most  buoyant  (non‐cellular)  portion  (Psychogios  et  al 






Many different analytical strategies have been used  (Psychogios et al 2011)  to gain access  to  the plasma 








al.  used  hexane  to  extract  lipids  after  protein  precipitation, while Ravenzwaay  et  al.  used  a mixture  of 
ethanol/dichloromethane with water  to  separate  the polar  and non‐polar  fraction  (Bird  et  al 2011;  van 
Ravenzwaay  et  al  2014). As  liquid/liquid  extractions  have  been  used  for  decades,  a  variety  of  different 
solvent combinations have been proposed (Takatera et al 2006; Sandra et al 2010; Ferreiro‐Vera 2012).  
An  alternative  to  liquid/liquid extraction  is  solid phase extraction  (SPE), using  a  solid phase  to  retain or 
remove the compound of interest. As suggested by Tulipani et al. SPE can be used to remove phospholipids 
after protein precipitation to  increase the  information of the remaining metabolites (Tulipani et al 2013). 
This  effect  is  due  to  the  fact  that  phospholipids  are  extremely  easy  to  ionize  in  electrospray  mass 
spectrometry, and will therefore give a significant bias towards phospholipids (matrix like effect). Removing 
these  will  most  likely  enhance  the  determination  of  the  remaining  metabolites  (Ferreiro‐Vera  2012; 
Tulipani et al 2013).  One of the challenges in analyzing more complex samples such as plasma, is the wide  
range    in  the  concentration  the metabolites which  goes  from  picomolar  to millimolar  (Psychogios  et  al 
2011).  For  the  purpose  of  identifying  all metabolites  in  plasma,  purification  or  cleanup  of  the  plasma 
samples might  be  necessary.  As  described,  a  simple  approach  to  remove  proteins,  or  a more  complex 
approach  using  SPE  or  liquid/liquid  extraction,  can  be  used.  However,  each  will  have  advantages  and 








Broadly  speaking,  two  different  approaches  are  used  when  evaluation  toxicity  by  metabolomics:  i)  a 
targeted approach that aims to determine a preselected set of metabolites and ii) a non‐targeted approach 




2010). The non‐targeted  approach  is normally based on  a  screening or  fingerprinting  strategy where  all 
detectable  metabolites  are  considered.  This  could  involve  a  crude  extraction  procedure  followed  by 
injecting  the extract directly  in a mass  spectrometer or  rough  LC‐MS  techniques  (Robertson et al 2011). 
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While  the  non‐targeted metabolomics  approach may  reveal more  information  from  each  sample,  the 
detection limit is far higher than that of the optimized target approach (100‐200 nM according to Wishart 
2010).  In  both  cases,  it  is  critical  to  note  that  the metabolome  data  obtained  depends  on  the  applied 
analytical  procedure  unless  a  validated  quantitative  target  approach  is  employed.  The  non‐targeted 
metabolomics approach presents a complex fingerprint of the sample that can be efficiently used to classify 
samples. However, in the non‐targeted approach it can be difficult to classify an identified metabolic profile 
(García‐Sevillano  et  al  2014),  as  the  differences  usually  are  small  compared  to major  component  (e.g. 
dominant primary metabolites).  In  the  targeted  approach,  selected  sets of metabolites  are determined, 
with  increased sensitivity and also allow  for quantification. However,  the most pronounced disadvantage 













provides molecular  structures,  thus  giving  certainty  in  the  identification  of metabolites  as  compared  to 
mass‐based  identification. One drawback  is the fitting of overlapping peaks, though recent research have 




metabolites.  One  drawback  is  the  need  to  render  all  analytes  more  volatile,  generally  through 






instruments,  such  that databases  can be  created  to  conduct  fast and accurate  identification. GC‐MS has 
been used since the early 1970’s and ever since the development of mass spectrometry the use of GC has 
proven  to be a  strong  tool  for analysis of a wide  range of  compounds  (Fiehn 2008). Hence, GC‐MS  is  a 
widely  used  and  powerful  method,  however  only  volatile  metabolites  can  be  analyzed  without 
derivatization (Gomase et al 2008; Zhang et al 2012a) 
HPLC‐MS has been used to study metabolites such as organic acids, sugars, lipids and phospholipids among 
others.  HPLC‐MS  is  a  strong  tool  that  can  analyze  a  wide  polarity  range.  One major  drawback  is  the 
identification  of  unknown metabolites.  Compared  to  GC‐MS  where  similar  fragmentation  patterns  are 
revealed, even on different instruments, HPLC‐MS does not necessarily show same MS pattern on different 
instruments.  Therefore,  it  can  be  difficult  to  identify  the metabolite  doing  non‐targeted metabolomics. 




analytes.  The  polar  compounds  (e.g.  amino  acids  analyzed  by  HPLC)  will  normally  be  separated  using 
normal  phase  chromatography.  The  normal  phase  has  a  polar  stationary  phase  retaining  the  polar 
compounds. A method  for  analyzing  very polar  compounds  such  as  adenosine‐triphosphate  is  available: 
hydrophilic  interaction chromatography (HILIC), which  is a part of normal phase chromatography. In HILIC 
the  stationary phase  is  surrounded by a water  layer which assists  in  the  separation of polar compounds 
(Alpert  1990;  Ta  et  al  1994).  For  analysis  of more  non‐polar  compounds  such  as  lipids,  reverse‐phase 
chromatography  is  used.  The  reverse  phase  has  a  non‐polar  stationary  phase  retaining  non‐polar 
compounds. The columns used for reverse phase chromatography is primarily C18 and C8 columns.  
RP‐HPLC  is  an  analytical  technique with high  reproducibility  and  sharp  chromatographic peaks. RP‐HPLC 




fatty  acids  of  human  plasma  (Ang  et  al  2012) while Garcia‐Sevilliano  et  al  have  shown  changes  in  the 
lipodome upon toxic exposure of inorganic arsenic (García‐Sevillano et al 2014). RP has a wide application 
in  metabolomics  and  can  analyze  a  wide  range  of  metabolites.  One  of  the  disadvantages  is  its  poor 
separation  of  polar  compounds.  However,  this  can  be  solved  by  HILIC which  can  separate  and  detect 
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extremely  polar  compounds  (Bajad  et  al  2006;  Callahan  et  al  2009).  Using  a  HILIC  system,  one  faces 
problems  with  peak  shape,  ion  suppression  from  the  high  ion  contents  in  the  solvent  and  poor 
reproducibility.  
In recent years two different kinds of analysis have been used, the 2 dimensional analytical approaches GC‐
GC  and  LC‐LC. GC‐GC  is  a  powerful  technique which  has  gained  increasing  attention  over  the  last  two 




such  as  sugar  phosphates  and  small  organic  compounds  (Klavins  et  al  2014).  The  drawback  of  a  LC‐LC 
method is a significantly longer analytical runtime.  
Today, MS  is  probably  one  of  the most  important  analytical  techniques within  biotechnology,  analyses 
ranging from small volatile compounds, complex natural products and proteins to intact viruses (Villas‐Bôas 
et al 2007). High  resolution  instruments can now possibly detect pM with a  resolution of 100.000 and a 
mass accuracy when internally calibrated at below 1‐2 ppm (Lu et al 2008). The use of high resolution mass 
spectrometry  increases the accuracy of the mass spectra, reducing the amounts of suggested metabolites 
when  conducting  database  searches.  The  high  resolution  mass  spectrometer  is  useful  for  analysis  of 
complex samples due to resolution, accuracy and sensitivity (Moco et al 2007). Using a qTOF  instrument, 
the  accurate  mass  along  with  MS2  can  help  identify  compounds  but  also  possible  impurities  in  the 
chromatography  (Wolff  et  al  2001).  For  the  analysis  of  well  characterized  samples,  a  simple  mass 
spectrometer (e.g. a single quadrupole) might be more robust and thus yield more reliable results for each 
sample.  For  identification of new  compounds,  this  instrument will not be useful while a high  resolution 
instrument  can  narrow  down  the  amount  of  possible  compounds,  thereby  increase  the  likelihood  of 





values  and  intensities.  To  create  a  matrix,  multiple  tools  are  needed,  such  as  time  alignment  of  the 



















as Mann‐Whitney  (Comparisons  and Dice  2002).  In order  to  analyze more  than  two  groups,  analysis of 




Models  are  often  applied  to  metabolomics  data  to  further  illustrate  the  differences  to  separate 
metabolomes. One  such model  is a PCA  (Ebbels and Cavill 2009). PCA  is a projection  technique which  is 
designed to extract, display and rank the variance in a dataset. The purpose is to reduce the dimensionality 
while  at  the  same  time  retain  the  information  in  the  dataset.  The  PCA  filters  out  the most  significant 
variables  in  the  original  matrix  so  instead  of  looking  at  a  large  number  of  variables  the  PCA  allows 
identification  of  the  most  influential  variables.  Another  model  used  for  interpretation  of  changes  in 
metabolism  is  the PLS  regression  (Shulaev 2006; Bartel et al 2013). PLS analysis also uses a collection of 
analyses which is translated into a matrix. The number of X variables corresponds to the number of column 
in the X table. However, a second table with sample  information  is also taken  into account. Hence, PLS  is 































































































































































































For  sample preparation  certain  factors have  to be  controlled.  Temperature, duration,  freezing,  thawing, 
order of analysis are some of the factors that can affect the results. Thawing samples at room temperature 
compared  to  thawing on  ice has been  shown  to  change  the metabolite  composition  (Breier et al 2014).  
However,  for many    lipid classes  in  the plasma metabolome,  the stability  is high even at 4 degrees  for 6 
hours  (Breier et al 2014). For analysis of primary metabolites  in microorganisms  it has been  shown  that 
quenching is required to ensure that the metabolite pool stays unchanged (Villas‐Bôas et al 2005). Another 










range of diseases and exposure  to  toxic  chemicals, biomarkers have been  identified  (Singh and  Li 2011; 
Austdal  et  al  2014).  A  biomarker  reflects  changes  in  a  normal  biological  process  and  can  assist  in  the 
diagnostics  of  disease  (Larson  et  al  2013).  Studies  have  been  conducted  where  an  analysis  of  the 
metabolites  is performed  in order to understand how diseases affect the metabolome  (Chen et al 2014). 
Biomarkers have been identified for diseases such as cancer, Alzheimer’s disease, diseases associated with 
pregnancy and Parkinson’s disease (Michell et al 2008; Yonezawa et al 2013; Kobayashi et al 2013; Austdal 
et al 2014). Metabolic changes have been analyzed  in  the hope of  identifying biomarkers of diseases,  to 
determine early stages of the diseases (Zhang et al 2012b; Jung et al 2013). A number of biomarkers have 
been identified e.g. blood glucose levels as biomarkers for the risk of acquiring diabetes, serum creatine for 
kidney  failure  and  prostate  specific  antigen  for  prostate  cancer  (Xia  et  al  2013a). Metabolomics  as  an 






The  aims  of  this  study were  to  achieve  new  insights  into  the  action  of  toxic  compounds  on  biological 
systems. A metabolomics approach was applied. The primary aim was  to develop a  sample preparation 
procedure  and  LC‐MS  analyses  to  detect  as many metabolites  as  possible  in  the  plasma metabolome. 
Further  to  use  this  procedure  for  the  analyses  of  plasma  from  rodents  exposed  to  combinations  of 
endocrine  disrupting  chemicals  for  identification  of metabolites  changed  in  concentrations which  could 
serve  as  biomarkers  of  toxic  effects.  Also,  to  investigate  whether  changes  in  concentrations  of  these 
biomarkers  could  be  observed  using  metabolomics  at  lower  exposures  not  resulting  in  toxic  effects. 
Specifically to:   
 Development of  an  analytical method  for determining  changes  in  the metabolome due  to  low‐dose 
exposure to toxic chemicals 


















and  standard  diet  (prod.  no.  1324  Altromin,  Brogården,  Gentofte,  Denmark).  The  animals  were 
administered test substances once a day by gavage for 14 days with corn oil (VWR ‐ Bie & Berntsen, Herlev, 
Denmark)  as  vehicle.  The  dosing  volume  was  1  mL/100  g  of  body  weight  (bw).  At  the  end  of  the 
experiments,  animals  were  anaesthetized  in  CO2/O2  and  decapitated.  Neck  blood  was  collected  in 
heparinized  tubes, and plasma was  isolated by  centrifugation at 1,000 x g, 4  °C  for 10 min. Plasma was 
stored at ‐80 °C. Around 1 ml of plasma from each of the 82 animals were obtained. 
4.2.1	BPA	experiment	
A  total of  110  time‐mated nulliparous,  young  adult Wistar  rats  (HanTac:WH,  SPF,  Taconic  Europe,  Ejby, 
Denmark) were supplied at gestation day (GD) 3 of pregnancy. 
The  animals were housed  in pairs until GD  17  and  alone  thereafter under  standard  conditions  in  semi‐
transparent  polysulfone  (PSU)  type  III  cages  (PSU  80‐1291HOOSU  Type  III,  Tecniplast,  Buguggiate,  Italy) 








At  the end of  the experiments, animals were anaesthetized  in CO2/O2 and decapitated. Neck blood was 




Briefly,  four‐week‐old,  specific pathogen‐free  (SPF)  female Wistar  rats were obtained  from Taconic M&B 












residue  was  then  extracted  by  adding  200 μl  of  methanol  (polar  fraction).  The  heptane  fraction  was 
















































and  a  retention  time window  from  30‐720s  and  30‐840s,  for  the  hydrophilic  and  hydrophobic  gradient 
system, respectively.   
For  the quantification of PFNA  in  the plasma samples, Quantanalysis 2.0  (Bruker Daltonics) was used. To 
quantify the PFNA concentrations, a standard curve was constructed between 10 ng/ml and 700 µg/ml. The 
high  concentration  PFNA  samples were  diluted  to  fit  in  the  linear  range  (Paper  II).  For  the  analyses  of 
plasma samples  from animals dosed with BPA, a standard curve between 0.01 µg/ml and 300 µg/ml was 
created; however BPA was not detected in the samples (Paper IV). 
MSMS  analysis was  performed  using  the  “auto MSMS”  function  in  the  data  analysis  software  (Bruker 








An NMR analysis was conducted on plasma  from  the PFNA exposed animals  (Paper  III). Centrifugal Filter 
Units  (Merck, Millipore, Darmstadt, Germany) was washed 5  times with 500 µl water  to  remove excess 
glycerol from the production. Five hundred µl of plasma was filtered by centrifugation at 10.000 rpm at 4O C 
for 35 min. Two hundred eighty‐five µl of the filtrate was transferred to an Eppendorph vial along with 35 








the  Feature  Extraction  software  version  10.7.3.1  according  to  protocol  GE1_107_Sep09  (Agilent 
Technologies) to generate feature extraction files for further analysis. Reads were quality controlled by the 






rays  using  quantile  normalization  (Smyth  and  Speed  2003)  prior  to  statistical  analyses.  Within‐array 
replicate  probes  were  replaced  with  the  average  expression  level.  To  identify  treatment‐specific  gene 
effects, we fitted a linear model for each gene and applied empirical Bayes statistics (Smyth 2004) for each 
relevant  two‐group  comparison.  The  false  discovery  rate  (FDR)  was  controlled  using  the  Benjamini‐
Hochberg method  (Benjamini  and Hochberg  1995).  Reported  p‐values  for  the  significantly  differentially 
expressed  genes  from  the  transcriptomics  analysis  were  all  adjusted,  and  p‐values  below  0.05  were 
considered statistically significant. 
4.4	Identification	processes		










2013),  Kyoto  Encyclopedia  of  Genes  and  Genomes  (KEGG.jp)  (Kanehisa  and  Goto  2000),  MassBank 
(MassBank.jp),  METLIN  (metlin.scripts.edu)  (Trauger  et  al  2005;  Smith  et  al  2005)  and  Lipidmaps 
(Lipidmaps.org)  (Sud  et  al  2007;  Fahy  et  al  2009).  These  projects  and  databases  can  help  to  identify 
metabolites  from  their  accurate mass.  Projects  combining metabolomics data with  transcriptomics data 
have been conducted, e.g. InMex (InMex.ca) (Xia et al 2013b). Such tools can, along with the knowledge of 










this approach. To  identify the  last 5 % a  list of the compounds of  interest would have to be created for a 
specific  MSMS  analysis  of  these  compounds.  For  a  sub‐fraction  of  the  significant  metabolites  MSMS 

















mass  is  searched  for  in  online  databases  by  accurate mass with  an  accuracy  of  2  or  20 mDa.  For  this  specific  example  29 




an  ion with  a mass  of  634.5402.  The MSMS  spectrum  shows  in  addition  to  the  parent  ion  the  pseudo 
molecular  ion  (M+H)+  (m/z  617.5139)  along  with  a  loss  of  water  (m/z  599.5033),  furthermore  two 
fragments of 337.2735 and 269.2369 are  found. HMDB  suggest DG(18:2/18:2) as a possible M+NH4  ion; 
which could be correlated to the neutral side chain loss (m/z 337.2735)  and loss of the acyl side chain (m/z 
263.2369) along with  loss of water. Comparing this MSMS pattern with the  in silico MSMS pattern of DG 
(18:2/18:2)  from Lipidmaps  shows  that all  the  fragments  fit and  that  the mass deviation  is  less  than 0.6 
ppm for all of the fragments. The compound was identified to be DG(18:2/18:2) as it only has one neutral 





























The MSMS  spectrum  contains  a psedo‐molecular  ion of 544.3399 was  found  along with  a  loss of water 




revealed  three  possible  compounds  with  the  same  elemental  composition.  A  standard  of  one  of  the 
















































































































































































































































































































































The method  is  similar  to  that  described  by  Tulipani  et  al.  (Tulipani  et  al  2013),  but with  extraction  of 
phospholipids for analysis since plasma phospholipid concentrations were found to be sensitive to chemical 
exposure.  Therefore,  the phospholipids were  extracted  from  the  column  for  analysis.  In  Figure 10  ,  the 
three analyzed sub‐fractions are shown. The reason  for having  three sub‐fractions was  to reduce  the  ion 




features  compared  to  a  traditional  protein  precipitation method  (Souverain  et  al  2004).  This  is  slightly 
overestimated,  since  the  selected method will  include  some  compounds  twice  as  these  are  equilibrium 
distributed  between  the  heptane  and  the methanol  extraction  solvent.  It  is  notable  that  the  selected 
method is based on a non‐targeted approach, which implies less knowledge about the contents of specific 
compounds. For analysis of the metabolites on the LC‐MS system  it was found that a C8 column was the 
best  compromise  to  give  a  good  chromatographic  separation  of  all  three  sub‐fractions:  polar,  lipid  and 
phospholipid. By using a single analytical column, all three sub‐fractions could be analyzed in one sequence, 
saving on time and cost of the analyses.  
The  importance of phospholipids has been described  in several studies, e.g.   Psychogios et al. (Psychogios 
et  al  2011)  and    Kim  et  al.  (Kim  et  al  2011), who  showed  that  phospholipids were  affected  by  hepatic 
steatosis. Furthermore, phospholipids are believed to have signaling activity (Chen et al 2011; Zhang et al 
2014).  Therefore,  changes  in  phospholipid  levels may  provide  information  on  specific mechanisms  and 
effects in mammals. Thus, we thought it important to include these compounds in the analysis.  
Using  the  new  SPE based method,  three major  classes of  the plasma metabolites were detectable;  the 
phospholipids, neutral  lipids and the polar fraction. We detected differences  in phospholipid, neutral  lipid 
and polar fractions of the plasma (Paper III, IV and V). The majority of detected changes  in phospholipids 












































































































































































































































































Histopathological analyses of  the  livers  revealed hepatic  steatosis  indicated by  increased cell  sizes and a 













effects  of  PFNA  with  or  without  Mix  analysis  of  the  plasma  metabolites  was  applied.  Furthermore, 
microarray gene expression analysis was used to determine the transcription of the liver gene mRNA levels.  
In animals exposed to Low PFNA only, we also observed changes to the blood metabolome, albeit different 

















classes;  PC  (phosphatidylcholine)  and  DG  (diacylglycerol).  Metabolite  levels  were  analyzed  statistically  for  each  group  by 









for a prolonged period  (14 days), potentially  resulting  in effects such as hepatic  injury. From  the highest 
exposure levels changes in the liver were found. It can be speculated that if the animals were exposed for a 
longer time period with mid dose of PFNA the animals might have developed macroscopic changes  in the 
liver.  Interestingly,  two  of  our  identified  lysophosphatidylcholines,  lyso‐PC(18:2)  and  lyso‐PC(20:4)  have 
both been  identified as potential blood biomarkers for drug‐induced hepatic phospholipidosis (Saito et al 
2014), and  in both  instances  the  response  is  reduced  levels. Then, as drug‐induced phospholipidosis has 
been associated with  liver  inflammation and  fibrosis  (Rigas et al 1986; Lewis et al 1989),  it could suggest 
































































































































































































Based  on  functional  annotation  of  genes  dysregulated  in  the  PFNA  ±  Mix  dosing  groups,  fatty  acid 
metabolism was the main biochemical function affected (Paper III Table 2). For instance, upregulated genes 
such as Crot, Crat, Acox1, Ehhadh, Hadha, Hadhb, Decr2, Eci2, Ech1, are all  involved  in peroxisomal  fatty 
acid  β‐oxidation,  whereas  Cpt2,  Slc25a20,  Acad11,  Acadl,  Acadm,  Acads,  Acadvl  are  all  involved  in 







the  peroxisome  proliferator‐activated  receptor  (PPARs),  was  activated.  In  Figure  15,  illustrating  the 




Figure  15  Illustration  of  a  putative  hepatic  signaling  network,  from  PPAR  (and  other  transcriptional  regulators)  activation 
through  regulation of gene expression  to ultimately dictate phenotypic outcomes. Orange  indicates predicted activation and 
blue  indicates  predicted  inhibition.  Shades  of  red  and  green  indicate  level  of  increased  and  decreased  gene  expression, 
respectively. The network was generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, 
www.qiagen.com/ingenuity (Paper III) (Skov et al 2015).  
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results  in decreased plasma  lipid concentration  (Lau 2012). Then, as perfluorinated alkyl acids are known 
PPAR‐activators  (Vanden Heuvel et al 2006; Lau 2012; U. S. Environmental Protection Agency 2014), effects 
observed  in  livers  from the PFNA groups could, at  least  in part, be explained by this regulatory pathway. 
Increased PPAR activation as displayed in Figure 15 could explain the effects shown at high‐dose exposure. 
As PPAR activation  leads to  increased oxidation, more  lipids would be present  in the  liver.  It would be of 
interest to explore if macroscopic effects such as hepatic steatosis would be observed if the mid dose study 
was prolonged to 30 days. 
NMR  can provide a more precise  identification of  the metabolites. The plasma  samples  from  the PFNA‐
exposed  animals  were  analyzed  by  NMR  at  the  Wishart  Lab,  Edmonton,  Canada.  The  samples  were 
analyzed  for  43 polar  compounds  (appendix  III)  and no difference between  control  and  Low PFNA was 
found. For the high dosed animals, seven metabolites were significantly different, at the mid dose only one 
metabolite, arginine, was changed. 
When using  the  conventional  toxicological approach, we  found  that  the animals exposed  to  the highest 
concentrations  developed  non‐alcoholic  liver  disease.  The  transcriptomics  and  metabolomics  data 
suggested changes to  lipid metabolism. The effects of changed  lipid metabolism could be correlated with 
activation of PPAR as suggested by the transcriptomics data. We found that the effects were measurable at 
a  lower  level  of  exposure  using  metabolomics  than  what  was  measurable  by  more  conventional 
histopathological analyses. The changes to the metabolome were less specific than a change in physiology. 
However,  the  metabolite  profile  of  the  plasma  can  help  to  understand  how  toxic  compounds  affect 





















As  shown above,  the metabolic platform was able  to detect effects even at  low  levels of exposure.  In a 
follow‐up study, effects of low dose exposure to BPA 25 and 250 µg/kg/day, as well as low dose exposure 
to selenium were examined.  In the BPA study, mothers were exposed orally to the compounds; offspring 
indirectly  via  placenta  and milk.  For  all  three  groups  of  animals,  significant  changes  to  the metabolite 
profile were found. The mothers exhibited decreased monoglyceride levels e.g. MG(18:0) and an increased 
cholesterol concentration (Paper IV). Female pups showed decreased levels of one diacylglycerol (Paper IV). 








BPA. The  concentrations  tested  in  this  study  should, according  to  conventional  toxicology approach, not 
cause any adverse effect on humans (Tyl 2013).  
In  the  selenium  study, metabolome  analysis was used  to examine  if  changes  in urine metabolites upon 
exposure to ionic selenium were different than those exposed to nano‐particle selenium. This could provide 











of  the  two metabolites  in  the animals exposed  to high  concentration of  selenium  from both  the  ionic and  the nanoparticle 
sources (Paper V).   
Multiple  studies have  suggested effects on  the plasma metabolome exposed  to a  low dose of chemicals 
(Vandenberg et al 2012; Chen et al 2014). The data evaluated  in this section are from  low dose exposure 
studies  of  PFNA,  BPA  and  selenium  (Paper  I,  III  and  V).  The  analysis  leads  to  questions  related  to  the 
relevance of such studies, which will be discussed below.  
 













In  the current  study, metabolomics was used  to  investigate  its usefulness  in  toxicology.  It was  to detect 
changes  in  the plasma metabolome upon exposure of  rats  to  low  concentration of  toxic  chemicals. The 
observed  changes  were  mainly  in  the  non‐polar  fraction  of  the  plasma  metabolome,  particularly 
phosphotidylcholine and glycerides, discussed in section 6.1. It can be questioned if an alternative method 





and V).  In  recent  years,  changes  in  the  lipid metabolome has  received  increasing  attention  (Ikeda  et  al 
2009; Chen et al 2011). It has been suggested that lipids are not only part of energy storage, but also affects 
signaling: For example, phospholipids are known regulators of cellular death (Saito et al 2014). Analysis of 
the  lipidome has a wide range of application e.g. analysis of cholesterol and triacylglycerol (TAG)  levels  in 
obesity  patients  (Adams  and  Lewis  1982;  Seidlová‐Wuttke  et  al  2005),  to  analyses  focusing  on  toxic 
chemicals such as arsenic.   Several studies have been performed that focus on changes  in the  lipid profile 
(Funk 2001; Sandra et al 2010; Ferreiro‐Vera 2012; Liu et al 2013; Choi et al 2014; García‐Sevillano et al 
2014) and  include phospholipid and neutral  lipid analyses  (Chen et al 2011; Liu et al 2013). The method 
performed well and yielded  information regarding phospholipids and neutral  lipids, as well as cholesterol. 





In  the BPA experiment we observe  changes  in neutral  lipid  concentrations; e.g. MG(18:0) and MG(16:0) 
(Paper  IV) and  in DG(18:1/18:3) and DG(18:2/16:0) as discussed  in Paper  II. This highlights  the need  for 
understanding what  impact  a  change  in  neutral  lipids  has  on  physiology when  evaluating metabolism. 
Furthermore,  increased  short  chain  phospholipid  levels were  observed  for  the male  pups  at  low‐dose 
exposure levels.    
A  comparison  between  the  study  conducted  by  Alonso‐Malanga  et  al.  and  our  BPA  study  (Paper  IV) 
suggests  that  a  low‐dose  exposure  of  BPA  can  interfere with  insulin  production,  resulting  in  increased 
glucose  uptake  (Alonso‐Magdalena  et  al  2008). Our  results  suggest  a  specific mode  of  action  involving 
changes  in  the  lipodome  (Paper  IV). This might be a  contributing  factor, alongside a general  increase  in 
obesity,  for  the  steady  increase  of  life‐style  diseases  in  the Western world,  including  decreased  semen 
quality  in  European  populations    (Skakkebaek  et  al  2006).  Lui  et  al.  (Liu  et  al  2013)  show  that  the 
phospholipid composition is changed in type 2 diabetes patients, which we also observed in male pups. Our 
results do not offer a specific answer to the question regarding the  impact of toxic chemicals on  life‐style 





(described  above),  enabled measurements  of  changes  in  the  rat metabolome.  By  using  two  different 
solvent  systems  for  the  UHPLC  protocol  (a  hydrophobic  and  a  hydrophilic  solvent;  see Materials  and 
Methods), we obtained better separation of the metabolites and a reduced  ion suppression compared to 
the protein precipitation method  (Paper  I).  In general,  the method  identified a wide  range of non‐polar 




2014).  In  the  present  project  (Paper  II),  NMR  was  used  to  identify  concentration  changes  in  polar 
metabolites, but no  significant  changes were  found at  low dose exposure. At higher doses,  the method 






The  interest  in  the non‐polar part of  the metabolome has  recently been highlighted  (Taguchi et al 2005; 
Takatera et al 2006; Sandra et al 2010; Ferreiro‐Vera 2012). Choi et al. (Choi et al 2014) have developed a 
method  based  on  a mixture  of  equal  amounts  of  isopropanol  and  acetonitrile  in  the  solvent  system  to 
improve the resolution and to provide a better separation of the phospholipids. This, in combination with a 
lower  percentage  organic  solvent  in  the  starting  condition  of  the  hydrophobic  gradient  system, might 
enhance the chromatography of the lipidome.  
Further  improvement of  the present procedure could be  to combine  it with other analytical  instruments 
such as gas chromatography. This has the advantage of being able to analyze the polar metabolites by GC‐










chemicals  (Paper  II and  III).  It was  found  that metabolome  analysis,  for  some parameters,  could detect 
effects  similar  to  those  using  conventional  toxicology  protocols  e.g.  an  increase  in  corticosterone.  To 
further  investigate  low dose exposure,  two additional experiments were  conducted; exposure of BPA or 
selenium.  
One major question following on from these studies, were if the observed effects were transient (that is, an 
acute but reversible physiological response to chemical  insult), or adverse  (as  in prolonged compromised 
physiology caused by chemical insult)?   
A toxic insult to an organism will likely cause a metabolome change, which is also seen where physiological 
effects are not observed.  In  the Selenium study  (Paper V), a difference  in  the PLS‐DA plots between  the 
clustering of bovine  serum  albumin  controls  and  the water  controls was observed  (see  Figure  18).  This 
indicates  that even  low dose exposure  to a non‐toxic  compound  can  result  in measurable effects  in  the 




we  conclude  that  it  is  highly  likely  that  two  different  formulations  of  Se  (nanoparticles  and  ions)  have 
similar mechanisms of action, although we could not specify the  identities of all the significantly changed 
metabolites (Paper V). 
The  conventional  toxicological  approach  is  to  establish  dose  levels  at which  compounds  exert  adverse 
effects. In traditional studies, pathological changes in clinical appearances or in tissues are  signs of adverse 





sensitivity  toward determination of NOAEL”;  for one case a  reduced body weight was observed  for both 
sexes, whereas a change in metabolite levels was observed in females, but not males (van Ravenzwaay et al 
2014). 
From the results obtained  in this thesis, there  is no clear answer as to whether  low doses of the specific 
chemicals  affect  metabolism  to  cause  adverse  effects.  Although,  the  effect  observed  for  PFNA  on 
corticosterone levels could be interpreted as an adverse effect. This, however, does not preclude that, for 
some  chemicals,  the  use of  systems  biology  in  general  and metabolome  analysis  in  particular will  yield 
information that can be extrapolated to adverse effects, e.g. effects on cholesterol metabolism or sets of 














The  aim  of  this  thesis  was  to  use  metabolomics  to  study  effect‐outcomes  in  toxicology  experiments, 
particularly at  low dose exposure. A method was developed  that allows  for analysis of plasma  from  rats 




a polar  fraction  followed by UHPLC‐qTOF analysis. The applicability of  the method was demonstrated by 
showing  changes  to  the metabolome of animals having been administered  a  chemical dose  comparable 
with  human  exposure  of  the  endocrine  disruptor  PFNA  (Paper  I).  Nevertheless,  there  is  still  room  for 
improvements  to  the  method,  for  instance  changing  the  phospholipid  solvent  and  running  the  polar 
fraction in HILIC mode.   
To further validate the method, comparisons to a conventional toxicology approach were performed. The 
observed  effect  a  low  dose  of  PFNA  had  on  corticosterone  correlated  with  observations  from  the 
conventional toxicology approach using a targeted LCMS approach (Paper II and III).     
To  investigate  the potential  impact of  low  dose  exposure,  experiments with  PFNA,  PFNA+Mix, BPA  and 
selenium were performed in rats. In the PFNA ± Mix exposure experiment, the addition of Mix resulted in a 
significantly different metabolite profile with decreased  levels of neutral  lipids and phospholipids  (Paper 
III). In the BPA experiment, the rat mothers showed a decreased level of MG(16:0) and MG(18:0), while the 
male pups showed increased levels of lyso‐phospholipids (Paper IV). The selenium experiment showed that 
ionic  selenium and nano‐particle  selenium  induced  similar  changes  in  rat urine, which  indicates a minor 
importance of the ionization state of selenium (Paper V). In all three experiments changes were observed 
following low‐dose exposures (Paper III, IV and V).         
An encouraging  finding was  that metabolomics assisted  in suggesting possible modes of action  for PFNA 
and BPA  toxicity. PFNA was suggested  to  induce hepatic steatosis  (Paper  III), while BPA changed plasma 
cholesterol and phospholipid concentrations (Paper IV).   
We observed that a mixture of 14 chemicals at high‐end human exposure  levels (Mix),  low‐ to mid‐range 






of  Mix,  suggesting  that  the  hepatic  effects  were  driven  by  PFNA.  Transcriptomics  analysis  suggests 
increased PPAR activation, resulting  in  lowered  lipid concentration and  increased β‐oxidation. Hence, this 
study demonstrates  that  low‐dose exposure  to chemical mixtures can affect  the metabolome and cause 
disturbed lipid homeostasis, and that ‘omics’ approaches are powerful tools to detect smaller changes not 
readily observable at the macroscopic level.   
The BPA experiment  revealed a change  to cholesterol  levels  in  the mothers and a general change  to  the 
lipidome, which could be related to effects due to higher levels of insulin in the plasma; in turn resulting in 
an increased biosynthesis of triacylglycerol and a decrease in mono‐ and diacylglycerols in the plasma. 
Using a metabolomics approach  reveals  changes  to  the metabolome which  could not be  foreseen using 
regular toxicological approaches. We applied a new protocol which can improve the understanding of toxic 
compounds  and  assist  in  toxicology‐testing  to  identify possible mechanism of  actions.  Furthermore,  the 
metabolomics approach  can help  in  identifying  specific pathways or  systemic  changes  caused by a  toxic 
chemical. The metabolite changes  in both the PFNA and BPA papers are very  interesting, but the changes 
might not give  the  full picture of how  the  respective compounds act. From  this  study, we  show  that an 
metabolomics  approach  can  be  used  to  increase  our  understanding  of  how  toxic  chemicals  affect 
physiological parameters. It can be discussed if metabolomics can be used as a “stand‐alone” approach, but 
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80‐05‐7  bisphenol A    plastic additive  0.004  0.01 
94‐26‐8  butyl paraben   preservative  0.21  0.52 





bis(2‐ethylhexyl)phthalate (DEHP)  plasticizer  0.03  0.09 







133855‐98‐8  epoxiconazole   pesticide  0.02  0.05 
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330‐55‐2  linuron  pesticide  0.002  0.004 
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Collision  energy  was  based  on  the  mass  of  the 









H‐NMR  spectra  were  collected  on  a  either  a  500 
MHz Inova (Varian Inc., Palo Alto, CA) spectrometer 
using the first transient of the tnnoesypresaturation 
pulse  sequence.  The  resulting  1  H‐NMR  spectra 
were  processed  and  analyzed  using  the  Chenomx 
NMR  Suite  Professional  software  package  version 





“Prior  to  spectral analysis, all FIDs were  zero‐filled 
to 64k data points, and a  line broadening of 0.5 Hz 
was  applied.  The  methyl  singlet  of  the  buffer 
constituent DSS  served as an  internal  standard  for 
chemical  shift  referencing  (set  to  0  ppm)  and  for 
quantification. All 1H NMR spectra were processed 
and  analyzed  using  the  Chenomx  NMR  Suite 
Professional  software  package  version  4.6 
(Chenomx  Inc., Edmonton, AB). The Chenomx NMR 
Suite  software  allows  for  qualitative  and 
quantitative  analysis  of  an  NMR  spectrum  by 
“fitting”  spectral  signatures  from  an  internal 
database  of  reference  spectra  to  the  full  NMR 
spectrum  [22].  Specifically,  the  spectral  fitting  for 
each  metabolite  was  done  using  the  standard 
Chenomx 500 MHz (pH 6–8) metabolite library, with 
a  set  of  additional  compound  signatures  (1,5‐
anhydrosorbitol,  dimethyl  sulfone,  2‐ 
oxoisovalerate,  3‐hydroxyisobutyrate)  that  were 
added  in‐house.  It has been previously shown  that 
this  fitting  procedure  provides  absolute 























Aim:  Increasing metabolite  information  from  a  rat plasma  sample by  solid phase  extraction  resulting  in 
three sub‐fractionations of the plasma metabolites.  
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a  b  s  t  r  a  c  t
Blood  plasma  is  a well-known  body  ﬂuid  often  analyzed  in  studies  on  the  effects  of toxic  compounds
as  physiological  or chemical  induced  changes  in  the  mammalian  body  are  reﬂected  in the  plasma
metabolome.  Sample  preparation  prior to LC–MS  based  analysis  of the  plasma  metabolome  is a  chal-
lenge  as  plasma  contains  compounds  with  very  different  properties.  Besides,  proteins,  which  usually  are
precipitated  with  organic  solvent,  phospholipids,  are  known  to cause  ion  suppression  in  electrospray
mass  spectrometry.
We have  compared  two  different  sample  preparation  techniques  prior  to LC-qTOF  analysis  of  plasma
samples:  the  ﬁrst  is  protein  precipitation;  the  second  is protein  precipitation  followed  by  solid phase
extraction  with  sub-fractionation  into  three  sub-samples:  a phospholipid,  a  lipid  and  a  polar  sub-fraction.
Molecular  feature  extraction  of  the  data  ﬁles  from  LC-qTOF  analysis  of  the samples  revealed  1792 molec-
ular features  from  the protein  precipitation  procedure.  The  protein  precipitation  followed  by  solid  phase
extraction  procedure  with  three  sub-samples  gave  a total  of  4234  molecular  features.  This  suggests  that
sub-sampling  into  polar,  lipid  and  phospholipid  fractions  enables  extraction  of  more  metabolomic  infor-
mation  as  compared  to  protein  precipitation  alone.  Chromatography  showed  good separation  of the
metabolites  with  little  retention  time  drift  (<1  s)  and  a mass  accuracy  below  3  ppm  was observed.  The
performance  of the  method  was  investigated  using  plasma  samples  from  rats  administered  the  environ-
mental  pollutant  perﬂuorononanoic  acid.
© 2014  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Metabolomics is an analytical strategy based on a comprehen-
sive analysis of ideally, all low molecular weight compounds in a
speciﬁc biological compartment [1]. This strategy is highly valu-
able in toxicological studies. It can be used to obtain a metabolic
ﬁngerprint that enables determination of changes in response to
exposure to xenobiotic chemicals [2]. Speciﬁcally, metabolomics
can be used to quantitate the amount of the xenobiotic as well as
its metabolites [2–4]. The latter can provide investigators with sug-
gestions on the nature of affected biochemical pathways and thus
the nature of toxic effects and mechanisms [2].
Several analytical techniques are available to determine the
metabolome. Nuclear magnetic resonance (NMR) and mass
Abbreviations: MG, monoacylglycerol; PLS-DA, partial least square discriminant
analysis; PC, phosphotidylcholine; PFNA, perﬂuorononanoic acid.
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spectrometry coupled to either gas chromatography (GC–MS)
or liquid chromatography (LC–MS) are the most frequent used
techniques. Each of these techniques has its advantages and disad-
vantages. NMR  requires little sample preparation but is reported
to have limited sensitivity [4]. GC–MS has excellent separation
capacity and good sensitivity but requires derivatisation of the
sample. LC–MS has good separation capacity and good sensitiv-
ity toward most compounds. However, very polar metabolites are
poorly retained on conventional LC columns [3,5]. An added beneﬁt
of high resolution accurate mass spectrometry is that it improves
the possibility to identify metabolites [6]. Often, the complexity of
the metabolome as described below, will nearly always call for a
combination of analytical techniques to obtain a comprehensive
picture of the metabolome [7].
Blood perfuse all organs in the body and its metabolome can
provide comprehensive information reﬂecting the status of the
whole bodies’ physiology. While the metabolome can readily be
measured in urine, representing a collection of metabolites elimi-
nated by the organism, analysis of the plasma metabolome, which
better reﬂects the physiology status of the organism, requires
http://dx.doi.org/10.1016/j.jchromb.2014.11.033
1570-0232/© 2014 Elsevier B.V. All rights reserved.
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a more laborious analytical procedure. Plasma contains a com-
plex mixture of compounds ranging from very hydrophilic to
very hydrophobic with a concentration range from picomolar to
millimolar [7–10]. This complexity challenges the analytical pro-
cedures [11]. In particular, the co-occurrence of peptides/proteins
together with phospholipids in plasma complicates the analy-
sis of metabolites. Before a chromatographic analysis of plasma
constituents proteins are usually removed by solvent precipita-
tion with methanol, acetonitrile, or perchloric acid [12,13]. It has
been shown that three volumes of acetonitrile per plasma vol-
ume  is the most efﬁcient protein precipitating agent [13]. After
protein precipitation, the remaining compounds mainly comprise
low molecular weight compounds including e.g. amino acids,
organic acids, hormones, urea and uric acids as minor constituents,
together with phospholipids and tri-, di- and mono-glycerides as
major constituents [7]. Phospholipids do not only interfere with
a good chromatographic separation, they also ionize very efﬁ-
ciently in electrospray ionization mass spectrometry, and hence
may  suppress signals from other analytes [14,15]. To obtain a
comprehensive metabolic picture it is an advantage to remove
phospholipids before a generic LC–MS analysis. For the present
investigation we suggest that chromatographic performance will
be improved by a fractionation of the remaining polar and non-
polar substances in two sub-fractions.
The objective of the present investigation was to develop a ‘fast
and easy method’ that includes a fractionation of the plasma prior
to liquid chromatography–mass spectrometry (LC–MS) analysis in
order to obtain good chromatographic performances for a wide
range of different compounds. The fractionation method is based
on Tulipani et al. [14] but developed further, to obtain valid data for
phospholipids, non-polar and polar compounds in plasma. The efﬁ-
cacy of the method for toxicological investigations was tested by
use of samples from rats administered the environmental pollutant
perﬂuorononanoic acid, currently observed in increased concentra-
tions in human plasma.
2. Materials and methods
2.1. Chemicals
All aqueous solutions were prepared using ultrapure water
obtained from a Millipore Milli-Q Gradient A10 system (Mil-
lipore, Bedford, MA). HPLC MS  grade methanol, isopropanol,
25% ammonium hydroxide, formic acid, Bergamottin (98%),
glabrindin (98%), bisphenol A (99.5%), butyl paraben (99%)
and 4-methylbenzylidene camphor (98%) were obtained from
Sigma–Aldrich (St. Louis, MO). LiChroSolv LC–MS grade acetonitrile
was obtained from Merck (Darmstadt, Germany). Dibutylphtalate
(96%), bis(2-ethylhexyl)phthalate (99%), octyl methoxycinnamate
(98%), dichlorodiphenyldichloroethylene (99%), epoxyconazole
(99%), linuron (99.7%), prochloraz (98%) and vinclozolin (99.5%)
were purchased from VWR, Bie & Berntsen, Herlev, Denmark.
2.2. Plasma extraction
100 l plasma sample (stored at −80 ◦C prior to analysis) was
added to an Eppendorpf vial containing 300 l ice cold (−20 ◦C) ace-
tonitrile with 2% formic acid. The mixture was incubated at −20 ◦C
for 20 min  in order to facilitate protein precipitation. After a cen-
trifugation at 10,000 × g for 7 min  at 4 ◦C (Ole Dich Instrument mak-
ers, Denmark), the supernatant was either transferred to an HPLC
vial (protein precipitation only procedure) and analyzed by LC–MS
or transferred to an SPE cartridge (30 mg  Hybrid SPE Phospholipid
column Supelco, Sigma–Aldrich, St. Louis, MO)  conditioned with
acetonitrile in order to sub-fractionate the sample prior to LC–MS.
The SPE column was  ﬁrst eluted by the addition of 300 l of 1%
formic acid in acetonitrile, and the eluate was  collected in a vial and
evaporated to dryness at 50 ◦C using a gentle stream of nitrogen. The
dry residue was then extracted by adding 200 l of heptane. The
heptane fraction was  then transferred to a clean vial. The residue
was then extracted by adding 200 l of methanol (polar fraction).
The heptane fraction was  evaporated at 50 ◦C using a gentle stream
of nitrogen. The dry residues of the heptane fraction was  dissolved
in 200 l of 50:50 (acetonitrile:isopropanol) (lipid fraction).
The hybrid SPE column was eluted by 300 l of 10% ammonium
hydroxide in methanol, in order to elute the phospholipids. The
phospholipid fraction was diluted with 200 l Milli-Q water and
500 l of methanol.
The three fractions obtained from each plasma sample were: (1)
a phospholipid fraction, (2) a lipid fraction and (3) a polar fraction.
The phospholipid fraction and the lipid fraction were analyzed by a
hydrophobic LC procedure and the polar fraction was analyzed by
a hydrophilic LC procedure (described in Section 2.4). The fraction-
ation lasted 8 h for 82 samples corresponding to 6 min  per sample.
The fractions were stored at −20 ◦C between the analyses. No degra-
dation was  observed by re-analysis of the sample after two weeks
storage at −20 ◦C.
2.3. Animal study
Male Wistar rats, six weeks of age were purchased and housed as
previously described [16]. Animals were divided into eight groups
with 8–10 animals in each group. The animals were administered
the following substances/mixtures by oral gavage:
(1) Vehicle (corn oil in a volume of 1 mL/100 g of body weight
(bw)); (2) perﬂuorononanoic acid (PFNA) at doses of 12.5 g/kg
bw/day; (3) 12.5 g/kg bw/day PFNA and a mixture of 14 chemicals
(Mix) (the content of the mixture is described below); and (4) Mix
alone.
The Mix  consisted of: Bergamottin 200 g/kg bw/day, glabridin
300 g/kg bw/day, bisphenol A 10 g/kg bw/day, butyl paraben
520 g/kg bw/day, dibutylphtalate (DBP) 60 g/kg bw/day,
bis(2-ethylhexyl)phthalate (DEHP) 90 g/kg bw/day,
4-methylbenzylidene camphor (4-MBC) 380 g/kg bw/day, octyl
methoxycinnamate (OMC), 680 g/kg bw/day dichlorodipheny-
ldichloroethylene (DDE), 6 g/kg bw/day, epoxiconazole 50 g/kg
bw/day, linuron 4 g/kg bw/day, prochloraz 60 g/kg bw/day,
procymidone 90 g/kg bw/day and vinclozolin 50 g/kg bw/day.
The total dose of the mixture was  2500 g/kg bw/day.
After a treatment period of 14 days, the animals were anaes-
thetized in CO2/O2, euthanized by decapitation and a blood sample
was collected in heparinized plastic tubes from the neck wound.
Plasma was isolated as the supernatant following centrifugation at
1000 × g, 4 ◦C for 10 min.
2.4. LC-qTOF MS
Liquid chromatography was conducted on a Dionex Ultimate
3000 RS (Thermo Scientiﬁc, CA) with an Ascentis Express C8
(100 mm × 2.11 mm,  2.7 m)  column (Supleco, St. Louis, MO). Two
other HPLC columns were tested and found not to be suitable
for the purpose: a Kinetex PFP column, 100 mm × 2.1 mm,  2.6 m
(Phenomenex, Torance, CA) and an Ascentis Express cyano propyl
column 100 mm × 2.1 mm,  2.7 m (Supleco, St. Louis, MO). The sol-
vent system consisted of (A) 5 mM ammonium hydroxide + 0.1%
formic acid in water and (B) 0.1% formic acid in acetonitrile. Two
different gradient systems were used:
The hydrophobic LC procedure: the solvent composition was iso-
cratic 70% B for 1 min, 75% B at 3 min, 100% B at 8 min and isocratic
100% B for 2 min, followed by re-equilibration at 70% for additional
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2 min. Column temperature was 50 ◦C. Backpressure of the column
at 75% acetonitrile was 161 bar.
The hydrophilic LC procedure:  the solvent composition was  0% B
for 1 min, 5% B at 3 min  followed by 100% B at 10 min, then isocratic
at 100% B for 2 min  followed by re-equilibration at 0% B for 2 min.
Column temperature was 40 ◦C. The backpressure of the column
was at the highest (15% acetonitrile) 190 bar.
The ﬂow was 0.3 ml/min and the injection volume for the
hydrophilic LC procedure and the hydrophobic LC procedure was
3 and 1 l, respectively. The LC system was connected to a Bruker
Daltonics, maXis qTOF mass spectrometer equipped with an elec-
trospray ion source (Bruker Daltonics, Bremen, Germany). The ion
source settings were as follows: nitrogen was  used as nebulizer,
drying and collision gas, the nebulizer pressure was  two  bars, the
drying gas ﬂow was 10 l/min, the dry gas temperature was  200 ◦C,
the capillary voltage was  4500 V. The scan range was  set to be from
50 to 1100 m/z  in both positive and negative ionization modes,
with an acquisition rate of 2 Hz. Sodium formate dissolved in 50%
2-propanol was introduced into the ion source in a 0.2–0.4 min
time segment and used for internal calibration of the data ﬁles.
Hexakis(1H,1H,2H-perﬂuoroethoxy)phosphazene was  used as lock
mass calibrant. Auto MS/MS  was performed on one sample from
each group and on reference samples, if available, in order to facil-
itate the identiﬁcation process.
2.5. Chemometric analysis
Data was analyzed with proﬁle analysis 2.1 (Bruker Dalton-
ics, Bremen, Germany) using the Find Molecular Features (FMF)
algorithm, including time alignment, quantile normalization and a
pareto scaling model. Data were subsequently analyzed by partial
least square discriminant analysis (PLS-DA), which is a method used
for interpretation and visualization of proﬁling data. PLS-DA is a
supervised method and describes the highest co-variation between
the metabolite data and the response variable [17].
2.6. Identiﬁcation of compounds
Identiﬁcation of the compounds, differing signiﬁcantly between
groups, was conducted by accurate mass search in the human
metabolome database (www.hmdb.ca), the Metlin database
(www.metlin.scripps.edu) and in the Lipidmaps database
(www.lipidmap.org). Identiﬁcation was based on comparison
of data on retention times, MS  and MS/MS  spectra with data
obtained from reference compounds or based on comparison of
data on MS  and MS/MS  spectra with similar data from the human
metabolome database and Lipidmaps.
3. Results
3.1. Method development
Plasma samples were analyzed by LC–MS after protein precip-
itation (data not shown) or fractionated into a polar, a non-polar
and a phospholipid fraction using a hybrid SPE column followed
by LC–MS analysis of each sub-fraction. Fig. 1 shows the ﬂow of
the sub-fractionation approach giving three sub-fractions: phos-
pholipid, lipid and polar (Fig. 1).
Three different HPLC columns were tested for separation efﬁ-
ciency of the three sub-fractions of the plasma samples, a Kinetex
PFP column (Phenomenex, Torance, CA), an Ascentis Express
cyanopropyl column (Supleco, St. Louis, MO) and an Ascentis
Express C8 column (Supelco, St. Louis, MO). Severe bleeding was
observed from the PFP column and further analyses on this col-
umn  was not attempted (data not shown); the cyanopropyl column
gave a satisfactory chromatography and separation of the lipid and
Fig. 1. Flow diagram of the SPE method. Proteins were precipitated by adding 300 l
acetonitrile with 1% formic acid followed by SPE clean-up of the supernatant in three
sub-fractions.
polar fractions, but performed poorly regarding separation of phos-
pholipids (data not shown). The C8 column resulted in satisfactory
chromatographic resolution of all three different classes of com-
pounds (Fig. 2). Examination of the data ﬁles using the molecular
feature extraction algorithm resulted in 1792 molecular features
from the LC–MS analysis of the protein precipitated sample. Molec-
ular feature extraction on the data ﬁles from LC–MS analyses of
polar, lipid and phospholipid sub-samples resulted in 3172, 804
and 258 molecular features, respectively. A limited number of the
compounds were observed in both the lipid and the polar fraction.
The sub-fractionation thus resulted in the extraction of totally 4234
molecular features compared to 1792 features using only protein
precipitation.
The chromatogram (Fig. 2a) shows the separation of the
phospholipid fraction which eluted in two groups of primar-
ily phosphocholine (PC) compounds. The ﬁrst group of peaks
eluting between 60 and 120 s were low molecular weight lyso-
phosphotidylcholine containing one fatty acid chain e.g. PC (20:0)
and PC (18:0) while the compounds eluting between 340 and 470 s
were high molecular weight compounds containing two  fatty acid
chains e.g. phosphotidylcholine (20:4/16:0). The phospholipid frac-
tion molecular features were identiﬁed by an accurate mass search
in HMDB, followed by MS/MS  examination of the chromatographic
peak. Each of the phosphotidylcholine compounds had a character-
istic 184.073 m/z fragment.
The chromatogram of the lipid fraction (Fig. 2b) contained the
neutral lipids such as tri, di- and monoacylglycerols. The small
peaks in the beginning of the chromatogram were relatively polar
lipids, while the sharp peaks around 400–500 s were one chained
lipids e.g. monoacylglycerols (MGs). The broader peaks between
500 and 700 s were neutral lipids with two  and three chains e.g.
di- and triglycerides. The lipids were identiﬁed by accurate mass
search and comparison of MSMS  pattern with the in silico MS/MS
pattern from Lipidmaps.
The chromatogram of the polar fraction (Fig. 2c) contained small
organic compounds, hormones such as cortisone and hydroxyl
cortisone, but also monoacylglycerol (16:0) and monoacylglycerol
(18:0). The peaks eluting around 300–400 s were low molecular
weight compounds with masses ranging from 300 to 500 m/z e.g.
corticosterone, while MG (18:0) was  present at a retention time
of 630 s. MG (16:0) and MG  (18:0) were identiﬁed based on exact
mass and by comparing MS/MS  data with data from a standard.
The presence of a double bond in the acyl chain of the fatty acid
reduced the retention time by approximately 30 s as compared to
the retention time of the saturated monoacylglycerols.
The repeatability of the LC–MS method was investigated by
multiple injections of a single sample on different time points on
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Fig. 2. Three base peak chromatograms from a sub-fractionated control plasma sample: (a) phospholipid fraction, (b) lipid fraction and (c) polar fraction. The (a) and (b)
were  analyzed by the hydrophobic gradient system (Section 2) while (c) was analyzed by the hydrophilic gradient system (Section 2).
Table 1
The differences in retention times, in peak intensity and the in mass deviation of
the  three sub-fractions after analysis of nine injections of a single sample on two
different days (n = 18). The values are based on three peaks eluting to different time
in  the chromatogram (data shown in supplementary materials).
Fraction Time (s) Intensity (%) m/z (ppm)
Phospholipids <1 2.9–10.4 1.4–1.6
Lipid <1 6.4–11.1 3.1–3.4
Polar <1 3.4–8.3 1.0–2.4
a single day as well as on different days. These chromatography
data showed a high degree of reproducibility (data not shown). The
retention time stability was within 1 s for peaks in all three fractions
and the mass accuracy and peak intensity only exhibited minor
variations as displayed in Table 1. To evaluate the repeatability of
the SPE method the intensity of three selected peaks from each of
the sub-fractions was determined in the control animals (n = 10).
The deviations (S.D.) were 21.1%, 33.1%, and 29.5% for the phos-
pholipid, lipid and polar fraction respectively. These deviations will
also include the variation between the animals in addition to the
variation SPE clean-up method.
The repeatability of the method was further investigated by
spiking of plasma samples with 12 different reference compounds,
i.e. three phospholipids, three lipids and 6 polar compounds. All
reference compounds were detected in the expected fractions; the
three phospholipids in the phospholipid fraction, the three neutral
lipids in the lipid fraction and the six polar compounds in the polar
fraction. The capacity of the Hybrid SPE cartridges was  exceeded
when the sample was spiked with high concentration of phospho-
lipids (0.3 mg/ml) in that case the sample size was  reduced.
3.2. Application of the method on an animal study
To test the performance of our analytical procedure, we ana-
lyzed plasma samples from an animal study designed to investigate
the effect on mammalian physiology of perﬂuorononanoic acid
(PFNA) administered in combination with a mix  of 14 chemicals
(Mix) [18].
Partial least squares discriminant analysis (PLS-DA) of LC–MS
data from the polar fraction and the phospholipid fraction of the
plasma sample is shown in Fig. 3. The two plots were used to illus-
trate the sensitivity of the method (Fig. 3).
The PLSDA score plot (Fig. 3a) of the polar fraction showed that
animals dosed with PFNA plus mix  clustered close to animals dosed
with mix alone, however distanced from animals dosed with PFNA
and controls suggesting that dosing with mix  clearly affects the
clustering results. Control animals and animals dosed with PFNA
alone were located more scattered in the score plot. The score plot,
Fig. 3b, of the phospholipid fraction also showed a tendency to clus-
tering of the animals dosed with PFNA plus Mix  and animals dosed
with Mix  alone and separated from the clustering of control animals
and animals dosed PFNA alone.
4. Discussion
4.1. Solid phase extraction vs. protein precipitation
The ﬁrst attempt on sample preparation of plasma samples was
based on a paper by Souverain et al., using protein precipitation
with an acidiﬁed organic solvent, in this case acetonitrile, followed
by LC–MS [13]. Chromatographic analysis of these extracts showed
poor chromatographic separation with high signals from the
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Fig. 3. PLS-DA score plots of data from the polar and the phospholipid fraction. Score
plot  of the polar fraction display a clustering of Mix  and PFNA low + Mix  distant
from control and PFNA low (a). The score plot of the phospholipid fraction display a
clustering of Mix  and PFNA low + Mix  separating from PFNA low and control (b).
phospholipids causing ion suppression in the mass spectrometer.
This resulted in a loss of low intensity ions with similar retention
times (data not shown). As a result of these observations, it was
concluded that a fractionation of the samples was  needed. Hence,
a method based on Tulipani et al. [14] was implemented in which a
solid phase extraction (SPE) column was used to remove the phos-
pholipids. However, as changes in the phospholipid pattern gives
important information on mammalian physiology the method was
extended to include these. Therefore, the extraction/SPE procedure
was adjusted. First the phospholipids were isolated. Then the elu-
ate was chemically separated into two fractions by ﬁrst extracting
with heptane to isolate a lipid fraction and then extracting with
methanol to isolate the polar compounds. As discussed by Tulipani
et al. [14] the removal of phospholipid reduces the ion suppres-
sion in the mass spectrometry, but at the cost of a reduced number
of identiﬁed molecular features. However, by eluting the phos-
pholipids from the SPE column information from this group of
compounds was retained.
Metabolic information on the phospholipids is important in
physiological studies [7], as exempliﬁed by Kim et al. [19] who
showed that phospholipids were affected by hepatic steatosis. Fur-
thermore, phospholipids are believed to have signaling roles in the
plasma [20] and inside cells. Therefore, changes in phospholipid
levels may  provide information on speciﬁc mechanisms and effects
in mammals. From this perspective it was important to have these
compounds included in the analysis.
The total number of molecular features extracted from the
chromatograms after the sub-fractionation approach were 4234.
Using only protein precipitation as described in Souverain et al.
1792 molecular features were extracted from the chromatogram
[13]. The 4234 molecular feature obtained after sub-fractionation
will include some compounds twice as these are equilibrium dis-
tributed between the heptane and the methanol extraction solvent.
The fractionation approach increases the amount of information
obtained on the plasma metabolome. Furthermore, the separa-
tion in three fractions yielded more chromatographic peaks and
increased the sensitivity as the ion suppression was  reduced. It
was found that a C8 column was the best compromise to give a
good chromatographic separation of all three sub-fractions: polar,
lipid and phospholipid. By using a single analytical column all three
sub-fractions could be analyzed in one sequence saving time and
reducing cost of the analyses.
Although to achieve good chromatographic separation two gra-
dient systems have to be used. The lipid and phospholipid fraction
required a gradient starting at 75% organic solvent to prevent pre-
cipitation on the column as these compounds are highly non-polar.
On the other hand, the polar fraction contains more water soluble
compounds; therefore we started the gradient as low as 0% organic.
In spite of the gradient starting at 0% organic, the chromatograms
showed only few early eluting peaks. This was  most likely due to
poor ionization of the polar compounds in the electrospray ioniza-
tion (ESI) interphase. Generally, it would be preferable to analyze
all the metabolites using a single chromatographic system. How-
ever, this is not possible with such a wide range of metabolites [21].
The repeatability was  evaluated using data from the control group
and the deviations (S.D.) were determined to be 21.1%, 33.1%, and
29.5% for the phospholipid, lipid and polar fraction respectively.
It was found that the HPLC system was  reproducible for all three
sub-fractions with a retention time deviation below 1 s. Though lit-
tle retention time change was  observed it may  still be possible to
improve the peak shape for the non-polar compounds. Choi et al.
suggested that addition of 50% isopropanol to the organic solvent
of the HPLC system yielded sharper peaks, at least for the phos-
pholipids [22]. However, this was not implemented in the current
study. The mass deviation was  found to be between 1 and 3.4 ppm
which is more than suitable for identiﬁcation of the compounds
present in the plasma metabolome.
4.2. Application of the method on plasma samples from an
animal study
The method was  established to provide maximum information
on the plasma metabolome from animal experiments designed
to study the effects of dosing with chemicals. The HPLC analyses
showed good chromatographic separation for each of the three
sub-fractions opening the possibility to identify critical compo-
nents based on the exact mass. Using a PLS-DA analysis it was
possible to detect differences in the metabolome even a low expo-
sure levels, as shown by the clustering in the score plot, Fig. 3. The
PLS-DA plot of both the polar and phospholipid fraction showed
a clustering of PFNA Mix  and Mix  dosed animals, distanced from
PFNA and control animals. This suggests that the change of the
metabolome is primarily driven by dosing Mix  rather than PFNA.
The Mix  was  administered to the animals at a dose comparable to
high end human exposure revealing the applicability of the analyt-
ical method.
5. Conclusion
We developed a method to improve sub-fractionate plasma
samples into a phospholipid, a lipid and a polar sub-samples. These
were analyzed by two  different LC gradient systems combined
with high resolution mass spectrometry. This method was more
time consuming than a protein precipitation approach, but the
improved chromatographic separation and reduced ion suppres-
sion compared to protein precipitation providing more data from
each plasma sample. Furthermore, the number of molecular fea-
tures detected increased from 1972 to 4234. The sub-fractionation
divided the samples into 3 different chemical classes and knowl-
edge of the chemical identity of the metabolites polar, lipids
and phospholipids is an advantage in the identiﬁcation of the
metabolites. The method was demonstrated to exhibit repeat-
able chromatographic results for each of the three fractions
with a time shift of less than 1 s and a mass deviation below
3.4 ppm. Furthermore, the injection on two separate days showed
similar peak intensity and chromatography, this shows that sep-
aration and puriﬁcation by the SPE column is reproducible. The
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usefulness of the method was demonstrated by the detection of
overall differences in the metabolome of animals administered a
dose comparable with human exposure of the endocrine disruptor
perﬂuorononanoic acid.
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Paper II: Perfluorononanoic acid in combination with 14 chemicals exerts low-dose mixture 
effects in rats 
 
Archives of Toxicology 
 
Aim: A toxicological study aimed at investigating whether adverse mixture effects do not occur at doses 
approaching high-end human exposure levels. 
 
Result: Indication of a toxicokinetic interaction was found, as simultaneous exposure to PFNA and the Mix 
caused a 2.8-fold increase in plasma PFNA concentrations at Low PFNA. Corticosterone, the stress 
hormone of rats was increased with PFNA alone; while androstenedione, testosterone and 
dihydrotestosterone were significantly increased in by 0.0125 mg/kg bw/day PFNA with mix and not low 
PFNA alone.       
 
Conclusion: PFNA affects the steroid hormone synthesis in rats. Corticosterone, was affected by PFNA 
while for androstenedione, testosterone and dihydrotestosterone the induced effect was caused by the 
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This combined with affected ACTH plasma concentrations 
and down-regulation of 11β HSD mRNA in livers indicates 
a disturbed pituitary-adrenal axis. In conclusion, our data 
suggest that mixtures of environmental chemicals at doses 
approaching high-end human exposure levels can cause a 
hormonal imbalance and disturb steroid hormones and their 
regulation. These effects may be non-monotonic and were 
observed at low doses. Whether this reflects a more general 
phenomenon that should be taken into consideration when 
predicting human mixture effects or represents a rarer phe-
nomenon remains to be shown.
Keywords Mixture toxicology · Steroidogenesis · 
Testosterone · Corticosterone · Pituitary hormones · 
Perfluorononanoic acid (PFNA)
Introduction
 Humans are concomitantly exposed to several chemi-
cals that can exert mixture effects. At doses close to no-
observed adverse effect levels or higher, chemicals usu-
ally act additively in experimental studies (Kortenkamp 
2014). However, we are lacking knowledge on the impor-
tance of exposure to complex real-world mixtures at more 
relevant human exposure levels. Only few in vivo studies 
performed with low-human relevant exposure levels have 
been reported. Wade et al. investigated a mixture contain-
ing 18 persistent contaminants at a dose of 1x the estimated 
safe level. This dose was based on the minimum risk lev-
els (MRLs) or the tolerable daily intakes and was dosed 
orally to male rats for 70 days. At this dose, increased 
natural killer cell lytic activity was observed (Wade et al. 
2002). Crofton et al. investigated whether deviations from 
additivity could be detected at low doses. They studied 
Abstract Humans are simultaneously exposed to sev-
eral chemicals that act jointly to induce mixture effects. At 
doses close to or higher than no-observed adverse effect 
levels, chemicals usually act additively in experimental 
studies. However, we are lacking knowledge on the impor-
tance of exposure to complex real-world mixtures at more 
relevant human exposure levels. We hypothesised that 
adverse mixture effects occur at doses approaching high-
end human exposure levels. A mixture (Mix) of 14 chemi-
cals at a combined dose of 2.5 mg/kg bw/day was tested in 
combination with perfluorononanoic acid (PFNA) at doses 
of 0.0125 (Low PFNA), 0.25 (Mid PFNA) and 5 (High 
PFNA) mg/kg bw/day by oral administration for 14 days 
in juvenile male rats. Indication of a toxicokinetic interac-
tion was found, as simultaneous exposure to PFNA and the 
Mix caused a 2.8-fold increase in plasma PFNA concentra-
tions at Low PFNA. An increase in testosterone and dihy-
drotestosterone plasma concentrations was observed for 
Low PFNA + Mix. This effect was considered non-mono-
tonic, as higher doses did not cause this effect. Reduced 
LH plasma concentrations together with increased andro-
gen concentrations indicate a disturbed pituitary-testis axis 
caused by the 15-chemical mixture. Low PFNA by itself 
increased the corticosterone plasma concentration, an effect 
which was normalised after simultaneous exposure to Mix. 
N. Hadrup · N. L. Hansen · L. O. Berthelsen · K. Kongsbak · 
J. Boberg · M. Dybdahl · U. Hass · A. M. Vinggaard (*) 
Division of Toxicology and Risk Assessment, National Food 
Institute, Technical University of Denmark, Mørkhøj Bygade 19, 
2860 Søborg, Denmark
e-mail: annv@food.dtu.dk
M. Pedersen · K. Skov · H. Frandsen 
Division of Food Chemistry, National Food Institute, Technical 
University of Denmark, Søborg, Denmark
 Arch Toxicol
1 3
thyroid disruptors in doses ranging from environmental 
background to 100x environmental background in rats for 
effects on serum total thyroxine. No deviation from additiv-
ity was found at the lowest doses (<0.2 mg/kg bw/day), but 
at higher doses (>0.67 mg/kg bw/day), synergy was found 
(Crofton et al. 2005). Stanko et al. found an increase in 
prostate inflammation with 0.09 mg/kg bw of an atrazine 
metabolite mixture following prenatal exposure of male 
rats (Stanko et al. 2010). Merhi et al. exposed mice to a 
mixture of six pesticides at levels derived from the human 
acceptable daily intake levels. Changes in blood cell counts 
were observed (Merhi et al. 2010). Demur et al. (2013) 
found dietary exposure to a low atrazine, endosulfan and 
chlorpyrifos mixture dose (25, 30 and 50 μg/kg food cor-
responding to approximately 4, 5, and 8 μg/bw/day) to 
decrease the red blood cell count and haemoglobin levels.
To further address exposure to human relevant mixtures 
of chemicals, we designed an experiment to test whether 
chemicals in food approaching high-end human exposure 
cause adverse mixture effects. We hypothesised that effects 
could occur via toxicokinetic metabolism effects compa-
rable to those described for food–drug interactions, e.g., 
as has been described for grapefruit juice and Ca2+ chan-
nel blockers (Bailey et al. 1989). For our investigation, we 
used steroid hormone metabolism as an effect measure. 
Steroid hormones are involved in multiple important male 
developmental processes and thus alterations in its plasma 
concentration may potentially be accompanied by adverse 
effects. We designed an experiment in which a single chemi-
cal known to affect the steroid hormone testosterone on 
its own was tested at increasing doses in the presence or 
absence of a fixed dose of a ‘background’ chemical mixture 
(Mix). On basis of its human toxicological importance and 
on basis of its ability to increase testosterone at a dose of 
1 mg/kg bw/day to rats (Feng et al. 2009), we selected the 
fluorosurfactant perfluorononanoic acid (PFNA) as the vari-
ably dosed chemical in this investigation. We exposed the 
rats to a fixed background dose of 14 chemicals—12 envi-
ronmental chemicals representing typical endocrine disrupt-
ing chemicals and two food ingredients. For the design of 
this Mix, we took advantage of the fact that testosterone is 
metabolized in the liver by cytochrome P450 3A4 (CYP3A4 
homologous to CYP3A23/3A1 in rat) and CYP2C9 (homol-
ogous to CYP2C11 in rat) (Cheng and Schenkman 1983; 
Guengerich 1999; Kenworthy et al. 1999; Martignoni et al. 
2006). CYP3A4 and CYP2C9 are inhibited by the grapefruit 
constituent bergamottin and the liquorice constituent glabri-
din (Bailey et al. 2003; Foti and Wahlstrom 2008; Kent et al. 
2002; Lim et al. 2005; Tassaneeyakul et al. 2000; Uesawa 
and Mohri 2006; Wen et al. 2002). These substances were 
included in the Mix along with twelve food contaminants 
(described in Table 2), each reported to exert endocrine dis-
rupting effects (Christiansen et al. 2012). The doses of these 
twelve contaminants were selected to reflect a high-end 
exposure level to the European human population. Thus, 
to test whether chemicals in food at human relevant doses 
caused adverse mixture effects, we administered PFNA at 
doses 0.0125 (Low PFNA), 0.25 (Mid PFNA) and 5 (High 
PFNA) mg/kg bw/day in the presence or absence of Mix at 
a total dose of 2.5 mg/kg bw/day (Table 2) to male rats for 
14 days. Steroid hormone plasma concentrations, pituitary 
hormone levels as well as classical toxicological parameters 
and mechanistic markers in testis, liver, adipose tissue and 
kidney were investigated.
Methods
Dose selection and chemicals
We aimed at selecting a PFNA dose to cover human internal 
exposure of the combined exposure to perfluorinated com-
pounds such as PFOA, PFOS and PFNA. Lau et al. (2007) 
gathered human exposure data from a large number of stud-
ies. The PFOS mean plasma concentrations in single studies 
were 10–73 ng/mL (see Table 1 for an overview of the data 
in table format), for PFOA the values were 2.1–354 ng/mL 
(second highest value was 41 ng/mL), and for PFNA 
0.8–2.2 ng/mL. This gives a possibility of a combined 
human exposure to these three perfluorinated compounds of 
13–429 ng/mL (or 13–117 ng/mL if only the second highest 
PFOA value is used) (Lau et al. 2007). For comparison, the 
high-end exposure (95th percentile) in the American popu-
lation as determined by the National Health and Nutrition 
Examination Survey (NHANES) is 67.6 ng/mL for PFNA, 
PFOA and PFOS combined (CDC 2009). The PFNA dose 
employed in the present investigation was chosen on basis 
of a study by Tatum Gibbs et al. (Tatum-Gibbs et al. 2011) 
in which an oral dose of 1 mg/kg bw to rats gave a serum 
concentration of approximately 10,000 ng/mL. From that 
we chose a dose of 0.0125 mg/kg bw/day for a 14-day inves-
tigation (Abbreviated: Low PFNA), predicted giving rise to 
a PFNA plasma concentration of 125 ng/mL. For a medium- 
and high-dose level, we included 0.25 (Mid PFNA) and 5 
(High PFNA) mg/kg bw/day.
We aimed to administer bergamottin in an amount cor-
responding to the content of one grapefruit. A grapefruit 
contains 25 μM bergamottin (Bailey et al. 2003) corre-
sponding to 1,700 μg bergamottin per grapefruit. Adjust-
ing according to body surface area as described (Reagan-
Shaw et al. 2008), a rat dose corresponding to a human 
intake of 100 mL grapefruit juice was calculated to be 0.2 
mg/kg bw/day. For glabridin, an amount corresponding to 
an intake of 100-g liquorice candy per day was determined 
in the following way. The extraction of glycyrrhizic acid 
and glabridin from Chinese (raw) liquorice gives 2.39 mg/g 
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glycyrrhizic acid and 0.92 mg/g glabridin (Tian et al. 
2008). This taken together with a reported 150 mg glycyr-
rhizic acid in 100 g of sweet liquorice (candy) (Sigurjons-
dottir et al. 2001), suggests an amount of 58 mg glabridin 
in 100 g of sweet liquorice, suggesting that a 70-kg per-
son takes in 0.8 mg/kg bw/day of glabridin when ingest-
ing 100 g of sweet liquorice. This suggests—by a body 
surface area conversion (Reagan-Shaw et al. 2008)—that 
we should give a dose of 4 mg/kg bw/day to rats. How-
ever, Furhman et al. previously reported that a glabridin 
dose to rats corresponding to the selected human intake 
was 0.3 mg/kg bw/day (Fuhrman et al. 1997) and to take 
a conservative approach we settled for this dose. Regard-
ing the remaining chemicals in the mixture, a previously 
designed mixture based on exposure levels of the European 
human population was used (Christiansen et al. 2012; Had-
rup et al. 2013). The dose reported to be a realistic ‘high-
end human exposure level’ (Christiansen et al. 2012) was 
0.32 mg/kg bw/day. By conversion to rat dose via body sur-
face area, this yields 2 mg/kg bw/day. The chemicals and 
their ratio in Mix are described in Table 2. Chemicals were 
purchased as follows: Bergamottin, glabridin, bisphenol A, 
butyl paraben and 4-methylbenzylidene camphor (4-MBC) 
were purchased from Sigma-Aldrich, Brøndby, Denmark. 
Dibutylphthalate (DBP), bis(2-ethylhexyl)phthalate (DEHP), 
4-MBC, 2-ethylhexyl-4-methoxycinnamate (OMC), dichlo-
rodiphenyldichloroethylene (DDE), epoxiconazole, linuron, 
prochloraz, procymidone and vinclozolin were purchased 
from VWR, Bie & Berntsen, Herlev, Denmark.
Animals and pathology
Male Wistar Hannover Galas rats, 6 weeks of age with 
specific pathogen-free health status, were obtained from 
Taconic M&B (Lille Skensved, Denmark) and allowed to 
acclimatise for 1 week. The animals were housed two per 
cage (Macrolon, Buguggiate, Italy) with light on from 7 
a.m. to 7 p.m. Room temperature and relative humidity were 
22 ± 1 °C and 55 ± 5 %, respectively. Rats were given ad 
libitum access to citric acid acidified tap water and standard 
diet (prod. no. 1324 Altromin, Brogården, Gentofte, Den-
mark). The animals were administered test substances once 
a day orally by gavage for 14 days with corn oil (VWR—
Bie & Berntsen, Herlev, Denmark) as vehicle. The dosing 
volume was 1 mL/100 g of body weight (bw). In total, 70 
male rats were randomly placed into eight groups, i.e., vehi-
cle control (n = 10), PFNA 0.0125 mg/kg/day (Low PFNA) 
(n = 10), PFNA 0.25 mg/kg/day (Mid PFNA) (n = 8), 
PFNA 5 mg/kg/day (High PFNA) (n = 8), Mix + PFNA 
0.0125 mg/kg/day (Low PFNA + Mix) (n = 10), 
Mix + PFNA 0.25 mg/kg/day (Mid PFNA + Mix) (n = 8), 
Mix + PFNA 5 mg/kg/day (High PFNA + Mix) (n = 8), 
Mix (n = 8). Animals were evaluated clinically and sub-
jected to necropsy in four different sets each starting 1 day 
after the prior. Each set comprised animals of each dosing 
group. For the euthanisation, the animals were anaesthe-
tised in CO2/O2 and decapitated. Neck blood was collected 
in heparinised tubes, and plasma was isolated by centrifu-
gation at 1,000×g, 4 °C for 10 min. Plasma was stored at 
−80 °C. To avoid bias, e.g., due to stress in animals, the 
sectioning of animals were randomised according to groups. 
Animals were given the last dose in the time span of 1 h and 
15 min to 1 h and 45 min before euthanisation. Body weight 
and organ weights (liver, kidney, testes) were recorded, and 
livers were fixed and processed for histopathological exami-
nation as previously described (Hadrup et al. 2012). Liver 
haematoxylin and eosin stained sections were evaluated by 
a pathologist blinded to treatment groups. Changes were 
described qualitatively, and in addition, selected parameters 
were scored in the following manner: Cell borders (score 
Table 1  Comparison of reported human perfluorinated compound levels with measured levels in rats
NHANES National Health and Nutrition Examination Survey, PFC perfluorinated compound
Reported human exposure levels to PFCs (ng/mL)
NHANES (geometric means)  
(CDC 2009)
NHANES 95th percentile  
(CDC 2009)
Mean value ranges from literature 
reviewed in Lau et al. (2007)
PFNA in serum 1.0 3.2 0.8–2.2 (n = 6)
PFOA in serum 4.0 9.8 2.1–354 (n = 9)
PFOS in serum 20.7 54.6 10–73.2 (n = 11)
Total PFC in serum 25.7 67.6 32.8–429
Measured rat exposure levels (ng/mL) Comparison human versus rat
Measured PFNA plasma conc. in rats at low dose 396 0.9- to 15-fold human exposure to total PFC
Sixfold human 95th percentile NHANES exposure
Measured PFNA plasma conc. in rats at mid dose 29,950 70- to 1,200-fold human exposure to total PFC
440-fold human 95th percentile NHANES exposure
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0 = not visible, score 1 = not clear, score 2 = clear) and 
cell size (score 1 = small/normal, score 2 = slight increase, 
score 3 = marked increase).
PFNA plasma concentration measurement
For each PFNA dose, plasma concentrations were meas-
ured. To 20 µl plasma, 60 µl ice-cold acetonitrile was added. 
The sample was incubated at −20 °C for 20 min and centri-
fuged at 10,000×g for 7 min. The supernatant was used for 
analysis. A matrix-assisted standard curve was established 
using PFNA and a standard plasma sample (Precinom U, 
Roche Diagnostics, Hvidovre, Denmark). Samples from 
the 0.0125 mg/kg bw/day administration group were not 
diluted, 0.25 mg/kg bw/day samples were diluted tenfold, 
and the 5 mg/kg bw/day samples were diluted 100-fold. 
The analysis was conducted using a high-resolution maxis 
qTOF instrument (Bruker Daltonics, Bremen, Germany) 
coupled to an Agilent 1200 (Agilent Technologies, USA) 
with a Supelco C8 (100 × 2.0 mm, 1.7 µm) run in nega-
tive mode ionisation with a mass scan from 50 to 800 m/z. 
The gradient was 0 % B, 0 min—5 % B, 2 min—100 % 
B, 10 min—100 % B, 12 min—0 % B, 12.1 min—0 % B, 
14 min. To test the repeatability of the method, the Low 
PFNA groups were analysed on two separate days. These 
measurements gave similar results. In order to investigate 
the metabolism of PFNA, a targeted approach was used 
to identify possible metabolites. The metabolites searched 
for were PFNA + glucuronic acid (+176 m/z value) and 
PFNA + glycine (+75 m/z value). The targeted approach 
was conducted using the Bruker Daltonics software: Target 
Analysis (Bruker Daltonics, Bremen, Germany).
Hormone measurements
Plasma samples were added internal standards (testosterone-
d2 and methyltestosterone-d3), deproteinised with addition 
of acetonitrile and ultracentrifugation, and steroid hormones 
were extracted using a C18 end-capped solid-phase extrac-
tion cartridge (500 mg, 3 ml) (Merck, Darmstadt, Germany). 
Impurities were removed from the cartridge with deminer-
alised water followed by elution of steroid hormones from 
the cartridge with methanol. The extract was evaporated to 
dryness with nitrogen and re-suspended in 40 % acetoni-
trile. Steroid hormones were separated, detected and quan-
tified using the LC–MS/MS method previously described 
(Mortensen and Pedersen 2007). However, to accommodate 
more hormones, minor modifications were made. An Ascen-
tis Express C8 column (2.1 × 100 mm, 2.7 µm) (Supelco) 
was added to the LC system (Agilent 1100). Steroids were 
measured with an injection volume of 10 μL in ESI+ mode 
with acetonitrile and water/0.2 % formic acid as the mobile 
phases (flow rate 0.25 mL/min, gradient method). The MS 
was a Quattro Ultima Triple Quadropole Instrument (Waters 
Corp., Milford, MA, USA). For quantification, external 
calibration standards were run before and after the samples 
at levels of 0.1, 0.5, 1.0, 2.0, 5.0 and 10 ng/mL (with 4.0 
ng/mL of internal standards). The absolute recoveries of the 
hormones in plasma samples were estimated to be 42–94 %, 
based on the absolute recoveries of the internal standards in 
>30 experiments. The limit of quantification (LOQ) of each 
of the hormones in the plasma samples was estimated as the 
concentrations corresponding to six times signal-to-noise 
and was <100 pg/mL for testosterone (α- and β-isomer), 
progesterone, corticosterone and hydroxycortisol, <200 
Table 2  Fourteen chemicals in fixed ratio mixture
CAS registry number Chemical name Source/use Ratio in mixture (weight) Rat dose (mg/kg bw/day)
7380-40-7 Bergamottin Grapefruit constituent 0.08 0.2
59870-68-7 Glabridin Liquorice constituent 0.12 0.3
80-05-7 Bisphenol A Plastic additive 0.004 0.01
94-26-8 Butyl paraben Preservative 0.21 0.52
84-74-2 Dibutylphthalate (DBP) Plasticiser 0.02 0.06
117-81-7 Bis(2-ethylhexyl)phthalate (DEHP) Plasticiser 0.03 0.09
36861-47-9 4-Methylbenzylidene camphor (4-MBC) Sun filter 0.15 0.38
5466-77-3 2-Ethylhexyl-4-methoxycinnamate (OMC) Sun filter 0.27 0.68
72-55-9 Dichlorodiphenyldichloroethylene  
(p,p′-DDE)
Pesticide 0.002 0.006
133855-98-8 Epoxiconazole Pesticide 0.02 0.05
330-55-2 Linuron Pesticide 0.002 0.004
67747-09-5 Prochloraz Pesticide 0.025 0.06
32809-16-8 Procymidone Pesticide 0.035 0.09
50471-44-8 Vinclozolin Pesticide 0.021 0.05
In total 14 Chemicals 1.0 2.5
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pg/mL for androstenedione and hydroxyprogesterone, and 
<2,000 for dihydrotestosterone and hydroxytestosterone. 
Pituitary hormone plasma concentration measurements 
were done by use of the Milliplex Map Rat Pituitary Kit 
(Prod no. RPT86K, Millipore Corporation, St. Charles, 
MO, USA). This was done according to the protocol of the 
manufacturer by use of a Luminex 100 apparatus (Bio-Rad, 
Hercules, CA, USA).
Table 3  Primer/probe sets for mRNA measurements
Gene Prod no./sequence Tissues tested
Aldo–keto reductase family 1 member C1 (AKR1C1) Prod. No. Rn01487552_m1, Life Technologies Europe BV, 
Nærum, Denmark
Liver
Benzodiazepine receptor (BZRP) Forward, 5′-TGG TTC CCT TGG GTC TCT ACA CT-3′ Testes
Reverse, 5′-CAC CCC ACT GAC AAG CAT GA-3′
Probe: 5′-FAM-AAA GCC CAG CCC ATC T-MGB-3′
Cytochrome P450 (CYP) 1A1 Prod. No. Rn00487218_m1, Life Technologies Europe BV, 
Nærum, Denmark
Liver
CYP1A2 Prod. No. Rn00561082_m1, Life Technologies Europe BV, 
Nærum, Denmark
Liver
CYP2B6 Prod. No. Rn00597739_m1, Life Technologies Europe BV, 
Nærum, Denmark
Liver
CYP2C11 Prod. No. Rn01502203_m1, Life Technologies Europe BV, 
Nærum, Denmark
Liver
CYP3A23/3A1 Prod. No. Rn03062228_m1, Life Technologies Europe BV, 
Nærum, Denmark
Testes
CYP11A Forward 5′-ACG ACC TCC ATG ACT CTG CAA T-3′ Testes/adipose tissue
Reverse: 5′-CTT CAG CCC GCA GCA TCT-3′
Probe: 5′- FAM-CCT TTA TGA AAT GGC ACA CAA CTT 
GAA GGT CA-TAMRA-3′
CYP17 Forward: 5′-GCC ACG GGC GAC AGA A-3′ Testes/adipose tissue
Reverse: 5′-CCA AGC CTT TGT TGG GAA-3′
Probe: 5′-FAM-CGT CAA CCA TGG GAA TAT GTC CAC 
CAG A-TMARA-3′




3β-hydroxysteroid dehydrogenase (3β HSD) Prod. No. Rn01789220_m1, Life Technologies Europe BV, 
Nærum, Denmark
Liver
11β HSD Prod. No. Rn00567167_m1, Life Technologies Europe BV, 
Nærum, Denmark
Liver
17β HSD Prod. No. Rn00588942_m1, Life Technologies Europe BV, 
Nærum, Denmark
Testes/adipose tissue
5α reductase Prod. No. Rn00575595_m1, Life Technologies Europe BV, 
Nærum, Denmark
Testes/adipose tissue
18 s-ribosomal RNA Forward:, 5′-GCC GCT AGA GGT GAA ATT CTT G-3′ Liver/testes/adipose tissue
Reverse: 5′-GAA AAC ATT CTT GGC AAA TGC TT-3′
Probe: 5′-FAM-ACC GGC GCA AGA CGA ACC AGA 
G-TAMRA-3′
Steroidogenic acute regulatory protein (StAR) Forward, 5′-CCC TTG TTT GAA AAG GTC AAG TG-3′ Testes
Reverse, 5′-TGA AAC GGG AAT GCT GTA GCT-3′
5′-FAM-CTG ACT CCT CTA ACT CCT GTC TGC CTA CAT 
GGT-TAMRA-3′
UDP-glucuronosyltransferase 2B15 (UGT2B15) Prod. No. Rn00755925_m1, Life Technologies Europe BV, 
Nærum, Denmark
Liver






Organs were stored in RNAlater at −20 °C until purifi-
cation by use of the RNAeasy Mini Kit (Qiagen, Hilden, 
Germany) and cDNA synthesis by use of the Omniscript 
RT kit (Life Technologies Europe BV, Nærum, Denmark). 
mRNA levels were next measured by quantitative (q)PCR 
using specific primer pairs in combination with TaqMan 
probes (sequences and investigated organs are specified in 
Table 3). Samples, primers and probes were added TaqMan 
Fast Universal PCR Master Mix (Life Technologies Europe 
BV, Nærum, Denmark) and run on a TaqMan 7900 HT 
qPCR machine (Applied Biosystems, Nærum, Denmark). 
Quantification was done by use of the comparative thresh-
old cycle (Ct) method, where the Ct value is the cycle num-
ber at which the fluorescence signal of the amplified target 
reaches a defined threshold (Schmittgen and Livak 2008). 
Ct data on the transcripts of interest were normalised by 
subtraction of the Ct value of 18 s ribosomal RNA to obtain 
the ΔCt value. To obtain normal distributed data, 2−ΔCt 
values were used for statistical analysis.
Kidney transporter protein-level measurements
Frozen whole kidneys were thawed on ice and homog-
enised with a Yellowline DI25 Basic Homogeniser 
(Bie & Berntsen, Glostrup, Denmark) in an ice-cold 
buffer containing 300 mM sucrose, 25 mM imidazole, 
1 mM EDTA, and 1:200 Calbiochem Protease inhibitor 
cocktail set II, EDTA-Free (prod. no. 539134, Calbio-
chem, Darmstadt, Germany). Protein determination and 
Western blotting were conducted as previously described 
(Hadrup et al. 2007) except that the employed primary 
antibodies were anti-organic anion transporter 1 (OAT1) 
(prod. no. ABIN653184, Antibodies-online, Aachen, 
Germany), anti-organic anion-transporting polypeptide 
1/3 (OATP1/3) (prod. no. Sc-47265, Santa Cruz Biotech-
nologies, La Jolla, CA) and anti-organic anion-transport-
ing polypeptide 4C1 (OATP4C1) (prod. no. Sc-136775, 
Santa Cruz Biotechnologies, La Jolla, CA). All antibod-
ies were used at a dilution of 1: 2,000. Moreover, the 
employed camera was a Gel Doc 2000 (Bio-Rad, Her-
cules, CA). To accommodate up to 36 samples, a total 
of three blots were run for each investigated PFNA dose 
level (0.0125 mg/kg bw/day (PFNA Low) and 0.25 mg/kg 
bw/day (PFNA Mid) and on each blot a standard sample 
with a pooled volume of eight randomly selected samples 
was included, and all samples on each blot were normal-
ised to this sample before data analysis.
Statistics
Regarding data on mechanisms of toxicity (hormone con-
centrations, mRNA data, protein-level data), only the 
Low and Mid PFNA doses were included in the statistical 
evaluation (and on the graphs). The High PFNA groups 
were excluded due to the severe toxicity observed on body 
weight and pathology. Data were analysed for normal dis-
tribution by use of the D’Agostino & Pearson omnibus 
normality test. In case of a lack of normal distribution, 
data were transformed using the logarithm function and 
again tested for normal distribution. For normally distrib-
uted data, one-way ANOVA with Dunnett’s post-test was 
employed to assess effects of PFNA and of PFNA + Mix, 
respectively. In case of lack of normality, the nonparamet-
ric Kruskal–Wallis test with Dunn’s post-test (exposed 
groups vs. controls) was employed. To assess differences 
between individual data points, a t test was employed. In 
case of lack of normality, differences between two groups 
were assessed by use of the Mann–Whitney test. In case 
of comparison with a group in which all data were below 
the limit of detection, one sample t test was employed. A 
p value of <0.05 was considered significant. The statistical 
software package was Graph Pad Prism (Graph Pad Soft-
ware, La Jolla, USA).
Fig. 1  Plasma concentration of PFNA in the rats. Rats were admin-
istered PFNA at 0.0125, 0.25 or 5 mg/kg bw/day for 14 days in the 
presence or absence of a mixture of 14 chemicals (Mix) at a total 
dose of 2.5 mg/kg bw/day. The PFNA plasma concentration was 
measured in blood from all rats at the end of the experiment using 
qTOF. PFNA was found in all PFNA treatment groups. At 0.0125 mg/
kg bw/day (Low) PFNA, the plasma level was 396 ng/mL for Low 
PFNA and 1,111 ng/mL for Low PFNA + Mix. At 0.25 mg/kg bw/
day, the values were 29,950 and 39,880 ng/mL for Mid PFNA and 
Mid PFNA + Mix, respectively. For 5 mg/kg bw/day, the values were 
602,000 and 541,700 ng/mL for High PFNA and High PFNA + Mix, 
respectively. Data are mean plus SEM. N was 8 except for control 
and Low PFNA + Mix where n was 10. A t test was applied with 





PFNA plasma concentrations following administration 
of 0.0125 mg/kg bw/day were 396 ng/mL for Low PFNA 
and 1,111 ng/mL for Low PFNA + Mix—a difference that 
was statistically significant (p = 0.0007). Following dos-
age with 0.25 mg/kg bw/day, the plasma concentrations 
were 29,950 ng/mL (Mid PFNA) and 39,880 ng/mL for 
Mid PFNA + Mix. Following dosage with 5 mg/kg bw/
day, the values were 602,000 ng/mL (High PFNA) and 
541,700 ng/mL for High PFNA + Mix (Fig. 1). Thus, at 
the low PFNA dose, the Mix caused a pronounced increase 
Fig. 2  At high-dose, PFNA induces toxicity as measured by body 
weight and pathology. Rats were administered PFNA at 0.0125, 
0.25 or 5 mg/kg bw/day for 14 days in the presence or absence of 
a mixture of 14 chemicals (Mix) at a total dose of 2.5 mg/kg bw/
day. A piece of liver was fixed in paraformaldehyde and processed 
into paraffin-embedded sections and stained with haematoxylin and 
eosin. Sections were then blinded to the observer and scored by use 
of microscopy. Upper image shows a section from a control rat, 
lower image shows a section from a rat administered 5 mg/kg bw/day 
PFNA. The upper graph shows that the end body weight is increased 
at High PFNA ± Mix. The lower graphs show scores of cells size 
and cell borders. Cell size is increased by High PFNA ± Mix, and 
cell borders are decreased by High PFNA ± Mix. Data are mean 
plus or minus SEM. N was 10 except for Mid PFNA, Mix and Mid 
PFNA + Mix where n was 8. Data are analysed by one-way ANOVA 
or Kruskal–Wallis test. ***p < 0.001 by Dunnett’s ANOVA post-test 
for PFNA versus control; and #p < 0.05 by Dunn’s Kruskal–Wallis 
post-test for PFNA + Mix versus control
 Arch Toxicol
1 3
in PFNA plasma levels, but this did not happen at higher 
PFNA doses.
Body weight, organ weights and pathology
General toxicity was observed with High PFNA with and 
without Mix. The end body weights were decreased in 
High PFNA and High PFNA + Mix groups (Fig. 2). Mac-
roscopic pathological examination showed steatotic liv-
ers and congestive hearts (pictures not shown) that were 
observed for High PFNA and High PFNA + Mix. Micro-
scopically, increased size of liver cells (hypertrophy) was 
observed with increasing doses of PFNA, reaching statisti-
cal significance in the High PFNA + Mix group (Fig. 2). 
Cell borders were less apparent in liver sections of rats 
receiving increasing doses of PFNA being statistically sig-
nificant in the High PFNA group.
Hormone plasma concentrations
The corticosterone plasma concentration was increased at 
the Low PFNA dose level without Mix (twofold). In the 
presence of the Mix, corticosterone was not increased at 
the Low and Mid PFNA groups (Fig. 3). For androsten-
edione, testosterone and dihydrotestosterone increases 
were found in the Low PFNA + Mix group as compared 
to Low Mix (Fig. 3). For androstenedione and testoster-
one, a decrease was found both in the High PFNA and the 
High PFNA + Mix groups (data not shown). This effect 
was not detected for dihydrotestosterone for which many 
measurements were below the level of quantification (data 
not shown). Regarding pituitary hormones (Fig. 4), Mid 
PFNA + Mix decreased the plasma concentration of lutein-
ising hormone (LH). The concentration of follicle stimulat-
ing hormone (FSH) was decreased by Low PFNA + Mix 
and adrenocorticotropic hormone (ACTH) was decreased in 
the Mid PFNA + Mix as compared to Mid PFNA. For pro-
lactin and brain-derived neurotrophic factor, PFNA showed 
higher concentrations as compared to PFNA + Mix at the 
Mid dose.
mRNA levels in testis, liver and fatty tissue
In the testes, 17β HSD was down-regulated at both Low 
and Mid PFNA + Mix as compared to control. This 
effect was not observed with PFNA alone (Fig. 5). For all 
other genes measured in testes, there were no significant 
effects at the mRNA levels of genes involved in regula-
tion of steroid metabolism when considering Low PFNA 
and Mid PFNA with or without Mix (data not shown). At 
the High PFNA, where severe toxicity was found, mRNA 
levels of steroidogenic acute regulatory protein (StAR), 
benzodiazepine receptor (BZRP), CYP11A, CYP17 and 
17β-hydroxysteroid dehydrogenase (17β HSD) were all 
found to be down-regulated by PFNA (data not shown).
In the liver, 11β HSD was down-regulated with 
PFNA + Mix at both Low and Mid doses. This effect was 
not observed for PFNA alone (Fig. 5). For all other genes, 
no effects were found at the Low and Mid PFNA groups. 
At the High PFNA groups, where severe toxicity occurred, 
the aldo–keto reductase family 1 member C1 (AKR1C1), 
UDP-glucuronosyltransferase 2B15 (UGT2B15), 
CYP2C11, CYP1A2 and CYP2B6 were all found to be 
down-regulated, whereas CYP3A23/3A1 was found to be 
up-regulated (data for the high-dose groups are not shown 
on the graphs).
In adipose tissue, CYP19 mRNA was up-regulated for 
Low PFNA + Mix as compared to Low PFNA (Fig. 5). At 
the toxic High PFNA, CYP11 was up-regulated (data not 
shown). There were no effects on the other steroid metabo-
lism enzymes: CYP17, 17β HSD and 5α reductase (data 
not shown).
Kidney transporter protein levels
OAT1 was increased in whole kidney homogenates when 
Low PFNA was combined with Mix (Fig. 6). OATP4C1 
was decreased by Low PFNA alone. This effect was nor-
malised by addition of Mix (Fig. 6). At the Mid dose 
level, no significant effects were found. OATP1/3 was not 
affected at any of the investigated dose levels (data not 
shown).
Discussion
Relevance of the employed PFNA doses in relation 
to human exposure levels
The hypothesis of the current study was that adverse mix-
ture effects occur at doses approaching high-end human 
exposure levels of food chemicals. Our aim was to reach 
a plasma level of PFNA covering the combined human 
Fig. 3  PFNA at a dose of 0.0125 mg/kg bw/day plus Mix induces 
an effect on androgens. Rats were administered PFNA at 0.0125or 
0.25 mg/kg bw/day for 14 days in the presence or absence of a mix-
ture of 14 chemicals (Mix) at a total dose of 2.5 mg/kg bw/day. Ster-
oid hormones were measured in plasma by use of LC–MS/MS. Low 
PFNA + Mix increased testosterone and dihydrotestosterone. A nor-
malising effect was seen on corticosterone with Low PFNA + Mix. 
Data are mean plus or minus SEM. N was 10 except for Mid PFNA, 
Mix and Mid PFNA + Mix where n was 8. Data were analysed by 
one-way ANOVA or Kruskal–Wallis test. **p < 0.01 by Dunnett’s 
ANOVA post-test for PFNA versus control. §p < 0.05 and §§p < 0.01 
by t test for PFNA versus PFNA + Mix. For dihydrotestosterone, a 
one sample t test was applied versus the detection limit of this hor-






plasma concentrations of perfluorinated compounds such as 
PFOA, PFOS and PFNA. According to Lau et al. (2007), 
human exposure means obtained from a substantial num-
ber of investigations gave a combined value of these three 
perfluorinated compounds of 13–429 ng/mL (or 13–117 
ng/mL if the second highest PFOA value is used). For com-
parison, the 95th percentile obtained from the NHANES 
study was 67.6 ng/mL for PFOA, PFNA and PFOS com-
bined (CDC 2009) which is in line with the Lau et al. data. 
A PFNA plasma concentration of 396 ng/mL was found 
in the Low PFNA group, indicating that PFNA in this 
study may be up to a factor of six higher than a high-end 
human exposure level (Table 1). However, this depends on 
the choice of a ‘high-end’ exposure for which a fixed, true 
value do not exist. In a study, not reported in the review by 
Lau et al., Emmett et al. found a mean of 423 ng/mL PFOA 
for persons not subjected to occupational exposure (median 
329, n = 312) and a mean of 824 ng/mL in persons with 
substantial occupational exposure (median 775, n = 18) 
(Emmett et al. 2006). Taking this into account, the present 
PFNA exposure in the rats was close to a combined human 
PFNA, PFOA and PFOS exposure. We made the assump-
tion that the applied PFNA exposure should represent 
exposure to other perfluorinated congeners, although it can 
be argued that the difference in structures of these mol-
ecules affects potency and binding specificity to different 
target molecules in the mammalian body. It is noted that a 
range of congeners different from PFNA, PFOA and PFOS 
exist, and these likely also contribute to the combined 
effects of perfluorinated compounds in humans.
Observed mixture effects and discussion on the presence 
of interactions
The aim of the present investigation was to test whether a 
relevant mixture of food chemicals at doses approaching 
high-end human exposure levels exerted adverse effects. 
The study was designed to target testosterone, and we found 
this steroid as well as its downstream metabolite, dihy-
drotestosterone and its precursor, androstenedione, to be 
affected by the mixture. There were no significant effects 
of Low PFNA or of Mix alone, whereas androgen levels 
increased considerably after exposure to Low PFNA in 
combination with Mix; thus for testosterone, dihydrotestos-
terone, and androstenedione a non-monotonic effect seemed 
to have occurred. Previously, additive mixture effects have 
Fig. 4  Effects of dose PFNA and Mix on pituitary hormone lev-
els. Rats were administered PFNA at 0.0125 or 0.25 mg/kg bw/day 
for 14 days in the presence or absence of a mixture of 14 chemi-
cals (Mix) at a total dose of 2.5 mg/kg bw/day. Hormones were 
measured by use of a Milliplex Map Rat Pituitary Luminex Kit. 
LH was decreased by Mid PFNA + Mix. FSH was decreased by 
Low PFNA + Mix. For ACTH, prolactin and brain-derived neuro-
trophic factor Mid PFNA + Mix was lower than Mid PFNA alone. 
Data are mean plus or minus SEM. N was 8 except for control 
(n = 10) and Low PFNA (n = 9). Data were analysed by one-way 
ANOVA. #p < 0.05 by Dunnett’s ANOVA post-test for PFNA + Mix 




been found for chemicals each present at doses for which 
measurement techniques are not sensitive enough to detect 
their individual effects (Hass et al. 2007; Silva et al. 2002). 
Feng et al. have previously demonstrated a non-mono-
tonic dose–response curve of PFNA on testosterone in rats 
with an increase at 1 mg/kg bw/day and a decrease at 5 
mg/kg bw/day. This supports the presence of such a non-
monotonic relationship although this was seen at higher-dose 
levels. Also Wade et al. (2002) found a non-monotonic dose–
response effect on natural killer cell lytic activity following 
exposure to a mixture containing 18 persistent contaminants at 
doses ranging from 1× to 100× the estimated safe level.
Looking at the PFNA plasma concentration, a toxicoki-
netic interaction was found in that the PFNA plasma con-
centration was increased at Low PFNA + Mix as compared 
to Low PFNA. PFNA could not be detected in animals only 
given Mix, indicating that no background PFNA levels, 
e.g., from the feed were present in the animals. Thus, the 
14-chemical mixture is able to increase the PFNA plasma 
levels at lower doses possibly by interference with ADME 
issues for PFNA. For corticosterone plasma levels, Low 
PFNA + Mix normalised an increase in corticosterone 
observed for Low PFNA. Also on the kidney OATP4C1 
transporter, the addition of Mix to Low PFNA normalised 
a Low PFNA-induced decrease in the protein level. These 
data suggest that in addition to reported food–drug inter-
actions (Bailey et al. 1989), food–environment chemical 
interactions may occur at the toxicokinetic level at doses 
approaching high-end human exposure levels. The effect of 
Mix on PFNA plasma levels is due to a toxicokinetic inter-
action between Mix and PFNA, but whether the effect on 
steroid hormone levels is due to kinetic or dynamic inter-
ferences is unknown. It is striking that we have detected 
potential non-monotonic low-dose effects. This gives food 
for thought concerning the extrapolation from high to low 
doses typically done in toxicological studies and concern-
ing future human risk assessment of chemicals.
In this study, possible effects of a chemical mixture were 
investigated in juvenile male rats 7 weeks of age at onset. 
Male Wistar rats are considered sexually mature when they 
Fig. 6  Effects of low-dose PFNA and Mix on protein levels of 
organic anion transporter 1 and organic anion-transporting poly-
peptide. Rats were administered PFNA at 0.0125 mg/kg bw/day for 
14 days in the presence or absence of a mixture of 14 chemicals 
(Mix) at a total dose of 2.5 mg/kg bw/day. Protein levels of OAT1 
(organic anion transporter 1) and OATP4C1 (organic anion-trans-
porting polypeptide-4C1) were measured by Western blotting. All 
samples were measured in a total number of three blots per protein. 
Only one blot is shown on the figure. A standard sample on each blot 
was used for normalisation to obtain a graph representing all samples 
(n = 9 for control, n = 8 for Mix, n = 10 for Low PFNA (0.0125 
mg/kg bw/day) and n = 10 for Low PFNA + Mix). OAT1 was 
increased at Low PFNA + Mix as compared to Low PFNA. OATP4C1 
was decreased at Low PFNA as compared to control, and this effect was 
normalised at Low PFNA + Mix. Data are mean plus or minus SEM. 
Data were not normal distributed and were therefore tested by use of the 
nonparametric Mann–Whitney test. ***p < 0.001 for PFNA versus con-




are around 50 days old; thus, we have investigated effects 
in rats just post-puberty. In our view, marked hormone 
changes may be considered as adverse. Increased testos-
terone in males has for example been linked to increased 
aggression (McGinnis 2004); and androgenic anabolic ster-
oid abuse has been linked to cardiac disease (Ahlgrim and 
Guglin 2009).
Possible mechanisms involved in the mixture effects 
on androgens
The possible mechanisms underlying the observed mix-
ture effects could provide a deeper understanding of how 
such effects develop in the mammalian body. Regarding the 
mixture effects on androgens, mechanisms involved could 
be related to (a) increased production or release of steroid 
hormones either via hormonal factors or locally induced 
(b) decreased tissue deposition of hormones (c) decreased 
metabolism of androgens and/or (d) decreased excretion 
of hormones. The pituitary hormone LH is involved in the 
regulation of testosterone production in the testes, and LH 
was decreased by Mid PFNA + Mix, and this may reflect 
a secondary negative feedback on the pituitary caused by 
disturbed steroid hormone levels.
In the testes, there were no findings to explain the effects 
seen on androgens except that a disturbed 17β HSD mRNA 
regulation may be part of the explanation. In adipose tissue, 
CYP19 was increased at Low PFNA + Mix as compared to 
Low PFNA. This suggests increased conversion of testoster-
one to estradiol when Mix is present. Among the chemicals 
in Mix, only DDE has shown a link to CYP19. Daughters of 
Michigan fish-eaters had increased gene expression of CYP19 
in blood leucocytes that was correlated to prenatal DDE levels 
(Karmaus et al. 2011). The fact that CYP19 was increased in 
the current study indicates that a compensatory mechanism to 
eliminate the excess testosterone might be in play.
In the liver, CYP expression was investigated because 
CYP3A4 and CYP2C9 (CYP3A23/A1 and 2C11in rats) 
are involved in the hydroxylation of testosterone, and these 
enzymes are known to be inhibited by bergamottin and 
glabridin constituents of the Mix (Cheng and Schenkman 
1983; Guengerich 1999; Kenworthy et al. 1999; Martignoni 
et al. 2006; Tassaneeyakul et al. 2000; Yamazaki and Shi-
mada 1997). Moreover, in the ToxCast (high throughput 
in vitro screening project) several perfluorinated carbox-
ylic acids including PFNA as well as BPA and prochloraz 
(constituents of the Mix) have been found in vitro to inhibit 
CYP2C9 (US_Environmental_Protection_Agency 2014). 
However, no effects on the mRNA levels of CYP3A23/1 or 
CYP 2C11 for Low PFNA in combination with Mix were 
found. Also, on the steroid glucuronidation pathway, there 
were no findings to explain the effects seen on androgens.
Fig. 5  mRNA levels of 17β HSD in testes, 11β HSD in liver tis-
sue and CYP19 in adipose tissue. Rats were administered PFNA at 
0.0125 or 0.25 mg/kg bw/day for 14 days in the presence or absence 
of a mixture of 14 chemicals (Mix) at a total dose of 2.5 mg/kg bw/
day. mRNA levels were measured by use of qPCR. 11β and 17β 
HSD were decreased by Low and Mid PFNA + Mix. CYP19 was 
higher for Low PFNA + Mix as compared to Low PFNA. Data are 
mean plus or minus SEM. N was 10 except for Mid PFNA, Mix and 
Mid PFNA + Mix where n was 8. Data were analysed by one-way 
ANOVA. #p < 0.05, ##p < 0.01 and ###p < 0.001 by Dunnett’s ANOVA 
post-test for PFNA + Mix versus control. §p < 0.05 and §§p < 0.01 by 
t test for PFNA versus PFNA + Mix
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To study interaction via excretion, we investigated 
organic anion transporters in the kidney because these 
transporters have been suggested to play a role in PFNA 
and testosterone excretion. OAT1 as well as OATP4C1 
transport organic anions from the blood into the kidney 
tubular cells for subsequent secretion into the pre-urine 
(Han et al. 2012). With Low PFNA + Mix, an increase in 
protein level of OAT1 was found (Fig. 6) but neither Mix 
nor PFNA individually exerted this effect. It has been 
shown that testosterone stimulates OAT1 (Cerrutti et al. 
2002; Ljubojevic et al. 2004) thus the increased testoster-
one level seen at Low PFNA + Mix correlates well with 
an increase in this transporter. This up-regulation, however, 
might also reflect that OAT1 could transport PFNA and that 
this transporter is up-regulated as a compensatory mecha-
nism in order to excrete the increased amounts of PFNA. 
For OATP4C1, the Mix normalised the Low PFNA-induced 
decrease in the protein level, suggesting that the Mix pro-
tects the body by allowing an increased transport of PFNA 
(Fig. 6). As for OAT1, OATP4C1 is increased by testos-
terone (Lu et al. 1996), again suggesting the increased 
testosterone level to be causing the normalisation of the 
OATP4C1 expression. Taken together, the data on kid-
ney transport do not readily explain the mixture effect on 
androgens at Low PFNA + Mix and may rather reflect 
downstream effects of the increased androgen levels.
Possible mechanisms underlying the increased PFNA 
concentration caused by Mix
The increase in the PFNA plasma concentration fol-
lowing Low PFNA + Mix as compared to Low PFNA 
may be explained by (1) increased PFNA absorption, (2) 
decreased metabolism, (3) decreased tissue deposition, 
or (4) decreased excretion. We looked for metabolites of 
PFNA but did not find any significant metabolism, and 
this is in accordance with the literature (Lau et al. 2007). 
Regarding proposed reabsorption of perfluorinated com-
pounds, the OATP1 is located on the luminal side of the 
tubular cells (Han et al. 2012) and has been demonstrated 
to have the ability to transport perfluorocarboxylates (Yang 
et al. 2009b). OATP1 was not found being affected by Low 
PFNA alone or in combination with Mix; thus, testoster-
one-stimulated reabsorption of PFNA via this transporter 
seems not to be underlying the increased plasma concen-
tration of PFNA. However, it should be noted that we did 
not measure two other OATs involved in perfluorocar-
boxylate transport, namely OAT2 and OAT3 (Kudo et al. 
2002). Whether the PFNA plasma-level effect is a cause or 
a consequence of (or not related to) the androgen levels is 
unknown. However, when we depict the effect on andro-
gen levels as a function of the internal PFNA plasma levels 
(graph not shown), we still observe a pronounced increase 
in androgen levels, indicating that there is more to the 
androgen effect than just affected toxicokinetics by PFNA 
alone.
Possible mechanisms underlying the normalisation 
of corticosterone
The mechanism underlying the normalisation of the corti-
costerone level by the Mix is likely explained by the dimin-
ished plasma ACTH observed when Mix was administered 
along with PFNA. Thus, a central effect on the pituitary 
may be evident. The enzymes responsible for inter-con-
version of corticosterone to the physiologically inactive 
11-dehydrocorticosterone in rats are 11β HSD (Thomson 
et al. 1998). We found PFNA + Mix to down-regulate this 
enzyme at the mRNA level. A differential regulation of this 
enzyme may be an explanation of the observed differential 
effect on corticosterone caused by PFNA with or without 
Mix.
Mixture-independent effects of PFNA suggest 
non-monotonic dose–response relationships
At Low PFNA dose, an increased corticosteroid effect as 
well as a diminished effect of the OATP4C1 protein level 
in kidney was observed (Fig. 6), suggesting that this chemi-
cal exerts low-dose effects on its own. The PFNA effect 
on corticosterone plasma levels could involve regulation 
of 11β HSD. PFNA has shown a potential to activate liver 
X receptor α (LXRα) (US_Environmental_Protection_
Agency 2014), and LXR negatively regulates expression 
of 11β HSD (Vogeli et al. 2013). At High PFNA, macro-
scopical and microscopical pathology of the liver as well 
as decreased body and organ weights showed that this dose 
is highly toxic to the animals. From that point of view, it 
is not surprising that the mRNA levels of several enzymes 
are down-regulated as seen for testes and liver, along with 
the testosterone and androstenedione plasma concentration 
being down-regulated at the high dose. Several enzymes 
like StAR, BZRP and CYP11A in the testes were down-
regulated and provide a suggestion for the decrease in 
testosterone and androstenedione at high doses. Steatosis, 
obscure hepatic cell borders and a decrease in testosterone 
have been shown for perfluorinated compounds by others 
previously (Fang et al. 2010; Feng et al. 2009; Yang et al. 
2009a). Notably, when these toxic effects occur, CYP1A2, 
CYP2B6 and CYP2C11 were down-regulated by PFNA, 
whereas CYP3A23/3A1 corresponding to the human 
CYP3A4 was up-regulated suggesting that this CYP is up-
regulated to increase elimination of multiple toxic metabo-
lites and confirming the broad substrate specificity of this 
enzyme. Our findings highlight the challenge of extrapolat-
ing from high-dose to low-dose effects, as is the ordinary 
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practice within toxicology and suggest that lower doses 
should be employed as well in toxicological studies.
Conclusion
We found that a human relevant mixture of fifteen chemi-
cals given to rats at doses approaching human realistic 
high-end exposure levels disturbed several plasma steroid 
and pituitary hormone levels. Androgen levels were non-
monotonically increased by >100 %, and corticosterone 
levels were decreased by 60 %. Moreover, a toxicokinetic 
interaction may have occurred as the Mix caused a mark-
edly increased PFNA plasma concentration. Our data sug-
gests that mixture effects of chemicals may be non-mono-
tonic and may occur even at doses approaching high-end 
human exposure levels. Further studies are warranted to 
determine whether this reflects a general phenomenon that 
should be taken into consideration when predicting human 
mixture toxicities.
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Aim: Increasing the information obtained from toxicological studies by profiling of the plasma metabolite 
composition and hepatic gene expression; focusing on low dose effects of toxic chemicals on the 
metabolome.  
 
Results: The metabolomics profiling displays a decrease in the phospholipids and neutral lipids. The mixture 
reduced mono- and diacylglycerols in the plasma. The primary effect is driven by the mixture. The 
transcriptomics profiling displays effect on PPAR mainly driven by PFNA.    
 
Conclusion: A low dose of chemicals affects the metabolome and the transcriptome. The mechanism of 
action can be difficult to determine though both mixture and low PFNA seemed to have effect on the lipid 
metabolism of the rat. The transcriptomics data suggests that PFNA have effect on the lipid metabolism by 
affecting PPAR.  
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Abstract Humans are constantly exposed to a significant
number of compounds and many are readily detected in
human body fluids. Worryingly, several of these compounds
are either suspected to be, or have already been shown to be
harmful to humans either individually or in combination.
However, the potential consequences of low-dose exposure
to complex mixtures remain poorly understood. We have
profiled the effects on rat blood plasma and liver homeostasis
using metabolomics and transcriptomics following 2-week
exposure to either a mixture of 14 common chemicals (Mix),
perfluorononanoic acid (PFNA) at low (0.0125 mg/kg/day)
or mid (0.25 mg/kg/day) doses, or a combination of Mix and
PFNA. In blood plasma, 63 and 64 metabolites were sig-
nificantly changed upon exposure to Mix alone or
PFNA ? Mix, respectively. Twelve of the metabolites were
identified and comprised mainly lipids, with various lipid
classes differentially affected across study groups. In the
liver, expression of 182 and 203 genes—mainly related to
energy homeostasis and lipid metabolism—were differen-
tially expressed upon exposure to PFNA alone or
PFNA ? Mix, respectively. In general, Mix alone affected
lipid metabolism evident in blood plasma, whereas effects on
lipid metabolism in the liver were mainly driven by PFNA.
This study verifies that a chemical mixture given at high-end
human exposure levels can affect lipid homeostasis and that
the combined use of metabolomics and transcriptomics can
provide complimentary information allowing for a detailed
analysis of affected signaling pathways.
Keywords Perfluorononanoic acid  Metabolomics 
Transcriptomics  Lipid homeostasis  Mixture toxicology
1 Introduction
Humans, particularly those living in industrialized coun-
tries, are continuously exposed to a plethora of compounds
through foods, cosmetics, pharmaceuticals, air inhalation
and more (Monosson 2005). A large number of studies
have reported on the presence of multiple compounds in
human body fluids (Calafat et al. 2007; NHANES 2013),
clearly showing that they are taken up by the body through
various routes. Also, epidemiological studies have shown
strong associations between compound mixtures and dis-
eases, for instance in relation to human reproduction
(Krysiak-Baltyn et al. 2012; Taylor et al. 2014). Therefore,
since animal studies have shown effects of human relevant
mixtures of environmental compounds given at doses close
to No Observed Adverse Effect Levels (NOAELs) for
single compounds (Christiansen et al. 2008, 2012; Axelstad
et al. 2014), the presence of many of these chemicals si-
multaneously is of real concern to human health.
The traditional approach for toxicological testing aims
at understanding the effect(s) of a single compound on
biological systems, from cells (in vitro) to animals
Kasper Skov and Kristine Kongsbak contributed equally to the work.
Electronic supplementary material The online version of this
article (doi:10.1007/s11306-015-0802-y) contains supplementary
material, which is available to authorized users.
& Anne Marie Vinggaard
annv@food.dtu.dk
1 National Food Institute, Technical University of Denmark,
Mørkhøj Bygade 19, 2860 Søborg, Denmark
2 Center for Biological Sequence Analysis, Department of
Systems Biology, Technical University of Denmark,
2800 Kongens Lyngby, Denmark
3 Inserm UMR-S 973, Mole´cules The´rapeutiques In Silico,




(in vivo). The compound is typically investigated at vary-
ing doses in order to obtain information on parameters such
as the NOAEL. A few studies on rats exposed to chemicals
or chemical mixtures at doses representing human expo-
sure levels have been reported (Moser et al. 2006; Chen
et al. 2014; Hadrup et al. 2015). These studies suggest that
even at low doses, certain compounds can have effects on
biological systems, for instance the plasma metabolome.
However, there still is a significant gap in knowledge re-
garding effects of low-dose chemical mixtures on either the
metabolome or transcriptome at the ‘omics’ level.
‘Omics’ technologies have provided new approaches to
evaluate the effects of toxic compounds. For instance,
fluorinated compounds have been shown to change the lipid
metabolism of both rats and zebrafish (Fang et al. 2012a;
Zhang et al. 2012) and endocrine disrupting compounds such
as bisphenol A have been shown to cause changes to the
metabolome even at doses far below the NOAEL (Chen et al.
2014). In general, changes in the transcriptome and meta-
bolome are detectable even after exposure to a low dose of
certain compounds, which suggests that these methods can
be valuable tools for understanding how the compounds af-
fect the organism where obvious phenotypes are absent
(Chen and Kim 2013). Furthermore, it has been shown that a
mixture of compounds at low doses can result in a marked
effect even when individual compounds show no detectable
effect and that this effect is marked even if they ‘only’ act
additively (Silva et al. 2002).
We wanted to investigate the effects of a mixture of com-
pounds (Mix) alone and together with increasing doses of the
perfluorocarboxylic acid, perfluorononanoic acid (PFNA), as
well as the effects of PFNA alone. The Mix was composed of
12 environmentally relevant endocrine disrupting compounds
at high-end human exposure levels (Christiansen et al. 2012)
and two food ingredients in doses corresponding to a high-end
daily intake of grapefruit and licorice. We hypothesized that
adverse effects would be observed with Mix alone or when
combined with low dose PFNA. By use of two complementary
omics methods, metabolomics and transcriptomics, we pro-
filed the effects in blood plasma and livers of exposed rats and
compared them to adverse effects observed at higher PFNA
doses. We found significant changes both to the metabolome,
as detected in plasma, and the liver transcriptome following
exposure to Mix and PFNA.
2 Materials and methods
2.1 Compounds and dosing
Compounds were selected as previously described (Hadrup
et al. 2015). Animals were dosed with a mixture of 12
compounds: bisphenol A, butylparaben, dibutyl phthalate
(DBP), bis(2-ethylhexyl)phthalate (DEHP), 4-methylben-
zylidene camphor, octyl methoxycinnamate, dichlor-
odiphenyldichloroethylene (p,p’-DDE), epoxiconazole,
linuron, prochloraz, procymidone, vinclozolin) and de-
scribed elsewhere (Christiansen et al. 2012; Hadrup et al.
2013), along with the two food components; glabridin from
licorice and bergamottin from grapefruit (Hadrup et al.
2015), both known to inhibit the activity of cytochrome
P450s (CYPs) metabolizing hormones and chemicals. The
total dose of the Mix was 2.5 mg/kg/day and the ratio of the
compounds is presented in Supplementary Table 1. The dose
of Mix was based on previously observed endocrine dis-
ruption (Christiansen et al. 2012), albeit 24-times lower
herein to reflect human exposure corrected for different body
surface areas of rat and human. In addition to Mix, animals
were exposed to three different doses of PFNA, the lowest
dose corresponding to a high-end human exposure level (Lau
et al. 2007). The two lowest doses were Low = 0.0125 mg/
kg/day and Mid = 0.25 mg/kg/day. A high dose of PFNA
(5 mg/kg/day) was part of the study as well but was excluded
from the mechanistic analyses in this paper due to the ob-
served severe toxicity (Hadrup et al. 2015) that would
hamper the interpretation of data.
2.2 Animals
The animal study has been described previously (Hadrup
et al. 2015). In brief, male Wistar Hannover Galas rats at
6 weeks of age were housed two per cage with a 12-h
light/dark cycle and ad libitum access to acidified tap water
and standard diet. The animals received vehicle (corn oil)
or test substances once daily by gavage for 14 days. Fifty-
four rats were randomly assigned into six groups (Table 1).
The last dose was administered to each animal 75–105 min
before euthanization. The rats were anaesthetized in CO2/
O2 prior to decapitation. Plasma was isolated from hep-
arinized neck blood by centrifugation at 1000g at 4 C for
10 min and subsequently stored at -80 C. Livers were
weighed and snap-frozen in liquid nitrogen.
2.3 Metabolomics
The procedure was as previously described (Skov et al.
2014). In brief, phospholipids were adsorbed on a
Table 1 Acronyms used for the different treatment groups and re-
spective number of animals per group
Without Mix With Mix Acronym
Control 10 8 Control/mix
0.0125 mg/kg/day 10 10 Low PFNA ± mix
0.25 mg/kg/day 8 8 Mid PFNA ± mix
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phospholipid SPE column (Supelco, Sigma-Aldrich). The
eluate was collected, dried and extracted using first 200 ll
heptane to isolate the lipids followed by 200 ll methanol to
extract the more polar compounds. The phospholipids were
eluted from the SPE column using 300 ll 10 % NH4OH in
methanol. The phospholipid, lipid and the polar fractions
were analyzed by an HPLC system combined with a Maxis
Quadrupol Time-of-flight mass spectrometer (Bruker Dal-
tonics, Bremen, Germany).
Data were analyzed with Profile Analysis 2.1 (Bruker
Daltonics, Bremen, Germany). Data were extracted using
the ‘‘find molecular features’’ algorithm in a mass range
from 50 to 1100 m/z value. The noise was reduced by
removing peaks that were present in \50 % of the samples
among all treatment groups and at the same time had a
peak intensity of B3000. The calculations were carried out
in R (R Core Team 2012). The data were uploaded to
MetaboAnalyst.ca (Xia et al. 2012) and analyzed with
t test, principal component analysis, and partial least
squares discriminant analysis (PLS-DA). The accurate
masses of significantly different metabolites were searched
for in databases such as the human metabolome database
(HMDB) (Wishart et al. 2009). The identities of the com-
pounds were verified by comparison of MS/MS patterns
with data from the databases HMDB, METLIN (www.
metlin.scripps.edu) (Smith et al. 2005), LIPID MAPS
(www.lipidmaps.org) (Sud et al. 2007) and MassBank
(www.massbank.jp) (Horai et al. 2010).
2.4 Statistical analysis
Initial analyses of the metabolome data were performed on
the Metaboanalyst server (Xia et al. 2012). Here, a one-way
analysis of variance (ANOVA) comparing PFNA-treated
animals to control animals and PFNA ? Mix-treated ani-
mals to control, respectively, formed the basis for initial
selection of significantly altered metabolites. All p-values
were adjusted using false discovery rate (FDR) according to
the protocol implemented in the Metaboanalyst workflow,
and 0.05 was used as cut-off for statistical significance. The
statistically significantly altered metabolites were subse-
quently analyzed and plotted using GraphPad Prism version
5.00 for Windows (GraphPad Software, San Diego, CA,
USA, www.graphpad.com). The D’Agostino and Pearson
omnibus normality test was used to test for normality of the
data. If data were normally distributed, an ANOVA was
performed using Dunnett’s multiple comparisons test to
adjust the p-values. If data were not normally distributed,
data were log-transformed and, if normally distributed after
transformation, analyzed by ANOVA. If not normally dis-
tributed, a non-parametric Kruskal–Wallis test followed by a
Dunn’s multiple comparisons test was conducted. The cri-
teria for statistical significance was p \ 0.05, p \ 0.01 and
p \ 0.001 denoted *, ** and ***, respectively. Statistical
comparisons not applicable to ANOVA tests were carried
out using an unpaired, two-tailed Student’s t test.
2.5 Transcriptomics
Total RNA from six rat livers each from vehicle control,
Low PFNA ? Mix, and Mid PFNA ± Mix groups were
separately converted into labeled cRNA and applied to the
One-Color Microarray-Based Gene Expression Analysis
(Low Input Quick Amp Labeling) version 6.5 (Agilent
Technologies, Santa Clara, CA). Labeled cRNA from each
rat was hybridized to Agilent Whole Rat Genome Oligo
Microarrays (G4122F) for 17 h at 65 C. The hybridized
microarrays were scanned using an Agilent DNA Mi-
croarray Scanner and evaluated using the Feature Extrac-
tion software version 10.7.3.1 according to protocol
GE1_107_Sep09 (Agilent Technologies) to generate fea-
ture extraction files for further analysis. Reads were quality
controlled by the software prior to release of the data.
Arrays that did not pass quality control were removed from
the dataset. Based on the quality control reports, two of the
six microarrays from the Mid PFNA ? Mix group were
excluded from further analysis. The remaining arrays, six
from each of control, Low PFNA ? Mix, and Mid PFNA
and the remaining four from Mid PFNA ? Mix were found
to be of high quality.
Extracted data were analyzed using the limma software
package (Smyth 2004, 2005) in R (R Core Team 2012).
Data were background corrected using the ‘normexp’
method (Ritchie et al. 2007) and normalized between ar-
rays using quantile normalization (Smyth and Speed 2003)
prior to statistical analyses. Within-array replicate probes
were replaced with the average expression level. To iden-
tify treatment-specific gene effects, we fitted a linear model
for each gene and applied empirical Bayes statistics (Smyth
2004) for each relevant two-group comparison. The FDR
was controlled using the Benjamini–Hochberg method
(Benjamini and Hochberg 1995). Reported p-values for the
significantly differentially expressed genes from the tran-
scriptomics analysis were all adjusted, and p-values B 0.05
were considered statistically significant.
2.6 Pathway analysis
Transcription data were analyzed with QIAGEN’s Inge-
nuity Pathway Analysis (IPA, QIAGEN Redwood City,
www.qiagen.com/ingenuity). IPA was used to map sig-
nificantly differentially expressed gene probes to genes,
and expression values were used for prediction of the in-
volvement of the differentially expressed genes in func-
tional networks, pathways, and diseases, and for graphical
representations. Using the Fisher’s Exact Test, we analyzed
Exposure to perfluorononanoic acid combined with a low-dose mixture…
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the overlap between the differentially expressed genes in
our dataset and genes known to be involved in disease
networks, pathways, and diseases available in the Ingenuity
Knowledgebase. p-values B 0.05 were considered statisti-
cally significant.
3 Results and discussion
3.1 Rats exposed to low/medium levels of a
14-chemical Mix, PFNA, or both displayed
no macroscopic phenotypes
Our main objective was to determine if exposure to low
doses of PFNA with or without a background exposure to a
low-dose chemical mixture (Mix) can have undesirable ef-
fects on the metabolome and transcriptome of animals
otherwise displaying little to no phenotypic abnormalities.
For this, we chose to analyze blood and liver samples from
male rats that had been exposed to various levels of che-
micals for a period of 14 days during juvenile age. This
in vivo experiment has been described previously with a
focus on low dose hormonal changes and pathological
findings at high dose level (Hadrup et al. 2015). In the initial
assessment of the animals, exposure to high levels of PFNA,
with or without Mix, indicated hepatic steatosis of the liver;
a state of retention of lipids in the liver. Animals exposed to
lower levels of PFNA ± Mix, which encompasses the dose-
groups included in this study, showed no obvious morpho-
logical phenotypes. However, significant plasma levels of
PFNA after the exposure period were measured to be 1.1
and 30 lg/ml for Low PFNA ? Mix and Mid PFNA ?
Mix, respectively. In animals exposed to Low-, and Mid
PFNA only, plasma concentrations were 0.4 and 40 lg/ml,
respectively. The former is in the range of, or up to six times
the human high-end combined exposure to PFOA, PFNA
and PFOS (67.6–824 ng/ml) (Emmett et al. 2006; Lau et al.
2007; NHANES 2013; Hadrup et al. 2015). Thus, the ad-
dition of Mix significantly increased the plasma levels of
PFNA (2.8-fold for Low PFNA), indicating altered ADME
(absorption, distribution, metabolism, excretion) properties
of PFNA when Mix is co-administered.
The dose of Mix was calculated from a high-end ex-
posure level in the European population (Christiansen et al.
2012) and corrected for body surface area of rats compared
to humans (Hadrup et al. 2015). Surprisingly, none of the
compounds in Mix, or their corresponding metabolites,
were found when extracted ion chromatograms were cre-
ated based on their accurate mass. This could be due to
rapid metabolism of the compounds or that the levels were
below the limit of detection in the LC–MS analysis. Nev-
ertheless, as clear effects of PFNA levels were observed
when co-administered with Mix, we chose to include all
the different combinations of low- to mid-range exposure
groups in our analyses aimed at discerning more subtle
molecular phenotypes.
3.2 The blood plasma metabolome of rats exposed
to low/medium levels of chemical mixtures,
including PFNA, was significantly altered
In order to establish any potential effects caused by PFNA
exposure with or without a Mix background, any effects
caused by Mix alone was analyzed first. When compared to
control animals, Mix exposure significantly affected 63 out of
a total of 882 molecular features. As shown in Fig. 1, affected
phospholipids were lysophosphatidylcholines such as (lyso-
PC)(20:4) and lyso-PC(18:2), whereas affected neutral lipids
included diacylglycerols (DG) such as DG(18:1/18:3) and
DG(18:2/16:0), all depressed in serum of exposed animals.
Plots of all significantly altered metabolites are shown in
Supplementary Figs. 1 and 2, again with most of the affected
metabolites being depressed relative to control.
Altered lipid metabolism is a common response to
xenobiotic exposure (Karami-Mohajeri and Abdollahi 2011;
Zhang et al. 2013; Androutsopoulos et al. 2013; Zhang et al.
2014). An initial stress-response to a xenobiotic insult can
increase carbohydrate metabolism to meet a changing en-
ergy requirement, subsequently met by increased lipid and
protein metabolism (Karami-Mohajeri and Abdollahi 2011).
The general decrease in plasma lipid levels observed in the
Mix-exposed rats could reflect this situation, particularly
since the exposure lasted for a prolonged period (14 days),
potentially resulting in effects such as hepatic injury. Inter-
estingly, two of our identified lysophosphatidylcholines,
lyso-PC(18:2) and lyso-PC(20:4) have both been identified
as potential blood biomarkers for drug-induced hepatic
phospholipidosis (Saito et al. 2014), and in both instances
the response is reduced levels. Then, as drug-induced
phospholipidosis has been associated with liver inflamma-
tion and fibrosis (Rigas et al. 1986; Lewis et al. 1989), it
could suggest that we are observing compromised livers in
our rats exposed to Mix, albeit not observed at the macro-
scopic level.
In animals exposed to Low PFNA only, we also ob-
served changes to the blood metabolome, albeit different to
what was observed with Mix only. Using PLS-DA of all
the three fractions, we were able to separate the various
exposure groups, with the lipid fraction depicted in Fig. 2.
There was a clear difference between Low PFNA and Mix
groups, but it was not possible to positively identify the
specific metabolites responsible for this separation.
In all 30 metabolites separated Mix-exposed animals
from animals exposed to Low PFNA (Supplementary
Fig. 1). Mix alone altered 22 of these metabolites. For 6 out
of 22 metabolites the concomitant exposure to Low PFNA
K. Skov et al.
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enhanced the effect on the metabolites. In the animals si-
multaneously exposed to Low PFNA and Mix, we observed
a general depression of lipid concentrations in blood plasma,
primarily diacylglycerols and the free fatty acid lignoceric
acid (Fig. 3a, b). The only metabolite directly affected by
Low PFNA, but not by Mix was the steroid hormone cor-
ticosterone, which was significantly elevated compared to
control animals (Fig. 3c). PFNA-exposure has previously
been shown to elevate plasma levels of both adrenocorti-
cotropic hormone and cortisol in mice, though only at the
highest dose of 5 mg/kg/day (Fang et al. 2008). Although it
is not clear why adrenocorticotropic hormone, and subse-
quently glucocorticoids, are elevated by PFNA-exposure, it
could be an inflammatory response, as PFNA can induce
immunotoxic responses (Fang et al. 2008), and elevated
endogenous glucocorticoid levels can subsequently suppress
the innate immune response (Liberman et al. 2007). None of
the metabolites that were altered by Mix and not by Low
PFNA ? Mix were identified.
We next performed the same analyses on animals having
been exposed to Mid PFNA doses with or without Mix.
Within these groups, we identified 24 metabolites with
Fig. 1 The six most significantly different metabolites in the Mix
group compared to the control group. In total, the levels of 63
metabolites were found to be significantly different between the two
groups (t test). The depicted metabolites belong to two metabolite
classes, diacylglycerols (DG) and lyso-phosphatidylcholines (lyso-
PC)
Fig. 2 PLS-DA plot of the
heptane fraction correlating the
four groups Control (n = 10),
Low PFNA (n = 10), Low
PFNA ? Mix (n = 10) and
Mix (n = 8). The plot illustrates
that Mix accounts for a major
part of the variance in the
dataset
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significantly changed plasma concentrations, out of which
17 were altered by Mix alone (Supplementary Fig. 2).
Three representative metabolites that were significantly
changed between groups are shown in Fig. 3d–f. As shown,
there was an increase in the plasma level of lyso-PC(20:4)
in Mid PFNA exposed animals, but not in those exposed by
Mix alone. Exposure to Mix depressed plasma levels of the
diacylated phospholipids PC(18:0/16:1), which was further
depressed by the simultaneous exposure to PFNA despite
Mid PFNA exposure alone not affecting levels of these
metabolites (Fig. 3e).
To further investigate the contribution of Mix towards the
PFNA-induced effects, we compared the significant metabo-
lites resulting from statistical analysis of Mix versus control
(t test) and PFNA ? Mix versus control (ANOVA). We ob-
served that 24 metabolites were affected by all treatments, out
of which 12 were positively identified (Supplementary
Fig. 3). These 12 metabolites comprised neutral short-chained
lipids such as monoacylglycerols and phospholipids. Mix
alone affected the diacylglycerols, whereas the PFNA ? Mix
groups affected the diacylated phospholipids. Surprisingly,
lyso-PC(20:4) and lyso-PC(18:1) were depressed by Mix
exposure, elevated by Mid PFNA exposure, but depressed
beyond Mix alone when simultaneously exposed to Mid
PFNA and Mix (Fig. 3d, f). Similarly, although not elevated
by Mid PFNA exposure, blood plasma levels of lyso-PC(18:0)
and lyso-PC(16:1) appeared to be depressed more when ex-
posed to Mid PFNA ? Mix than when exposed to Mix alone
(Fig. 3e). It is difficult to discern a putative mechanism behind
these observations, but it likely reflects the complex regula-
tory mechanisms underpinning organismal homeostasis,
highlighting the importance of employing systems approaches
when analyzing effects caused by mixtures of compounds.
However, in some ways these metabolite changes are similar
to those associated with metabolic syndrome.
Over the last decades, there has been a worldwide in-
crease in metabolic syndrome (World Health Organization
2000), carrying with it an increased risk of developing
diabetes and cardiovascular disease. Some studies have
shown decreased phospholipid levels in blood plasma of
diabetics (Wang et al. 2005; Liu et al. 2013) and an ab-
normal ratio between lyso-PC and PC levels, which may
indicate a systemic change in relation to diabetes (Altmaier
et al. 2008). PCs are involved in the biosynthesis of mul-
tiple compounds and a decrease in PC levels can reflect

























































































































































































Fig. 3 Representative metabolite changes in the Low PFNA ? Mix
group. The plotted metabolites belong to two metabolite classes; PC
(phosphatidylcholine) and DG (diacylglycerol). Metabolite levels
were analyzed statistically for each group by comparison to control
(t test). For corticosterone (c) and lyso-PC(20:4) (d), PFNA alone
caused an increased metabolite level, whereas the combination of Mix
and PFNA generally caused a decreased metabolite level (DG(22:5/
18:3 (a) and PC(18:0/16:1) (e)). For lignoceric acid (b) and lyso-
PC(18:1) (f) the effect by Mix ? PFNA is stronger than the effect of
Mix or PFNA alone. #p-value of 0.053
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(Lagace and Ridgway 2013). Thus, the changes we ob-
served in the metabolome in rats following exposure to
Mix alone and PFNA ? Mix were comparable to the dif-
ferences observed in patients with metabolic syndrome
(Ferrannini et al. 2013). Also, lyso-PCs have been shown to
be elevated in metabolic syndrome patients (Chen et al.
2011).We observed elevated lyso-PCs for Mid PFNA ex-
posure, but not for the other exposure groups. This could
suggest that Mix, or components therein, protects against
some of the effects caused by PFNA. However, a more
likely scenario is that Mix exposure causes systemic
changes that lead to a metabolic response in order to
maintain tissue/serum homeostasis or to a suppressed im-
mune response, which subsequently leads to differing re-
sponses to PFNA.
The effects observed on lipid homeostasis following
exposure to Mix with or without PFNA may be attributed
to the presence of glabridin, a naturally occurring iso-
flavonoid from licorice that has been shown to inhibit the
activity of CYP2C9 in the liver (Kent et al. 2002). Studies
have shown that CYP2C9 is involved in the regulation of
lipid metabolism in the body (Kent et al. 2002; Kirchheiner
et al. 2003). Furthermore, people carrying a polymorphism
in CYP2C9 have a tendency towards having lower levels of
the lipid carriers LDL and HDL (Kirchheiner et al. 2003).
A decrease in LDL and HDL may result in decreased levels
of plasma lipids, including cholesterol and cholesterol
derivatives, as these are carrying lipids in the blood stream
(Kent et al. 2002). It could also be attributed to PFNA
inhibiting the activity of CYP2C9 similarly to glabridin (U.
S. Environmental Protection Agency 2014).
3.3 The liver transcriptome of rats was affected
by exposure to chemical mixtures, including
PFNA
For global gene expression analyses, we selected to study
the livers of animals exposed to Low PFNA ? Mix and
Mid PFNA with or without Mix relative to control, as we
expected little changes in the Mix alone group. As evident
in Supplementary Table 3, we observed no statistically
significant (p B 0.05) changes in transcript levels of any
gene in livers from Low PFNA ? Mix exposed rats. Fur-
ther, few genes in these groups displayed significant fold-
change differences in transcript abundance, with only three
genes displaying more than 1.5-fold difference: Cyp4a11
1.6-fold, Cyp2b6 2.0-fold and Acot1 2.1-fold. Allowing for
an adjusted p-value B 0.1 without a fold-change cut-off
value, 31 genes could be identified as differentially ex-
pressed between the exposed and control rat livers, and are
included in Table 2, which lists differentially expressed
genes related to energy homeostasis. The remaining genes
are listed in Supplementary Table 3.
Next we analyzed the transcriptome of livers obtained
from rats exposed to Mid PFNA ± Mix. Here, only an-
notated genes contained in the IPA database were included
when compiling lists of differentially expressed genes, thus
excluding most expressed sequence tags and genes without
adequate literature-based information for robust down-
stream analysis. At the statistically significant level of
p B 0.05, 203 genes from the PFNA ? Mix group and 182
genes from the PFNA only group were annotated as dif-
ferentially expressed (Supplementary Table 2). Of these,
the majority showed an upregulation in the exposed groups
as compared to controls.
Based on functional annotation of genes dysregulated in
the PFNA ± Mix dosing groups, fatty acid metabolism
was the main biochemical function affected (Table 2). For
instance, upregulated genes such as Crot, Crat, Acox1,
Ehhadh, Hadha, Hadhb, Decr2, Eci2, Ech1, are all in-
volved in peroxisomal fatty acid b-oxidation, whereas
Cpt2, Slc25a20, Acad11, Acadl, Acadm, Acads, Acadvl are
all involved in mitochondrial b-oxidation. Genes associ-
ated with lipid transport, fatty acid activation, and per-
oxisomal transport (Apoa2, Abcd3, Cd36, Slc27a2) were
also upregulated. Amongst the downregulated genes was
Fatty acid binding protein 5 (Fabp5). Similar effects on
lipid homeostasis have been shown in other studies (Gu-
ruge et al. 2006; Rosen et al. 2007; Fang et al. 2012a, b, c).
Here, the effects on lipid metabolism seem to be mainly
driven by PFNA exposure, as the effects are comparable
between animals exposed to Mid PFNA only and Mid
PFNA ? Mix.
With regards to aerobic respiration, a different tran-
scriptional profile was observed for Mid PFNA ? Mix
compared to Mid PFNA alone (Table 2). For instance, the
citric acid cycle enzymes, aconitase 2 (Aco2), isocitrate
dehydrogenase 3 (NAD?) beta (Idh3b), and succinate-CoA
ligase (Sucla2 and Suclg1) were significantly upregulated
by Mid PFNA, but not by Mid PFNA ? Mix. Only Aco2
and Suclg1 were upregulated in both groups relative to
control. Similarly, for enzymes in the electron transport
chain (Ndufa10, Ndufab1, Ndufs3 (complex I), and Sdhb
(complex II)) only Ndufa10 was significantly upregulated
in both groups. The other enzymes were only upregulated
in the Mid PFNA group. Finally, expression of genes en-
coding enzymes involved in glucose metabolism were
mainly disrupted by Mid PFNA ? Mix, except for a few
genes such as phosphofructokinase (Pfkm) that were only
significant with Mid PFNA and carbonic anhydrase VII
(Ca7) and STEAP family member 4 (Steap4), which were
differentially expressed by both groups. Thus, the tran-
scriptional profiles of Mid PFNA ± Mix are relatively
similar with only subtle differences observed based on
z-scores and p-values. Notably, a statistical comparison
between Mid PFNA and Mid PFNA ? Mix did not yield



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































K. Skov et al.
123
any differentially expressed genes, hence further studies
with larger sample sizes are required to verify some of the
subtle differences indicated by this study.
The IPA has a function to predict the activity of po-
tential upstream regulators based on differentially ex-
pressed genes. Using our dataset, we could predict an
increased activity of several transcription factors and other
central proteins in livers from exposed animals (Table 3).
Downstream of the differentially expressed genes, IPA
predicts regulatory effects such as diseases and functions
likely to be perturbed due to the changes in gene expres-
sion. As illustrated in Fig. 4, activation of the upstream
regulators PPARa, PPARc, PPARd, RXRa, PPARgc1a,
and MED1 results in altered gene expression (Table 2) that
subsequently leads to increased oxidation of lipids, in
particular fatty acids. This, in turn, protects against accu-
mulation of lipids in the liver and therefore also against
hepatic steatosis. This is consistent with our observations in
livers from rats having been exposed to Low- and Mid
PFNA doses, with no indications of lipid accumulation,
increased cell size, or compromised cell borders (Hadrup
et al. 2015). However, as exposure to high PFNA doses
causes adverse effects such as steatosis (Hadrup et al.
2015), it can be speculated that livers from at least the Mid
PFNA exposed rats could become affected over time. The
fact that hepatic steatosis was evident at the high PFNA
dose (5 mg/kg/day) and that signs of protection against
hepatic steatosis was observed at the mid PFNA dose
(0.25 mg/kg/day) illustrates the problem of extrapolating
from toxicological observations at higher doses to effects at
lower doses, which is common practice in risk assessment
of chemicals.
PPARs are known regulators of fatty acid b-oxidation
(Kanehisa and Goto 2000), and increased b-oxidation re-
sults in decreased plasma lipid concentration (Lau 2012).
Then, as perfluorinated alkyl acids are known PPAR-acti-
vators (Vanden Heuvel et al. 2006; Lau 2012; U. S. Envi-
ronmental Protection Agency 2014), effects observed in
livers from the PFNA groups could, at least in part, be
explained by this regulatory pathway. Further, the Mix
contains two phthalates, DBP and DEHP, which are both
known PPAR activators (Desvergne et al. 2009), poten-
tially adding to the effect in the PFNA ? Mix groups. In
fact, additional compounds in the Mix such as butyl-
paraben, linuron, and vinclozolin, can stimulate PPAR-
dependent transcription (U. S. Environmental Protection
Agency 2014), further adding to the overall effect. How-
ever, at the doses used in our study, the contribution of Mix
Table 3 Upstream regulators predicted to regulate effects caused by Mid-PFNA ± Mix
Upstream regulator Mid PFNA ? Mix Mid PFNA Genes
z-score p-value z-score p-value
PPARa Peroxisome proliferator-
activated receptor a
5.3 2e–24 5.1 5e–28 Abcd3, Acaa1, Acaa2a, Acadl, Acadm, Acads, Acadvl,
Acat1, Acot1a, Acot2, Acox1, Adtrp, Cd36, Cpt2,
Crot, Cyp2b6, Cyp4a11, Cyp4a14, Decr1, Decr2,
Ech1, Eci2, Ehhadh, Fabp5, Gpd1, Hadh, Hadha,
Hadhb, Rt1-Baa, Hmgcs2, Mlycd, Pex11a, Plin5,
Slc25a20, Slc27a2, Vnn1, Aadacb, Apoa2b, Cfhb,
Ftcdb, H2afzb
KLF15 Kru¨ppel-like factor 5 3.2 3e–18 3.0 5e–17 Acadl, Acadm, Acadvl, Acot1a, Acox1, Cd36, Cpt2,
Decr1, Ehhadh, Fabp5, Hadha, Hadhb, Mlycd,
Slc25a20
ACOX1 :Peroxisomal acyl-
coenzyme A oxidase 1
-2.4 5e–15 -2.474 3e–13 Abcd3, Acaa1, Acadl, Acadm, Acadvl, Acot2, Acox1,
Aig1, Cd36, Crat, Cyp4a11, Cyp4a14, Ehhadh, Rt1-
Baa, Hsd11b1a, Pex11a, Slc27a2, Tnfrsf10aa, Hspa5b
PPARc Peroxisome proliferator-
activated receptor a
3.9 8e–14 3.3 1e–13 Acaa1, Acaa2a, Acadl, Acadm, Acads, Acox1, Adrb3a,
Cd36, Cpt2, Crat, Cyp4a11, Cyp4a14, Ehhadh, Fabp5,
Fbp2a, Gpd1, Hadha, Hadhb, Hmgcs2, Mlycd, Pepd,




-2.8 1e–12 -2.8 6e–13 Abcd3, Acaa1, Acot2, Acox1, Cd36, Cyp4a11,
Cyp4a14, Pex11a
HSD17B4 :Peroxisomal
multifunctional enzyme type 2
-3.0 1e–12 -2.8 4e–11 Abcd3, Acaa1, Acot2, Acox1, Cd36, Cyp4a11,
Cyp4a14, Hoxd13a, Pex11a
An arrow indicating up- or downregulation marks upstream regulators that are differentially expressed genes. Negative z-scores indicate that the
upstream regulator is inactivated, whereas positive z-scores indicate activation
a DEG only present in Mid PFNA ? Mix
b DEG only present in Mid PFNA
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towards PPAR activation is likely minor since (i) we ob-
served very small differences in transcript levels between
the Mid PFNA and Mid PFNA ? Mix groups, and (ii) we
did not observe any significant changes in gene expression
in animals exposed to Low PFNA ? Mix.
A summary of the functions of the Mid PFNA ± Mix is
given in Supplementary Table 4, together with genes that
displayed highest fold-change difference in transcript
levels between Mid PFNA ? Mix and Mid PFNA alone.
As discussed, altered CYP2C9 activity might play a role in
the changed plasma lipid concentrations. However, our
data do not suggest downregulation of the rat CYP2C9
homologue, Cyp2c11. On the other hand, the HDL-con-
stituent, apolipoprotein A-II (encoded by Apoa2) is
upregulated by PFNA but not by PFNA ? Mix. The effects
observed for Mix and PFNA ? Mix might therefore be
caused by a combination of decreased CYP2C9 activity
and PPAR activation.
4 Concluding remarks
The characterization of potential toxic effects caused by
prolonged exposure to various compounds can be a chal-
lenge. When a large number of compounds are present at
the same time, as in humans, the challenge is even greater.
In an effort to better understand the complex interaction
between multiple exogenous compounds and the living
organism, we profiled the plasma metabolome and the liver
transcriptome in rats after exposure to a low dose of
bioavailable chemicals. We observed that a mixture of 14
chemicals at high-end human exposure levels (Mix), low-
to mid-range doses of PFNA, or a combination of the two,
had the potential to alter the blood plasma levels of
diacylglycerols, PCs, and cholesterol derivatives, mimick-
ing some of the features of metabolic syndrome. These
effects can also suggest an inflammatory response, but in
either case warrant further investigations. We also ob-
served more subtle changes to the liver transcriptome fol-
lowing Mid PFNA exposure irrespective of Mix,
suggesting that the hepatic effects were driven by PFNA. In
conclusion, this study demonstrates that low-dose exposure
to chemical mixtures can affect the metabolome and cause
disturbed lipid homeostasis, and that ‘omics’ approaches
are powerful tools to detect smaller changes not readily
observable at the macroscopic level.
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Fig. 4 Illustration of a putative hepatic signaling network, from PPAR
(and other transcriptional regulators) activation through regulation of
gene expression to ultimately dictate phenotypic outcomes. Orange
indicates predicted activation and blue indicates predicted inhibition.
Shades of red and green indicate level of increased and decreased gene
expression, respectively. The network was generated through the use of
QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN Redwood
City, www.qiagen.com/ingenuity) (Color figure online)
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Paper IV Effect of BPA on rats and their offsprings – a metabolic profiling of low dose exposure 
to BPA 
 
Manuscript in progress 
 
Aim: Determination of low dose effects of BPA on the plasma of mother rat and offspring.  
 
Results: The dosing of BPA affected the mother animals and offspring differently. The metabolic change of 
the mother animals suggests changes of the lipid metabolism with an increase level of cholesterol and a 
decreased level of monoacylglycerol. The plasma of male offspring showed an increased amount of 
phosphotidylcholine compounds.  
 
Conclusion: Low dose effects on the rat metabolome are observed as they are exposed to Bisphenol A. 
The mother animals had a difference in plasma concentration of monoacylglycerol and cholesterol. The male 
offsprings had an increase in plasma concentration of lyso-phosphotidylcholine concentration.  
Metabolic Profiling of Rats and their Offspring Exposed to Low Doses of 
Bisphenol A.  
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Abstract 
Bisphenol A (BPA) is an industrial chemical used to manufacture polycarbonate plastics, epoxy resins and 
thermal printings. BPA is detectable in consumer products, food, water and dust. Human exposure has 
been confirmed by analysis of urine, blood and tissue. Metabolomics analysis was performed analyzing 
plasma of rats exposed to two doses of BPA, 0.025 and 0.25 mg/kg bw/day. This concept was used to 
identify low dose effects on the plasma from both dams, as well as male and female offspring. 
The metabolome of the dams and offspring were analyzed by a PCA plotting. The dams and the offspring 
located into two distinctive groups reflecting differences in age and route of exposure. Moreover, the male 
and female offspring had similar clustering in the PCA plot. To identify difference between control and 
exposed animals, PLS-DA plots of each of the three animal groups were conducted. Twenty-seven 
molecular features out of 347 were found to be significantly different between controls and male offspring. 
For lyso-phosphatidylcholine compounds a “dose response” trend was observed, while for the neutral lipids 
and for a metabolite with the molecular weight 359.149 there were only effects at BPA-0.25. For the dams 
a BPA induced increase in cholesterol in the plasma was observed.  
A difference in the metabolome between male and female rats was observed. Another observeda 
difference was between dams administered to BPA directly and the offspring exposed through the dams 
(via placenta and milk in lactation period). The lyso-phospholipids was increased male offspring when 
exposed to BPA-0.25. In conclusion, the dams showed increased levels of cholesterol and a decreased level 
of monoacylglycerols while the males and the female offspring showed an effect on diacylglycerol.   
Introduction 
Bisphenol A (BPA) is an industrial chemical used to manufacture polycarbonate plastics, epoxy resins and 
thermal printings (Boucher et al. 2014). BPA is detectable in consumer products, food, water and dust 
(Alonso-Magdalena et al. 2008; Asahi et al. 2010; Boucher et al. 2014). Human exposure has been 
confirmed by analysis of urine, blood and tissue (Asahi et al. 2010). The biomarkers of BPA is the compound 
itself along with the major metabolite; glucuronidated BPA (Bjerregaard et al. 2007). Exposure is correlated 
with diseases such as diabetes and obesity (Alonso-Magdalena et al. 2008), though no specific mechanisms 
of action have yet been determined (Asahi et al. 2010; Boucher et al. 2014). Correlations between BPA 
concentration and diseases such as heart failure and diabetes have been shown (Srivastava and Godara 
2013). Furthermore, BPA have been shown to be transferred from mother to child in placental cord blood 
(Srivastava and Godara 2013). In children chronically exposed to BPA gastrointestinal problems, reduced 
immune system, toxic overload and neurological disorders have been demonstrated (Srivastava and Godara 
2013). The dose of the previously described studies is above the “no observed adverse effect level” 
(NOAEL) of 5 mg/kg bw per day. In the offspring that are also included in the current study both male and 
female anogenital distance was significantly decreased at birth at low doses (from 0.250 mg/kg in males 
and from 0.025 mg/kg in females) and above. Moreover, the incidence of nipple retention in males 
appeared to increase dose relatedly and the increase was statistically significant at 50 mg/kg per day 
(Christiansen et al. 2014). Multiple studies have suggested that even exposure to low doses of BPA during 
development will have effect on a range of different endpoints. Studies in rodents have reported effects of 
BPA at or below 50µg/kg per day on reproductive organ weights, mammary gland development and 
behavior (Christiansen et al. 2014; Xu and Xu 2013). These effects of BPA emphasize the need to 
understand the mechanism of action for BPA. The mechanism of action is not clarified and may involve 
several differential mechanisms of actions. It is probably not limited to the classical estrogenic mechanism 
(Shelby 2008) but likely also comprises several other signaling pathways (Reif et al. 2010). 
In the recent years new methods have been used to analyze the effects of BPA administered at low doses. 
Among these methods are the “omics” methods; transcriptomics, proteomics and metabolomics. 
Metabolomics is the comprehensive analysis of all the metabolites in a given organism, normally 
compounds with a molecular weight of less than 1 kDa (Brown et al. 2005; Goodacre et al. 2004; Oliver et 
al. 1998). Changes in the metabolome have been found in zebrafish and rats at doses of BPA at least ten 
times lower than the NOAEL value of 5 mg/kg bw/day. Grasselli et al. show difference in the transcriptome 
involved in the lipid and glucose homeostasis in rat hepatoma cells (Grasselli et al. 2013). This is supported 
by Chen et al. showing changes in the lipid metabolome in rats exposed to BPA (Chen et al. 2012) and 
Alongo-Magdalena who has shown that BPA induces insulin producing in the Langerhans islets (Alonso-
Magdalena et al. 2008). Furthermore, Xu and Xu showed changes in the polar fraction of the metabolome 
when exposing rats to a low dose of 1 µg/kg bw/day for 45 days (Xu and Xu 2013).  
Well above 600 articles have been published on toxic effects of BPA; however several modes  of action has 
yet been established (Asahi et al. 2010; Reif et al. 2010). The aim of the present study was to investigate 
the effect of perinatal low dose exposure of BPA on the metabolome of female Wistar rats and their 
offspring to obtain data that may help determine a mechanism of action. Metabolomics analysis of two 
doses of BPA, 0.025 and 0.25 mg/kg/day, corresponding to 200 and 20 times below the no observed 
adverse effect level, was done. Analysis of the early sexual development such as anogenital distance and 
nipple retention from the same study  is described elsewhere (Christiansen et al. 2014). By use of 
metabolomics we identified low dose effects on the plasma from both dams, as well as male and female 
offspring, effects that may be a first step towards identifying a mode of action. 
 
Materials and methods 
Chemicals 
BPA (purity of 99.5%, CAS no. 80-05-7) was purchased from Sigma–Aldrich. Corn oil used both as negative 
control and as vehicle was purchased from Sigma–Aldrich. The corn oil was provided to the laboratory in 
glass bottles. The dosing solutions were kept in glass bottles in the dark, at room temperature, and 
continuously stirred during the dosing period. The levels of BPA in the solutions were verified by chemical 
analysis as described in Christiansen et al. (2014). 
Animals and treatment 
The Animal study was carried out at the DTU National Food Institute (Mørkhøj, Denmark) facilities. Ethical 
approval was given by the Danish Animal Experiments Inspectorate. The authorization number given: 2012-
15-2934-00089 C4. The experiments were overseen by the National Food Institutes in-house Animal 
Welfare Committee for animal care and use.  
A total of 110 time-mated nulliparous, young adult Wistar rats (HanTac:WH, SPF, Taconic Europe, Ejby, 
Denmark) were supplied at gestation day (GD) 3 of pregnancy. 
The animals were housed in pairs until GD 17 and alone thereafter under standard conditions in semi-
transparent polysulfone (PSU) type III cages (PSU 80-1291HOOSU Type III, Tecniplast, Buguggiate, Italy) 
(15x27x43 cm) with Aspen wood chip bedding (Tapvei, Gentofte, Denmark), Enviro Dri nesting material 
(Brogaarden, Lynge, Denmark) and Tapvei Arcade 17 (Aspen wood) shelters (Brogaarden). The study was 
performed using three blocks (separated by 1 week), and all dose groups were equally represented in the 
blocks, i.e. the 22 time-mated rats per dose group were allocated among blocks. The dams were distributed 
into five dose groups (0, 0.025, 0.250, 5 or 50 mg/kg bw per day respectively). Details on study design are 
described in Christiansen et al. (2014).  
Samples for metabolomics 
On PD (pupday) 22 the dams as well as one male and one female from 10 litters per dose group (0; 0.025; 
0.25 mg/kg) were weighed and decapitated, blinded with respect to exposure groups. The dams were 
dosed 1½-2 hours prior to section to take into account the toxicokinetics of the compound. Serum was 
frozen for metabolomics (see Table 1 below). 
Table 1 Dams and offspring analyzed by metabolomics 
  Dams Males females 
1: Control 10 10 10 
2: BPA-
0.025 10 10 10 
3: BPA-0.25 10 10 10 
 
Metabolomics analysis 
The applied procedure is described in (Skov et al. n.d.). The main difference to this procedure is that in this 
study only 40 µl of plasma was used for the analysis. Furthermore, the extraction solvents were reduced to 
100 µl. In brief, phospholipids were removed using a phospholipid SPE column (Supelco, Sigma-Aldrich). 
The eluate was collected, dried and extracted by 100 µl heptane in order to remove the lipids. This was 
followed by addition of 100 µl methanol in order to extract the more polar compounds. The phospholipids 
were next eluted from the SPE column using 300 µl 10 % NH4OH in methanol. The phospholipid, lipid and 
the polar fractions were analyzed by an HPLC system combined with a maxis qTime-of-flight mass 
spectrometer (Bruker Daltonics, Bremen, Germany) (Skov et al. n.d.). All samples within each fraction were 
randomized before analysis. 
Data analysis 
The LC data was analyzed by Profile Analysis 2.1 (Bruker Daltonics, Bremen, Germany) using the find 
molecular features algorithm. The  data matrix was extracted and noise was reduced by use of an R script 
(R Core Team 2012). This served to remove peaks that were present in < 50% of the samples among all 
treatment groups and at the same time had a peak intensity of ≤ 3000. The data from each group of 
animals were then uploaded to the online software program Metaboanalyst (Metaboanalyst.ca) (Xia et al. 
2009). Metabolites that were changed in their blood concentrations were identified by doing normalization 
by the sum of all peaks, LOG transformation and Pareto scaling followed by ANOVA analysis in 
Metaboanalyst. A P>0.05 false discovery rate correction was applied to adjust for the high number of 
metabolites present in blood. These findings were used to select pseudo ions of interest that were further 
analyzed statistically as described below. Accurate mass searches MSMS patterns were used to suggest 
metabolites of interest.  The MSMS pattern was compared with in silico data from lipidmaps or the Human 
Metabolome Database (Fahy et al. 2009; Xia et al. 2009, 2012, 2013). 
Statistical analysis 
The D’Agostino and Pearson omnibus normally test was used to test for normality of the data. If data were 
normally distributed, one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons 
test was performed on plasma level of metabolites, and pathology data. Otherwise, data was LOG 
transformed and, if normally distributed, analyzed by ANOVA. If not normally distributed a non-parametric 
Kruskal-Wallis test followed by a Dunn’s multiple comparisons test was conducted. The criteria for 
statistical significance was p<0.05, p<0.01 and p<0.001 leading to marking *, ** and ***, respectively. 
Determination of metabolite identities 
Significantly different metabolites were identified by accurate mass search on databases such as human 
metabolome database (hmdb.ca) (Wishart et al. 2007), lipidmaps (lipidmaps.org) (Fahy et al. 2009), 
massbank (massbank.jp) and metlin (metlin.scripts.edu) (Trauger et al. 2005). If a possible metabolite was 
suggested the MSMS pattern was correlated with MSMS patterns from lipidmaps or HMDB databases. For 
some of the compounds was a standard of the compound purchased and the spectra and retention time of 
the standard correlated with spectra and retention time of the significantly changed metabolite. 
Results 
Toxicological findings 
Analysis of the early sexual development in the current study showed a significantly decreased anogenital 
distance at birth at low doses (from 0.250 mg/kg in males and from 0.025 mg/kg in females) and above. 
Moreover, the incidence of nipple retention in males appeared to increase dose relatedly and the increase 
was statistically significant at 50 mg/kg per day (Christiansen et al. 2014).   Metabolomics 
A Partial Least square-discriminant analysis (PLS-DA) was conducted separately for dams, female and male 
offspring (Figure 1). The dose groups were clearly separated in the PLS analyses. 
 Figure 1 PLS-DA plots of the methanol fraction of male offspring, female offspring and dams. As shown on the plots are the 
groups and QC samples located closely together. The female and male offspring seem to have the same kind of separation while 
the change in the metabolites of the dams seems to be a bit more separated. 
The metabolome of the dams and offspring were analyzed by a PCA plot (data not shown). The dams and 
the offspring located into two distinctive groups reflecting differences in age and route of exposure. 
Moreover, the male and female offspring had similar clustering in the PCA plot. To identify differences 
between control and exposed animals, PLS-DA plots of each of the three animal groups was conducted. The 
location of the different treatment groups of male and female offspring, were similar on the PLS-DA plot. 
However, the metabolites accounting for a dose dependent difference in between all groups the metabolic 
change were not the same. The PLS-DA plot for the dams showed a greater change, but a closer clustering 
of the exposed and control animals. The significantly changed metabolites are described below. 
Changes in dams: 
 
Figure 2 Metabolites significantly changed in the metabolome of the dams. The first three metabolites (a-c) are 
monoacylglycerols (MG) which are all down-regulated by BPA-0.25. MG(18:0) and MG(16:0) and their adducts account for 10 of 
the 29 molecular features found significantly changed between control and BPA exposed animals. Furthermore, cholesterol was 
found as a loss of water and as a Na adduct both were increase compared to control. F is a metabolite not identified. The criteria 
for statistical significance was p<0.05, p<0.01 and p<0.001 leading to marking *, ** and ***, respectively. 
 
The one way ANOVA yielded 26 significantly changed molecular features out of 341 molecular features. It 
was found that 11 molecular features accounted for monoacylglycerols (MG); MG(18:0), MG(16:0) and 
MG(14:0). The overall effect of the MGs was decreased levels in the plasma when exposed to BPA-0.25. 
Cholesterol was increased when rats were exposed to BPA-0.25. One metabolite found to be decreased 
already at BPA-0.025. This metabolite had an m/z of 359.149. It was not possible to identify a compound 
with this accurate mass on data base searches. Three of the molecular features match in identities with 
docosenamide, found both in the lipid and the polar fraction and for both a significantly decreased level in 
BPA-0.25; however as this metabolite is not normally present in mammalian plasma it was classified as an 
impurity and the data was not further analyzed. In the phospholipid fraction no metabolites were found to 
be different. The rest of the significantly changed metabolites are shown in supplemental materials 
(supplemental materials) 
Changes in female offspring: 
 
Figure 3 Metabolites from the plasma of the female offspring exposed to BPA at concentrations of 0.025 and 0.25 mg/kg 
bw/day. The results are shown as peak area ± SEM. As shown in the graphs there were significant decreases of MG(18:0) and 
DG(20:4/20:5), while no significant effect ass seen on cholesterol or the two unidentified metabolites with pseudo ion 
monoisotopic masses of 233.138 and 359.149. The criteria for statistical significance was p<0.05, p<0.01 and p<0.001 leading to 
markings of *, ** and ***, respectively.  
It was found that 36 out of 671 molecular features were significantly different between control and BPA 
exposed animals for the female offspring. Several of these could not be identified as chromatographic 
peaks; ten molecular features were discarded due to this. Two diacylglycerols (DGs) and a MG were found 
to be decreased in the BPA-0.025 exposure group. Two other molecular features were found to be 
increased though it was impossible to establish their identities by use of accurate mass and MSMS patterns. 
Based on the increase in cholesterol from the dams, a targeted analysis using loss of water and Na adduct 
of cholesterol was conducted; however the concentration was not different between control and exposed 
animals. 
Changes in male offspring animals: 
Twenty-seven molecular features out of 347 were found to be significantly different between controls and 
exposed animals (See supplemental data). Of these 27 potential metabolites the identity of seven could be 
established. In figure 4 five of the six identified metabolites are depicted, see Figure 4. There were 
increases in the concentrations of lyso-phosphotidylcholine (lyso-PC) and DG concentrations. For all the 
lyso-PC compound a “dose response” trend was observed, while for the neutral lipids and 359.149 there 
were only effects at BPA-0.25. 
 
 
Figure 4 Significantly changed metabolites of male offspring exposed to BPA. The results are shown as peak area ± SEM. For the 
lyso-phosphotidylcholine (lyso-PC) (a-c) are increased when exposed to BPA-0.25. Furthermore was there an increase in two 
diacylglycerides and a compound with an accurate mass of 359.149.  The criteria for statistical significance was p<0.05, p<0.01 
and p<0.001 leading to markings of *, ** and ***, respectively.  
Cholesterol was searched for by accurate mass searching for the sodium adduct and loss of water. 
However, no difference was found in the cholesterol plasma concentration in the male offspring. 
Furthermore, no effect was observed on the levels of MG(18:0) or MG(16:0) of the plasma from the male 
offspring (data not shown). 
Discussion 
In this study we found effects on the metabolome in dams and offspring of low doses of BPA administered 
prenatally. To evaluate the low dose toxic exposure metabolomics analysis was performed. The primary 
effect of BPA was evaluated by analysis of the plasma of the dam exposed during pregnancy and during the 
lactation period. Furthermore, the plasma of female and male offspring was analyzed to evaluate whether 
an effect was seen after exposure through placenta and lactation.   
The data from the dams displayed a significant change in the lipid metabolome. The small neutral lipids 
MG(18:0), MG(16:0) and MG(14:0) were significantly decreased when exposed to BPA-0.25 while 
cholesterol was found to be increased when exposed to BPA-0.25. This correlates with previously obtained 
results by Miyawaki et al. who have shown that cholesterol is increased in animals administered BPA orally 
in a concentration of 1 and 10 µg/kg bw/day (Miyawaki et al. 2007). However, this were not observed in 
neither male nor female offspring indicating that a direct exposure of BPA induces other effects than the 
secondary effect from the exposure via placenta and milk. 
The metabolic pattern was significantly different between dams and offspring, though some of the 
metabolites were similar. The dams and the female offspring both suggest a lowering in MG(18:0). The 
male offspring furthermore have an increased concentration of lyso-PCs. These are involved in metabolism 
as well as used as signaling compounds in the body. The specific change of neutral lipids and lyso-PC is not 
fully understood in relation to their effects on health. Williams et al. (Williams et al. 2013) have shown that 
the lipid concentration is decreased in fruit flies when exposed to BPA and Boucher et al. (Boucher et al. 
2014) have shown that TG accumulation is increased in adipose cells when exposed to BPA. Alonso-
Magdalena et al. have proposed that administering BPA to mice increases the biosynthesis of insulin 
(Alonso-Magdalena et al. 2008). The increased level of insulin would increase the glucose uptake from the 
plasma thus inducing high energy state in the cell probably leading to an increase in biosynthesis of lipids. 
      One metabolite especially in focus in this study had a pseudo ion with accurate masse of 359.1493 ± 2 
mDa. The metabolite is interesting as it was significantly decreased in the dam animals but significantly 
increased in both male and female offspring. The compound was searched for by accurate mass and a 
feature of Data Analysis 4.1 (Bruker Daltonics) suggested that the compound had the elemental 
composition C20H22O6 but the exact identity of this compound could not be established.  
       The changes in the metabolomes of the dams and the offspring were not similar in the present 
investigation. However, some specific compounds were both found to be changed in dams and female 
offspring and dams and male offspring, respectively. It was not possible to detect one single mechanism of 
action for BPA from these data although it might involve changes of the lipid metabolism. At least such 
changes could be hypothesized to seriously impact the biochemistry and physiology of the body. A 
disruption in the non-polar part of the metabolome could explain some of the difference for this. Although 
it will be difficult to suggest a clear mechanism of primary and secondary exposure to BPA, we believe that 
the data obtained from this study will support, via metabolic changes, which mechanism of actions BPA 
possess. 
Conclusion 
The effect of BPA is measurable even at concentration levels 20 and 200 times below no-observed-adverse-
effect level. There is a difference in the metabolome between male and female rats. Furthermore, there is 
difference between dams administered to BPA directly and the offspring exposed through the dams (via 
placenta and milk in lactation period). One group of compounds namely the lyso-phospholipids, equally 
affected both dams and offspring as all were increased in concentration when exposed to BPA-0.25. The 
dam showed increased levels of cholesterol and a decreased level of monoacylglycerols while the male and 
female offspring showed an effect on diacylglycerol. One unidentified metabolite with m/z of 359.149 was 
of great interest as it was decreased in the dams while increased in male and female offspring. We believe 
that measuring the non-polar part of the metabolome has revealed new insight in the mechanism of action 
for bisphenol A, bringing us one step closer to understand how it affect animals as well as humans.  
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Paper V Metabolite profiling of urine from rats dosed with Selenium nanoparticles or Selenium ions 
Manuscript in progress 
 
Aim: In the present investigation we utilized urine samples from rats administered with selenium in two 
different physical formulations (as nanoparticles and as sodium selenite) to assess the usefulness of 
metabolite pattern determination for comparing effects on mechanism of action of different chemicals. 
 
Results: We found that when evaluating all significantly changed metabolites, nanoparticles and sodium 
selenite induced similar patterns of regulation. In the urine 13 metabolites were significantly different after 
exposure to selenium. Moreover we estimated the potencies to be similar. This suggests that selenium 
nanoparticles are completely dissolved into ions in the gastrointestinal system of the rat, and exhibit a 
bioavailability and mechanism of action similar to that of selenium ions. 
 
Conclusion: We found that metabolite profiling in urine can be used to compare different chemical 
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Introduction: In pharmacology and toxicology, there is often a need to determine differences in the 
biological effect profiles of chemical congeners. This is important in order to assess whether 
alterations in the chemical composition or formulation have an impact on the biological effects of 
the substance. Using metabolite pattern determination, differences in the effect profile can be 
assessed by determining whether there are differences among the sets of metabolites altered by the 
various congeners. Methods: We utilized urine samples from rats administered selenium in two 
different physical formulations (as nanoparticles or as sodium selenite) to assess the utility of 
metabolite pattern determination in comparisons of different congeners. Results: Evaluations of all 
significantly changed putative metabolites showed that selenium nanoparticles and sodium selenite 
induced similar patterns of regulation. Moreover, we estimated the bioavailability to be in a similar 
range with a tendency to a higher bioavailability of selenite compared to selenium nanoparticles. 
Discussion: metabolite pattern determination demonstrated that selenium nanoparticles exhibit an 
effect profile similar to that of selenium ions. This suggests that the effects of nanoparticulate 





In pharmacology and toxicology, there is often a need to determine differences in the effect profiles 
of chemical congeners. This is important in order to provide a picture of whether a (physico) 
chemical change or alterations in formulation alters the effect of each congeners on the mammalian 
body. This may be in general but when specific mechanisms are known and measured a picture of 
efficacy profile versus toxicity profile as well as information on bioavailability may be assessed 
specifically. Examples of such congeners are different physico-chemical states of elements (e.g., 
nanoparticles vs. ions) or different functional groups applied to principal structures in drug research. 
Metabolite pattern determination draws on the concept of metabolite profiling (metabolomics) to 
enable the concomitant measurements of a large number of chromatogram peaks containing 
potential metabolites (Robertson, Watkins, & Reily, 2011). Using metabolite pattern determination 
on a body compartment such as urine or blood plasma, differences in the biological effects can be 
assessed by comparing the sets of metabolites that are altered by each congener. This provides a 
combined picture of pharmaco- and toxicodynaimcs as well as –kinetics .  
     Selenium (Se) is an element that, in trace amounts, is essential for humans. Se is incorporated as 
selenocysteine, and selenium is necessary for the synthesis and catalytic function of selenoproteins 
such as peroxidases and reductases (Levander, 1982). At high doses, Se becomes toxic, exhibiting 
effects such as emaciation and weight loss (Nogueira & Rocha, 2011). To provide more effective Se 
dosing regimens, nanoparticle formulations have been developed. The concept is that the Se 
nanoparticles provide a slow release of Se ions, thereby reducing acute toxicity. Several studies 
have demonstrated a lower toxic potency of Se nanoparticles than of ionic Se, suggesting that to 
some extent, Se nanoparticles remain intact in the gastrointestinal  tract (Benko et al., 2012; Jia, Li, 
& Chen, 2005; J. S. Zhang, Gao, Zhang, & Bao, 2001; J. Zhang, Wang, Yan, & Zhang, 2005). It 
has been shown that smaller Se nanoparticles are more toxic than larger particles. This finding 
suggests that the rate of release of Se ions may depend on the nanoparticle size and thus on the 
surface area per unit weight (Peng, Zhang, Liu, & Taylor, 2007). Whether Se nanoparticles exhibit 
unexpected effects that cannot be attributed to Se ions but rather to the physical form of the 
nanoparticles themselves remains unknown. In the present investigation, we used equimolar 
amounts of Se formulated in two different ways (nanoparticles vs. ions), to study the utility of 
metabolite pattern determination for the differentiation between the biological effects of chemical 
congeners. We used LC-MS to analyze urine samples obtained after 14 days of oral administration 
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of Se nanoparticles (19 nm in mean diameter) or sodium selenite in equimolar doses of 0.05 and 0.5 
mg Se/kg bw/day. A maximal safe dose in humans is 5 µg/kg bw thus these doses reflect 10 and 
100 fold that dose. The affected metabolites were determined using the MetaboAnalyst web-tool 
(Xia, Psychogios, Young, & Wishart, 2009), and the curves obtained were assessed for equal effect 
patterns to compare differences in biological effect profiles for the different congeners.  
 
2. Materials and methods 
2.1. Nanoparticles 
Se nanoparticles with a mean diameter of 19 nm (ranging in size from 10 to 80 nm) were produced, 
stored and characterized as previously described (Loeschner et al., 2014; J. S. Zhang et al., 2001). 
Briefly, images to assess the size and shape of the Se nanoparticles were generated by transmission 
electron microscopy (TEM) (Figure 1) using a TEM Philips CM100 instrument (FEI, Eindhoven, 
The Netherlands) at 80 kV accelerating voltage (Loeschner et al., 2014).  
2.2. Animal study 
Urine samples were obtained from a previously reported Se bio-distribution study (Loeschner et al., 
2014). Briefly, four-week-old, specific pathogen-free (SPF) female Wistar rats were obtained from 
Taconic M&B (Lille Skensved, Denmark). The rats were allowed to acclimatize for one week.  The 
rats were housed in pairs with a 12:12-h light/dark cycle with the lights on from 7 a.m. to 7 p.m. 
The room temperature was 22 ± 1 oC, and the relative humidity was 55 % ± 5 %. The rats were 
given ad libitum access to a standard diet (Prod. no.1324, Altromin International, Lage, Germany) 
and citric acid acidified tap water. The animals were randomized by weight. The test substances 
were administered by oral gavage in a volume of 10 mL/kg bw once a day for 14 days. The 
treatment groups were as follows: 1. Vehicle-BSA (bovine serum albumin 4 g/L) control (n=8); 2. 
Se nanoparticles 0.05 mg Se/kg bw/day stabilized with BSA (4 g/L) (n=6); 3. Se nanoparticles 0.5 
mg Se/kg bw/day (n=6) stabilized with BSA (4 g/L); 4. Vehicle-H2O (n=8); 5.  Sodium selenite 
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0.05 mg Se/kg bw/day (n=8); and 6. Sodium selenite 0.5 mg Se/kg bw/day (n=8). No BSA was 
added to groups 4, 5 and 6; thus, group 4 acted as the control group for the sodium selenite groups. 
Sodium selenite (Na2SeO3) was obtained from Sigma-Aldrich (Copenhagen, Denmark). On 
experimental day 14, the rats were placed individually in metabolism cages for 24 hours for the 
collection of urine. During the 24-hour period, the urine samples were frozen by collection on dry-
ice. Subsequently, the samples were stored at -80 °C. In the metabolism cages, the rats had access to 
drinking water but not to feed. The animal study was conducted under conditions approved by the 
Danish Animal Experiments Inspectorate and the in-house Animal Welfare Committee. 
    
2.3. HPLC/MS metabolite profiling analysis 
Metabolite profiling of the urine was performed as previously described (Hadrup et al., 2012). In 
brief, the urine samples were precipitated with two volumes of methanol and centrifuged (10 min at 
10,000 x g). The supernatants were collected and analyzed by HPLC coupled to a qTOF-MS. 
Sample injection volumes were normalized to the creatinine concentration of the urine to adjust for 
differences in diuresis. The metabolites were separated on an Avensis Express C8, 2.7 µm, 100 x 
2.1 mm column (Supelco, Bellefonte, PA, USA, product no. 53832-U). The metabolites were next 
detected by use of a Bruker microTOFq time-of-flight mass spectrometer equipped with an 
electrospray ion source (Bruker Daltonics, Bremen, Germany). The samples were analyzed in both 
positive and negative ionization modes. The data obtained are reported as the mass-to-charge (m/z) 
ratios and HPLC retention times of the metabolites. These are given in the format of xxxx.xxx Da, 
yyy.y s (seconds).  
      The analyses of the chromatograms were conducted using the Profile Analysis 2.1 software 
package (Bruker Daltonics, Bremen, Germany). Data buckets were constructed using a time 
window from 60 to 720 s with an m/z ratio range of 100 to 700 using the “find molecular feature” 
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algorithm including time alignment. The noise was reduced using R (R Core Team, 2012) by 
removing peaks that were present in < 50% of the samples of each treatment groups and had peak 
intensities of ≤ 3000 counts per s (cps). The raw intensity data were next transferred to the online 
MetaboAnalyst server (Xia et al., 2009). The data were normalized as the sums, and Pareto-scaling 
was performed. Partial least squares (PLS) discriminant analysis was performed for all datasets 
collectively. ANOVA was applied to the BSA-vehicle vs. Se nanoparticle groups and separately to 
the H2O vehicle vs. sodium selenite groups. Discriminatory metabolites were selected based on a 
false discovery rate-adjusted p value of 0.05. The corresponding raw data for these metabolites were 
then transferred to Graph Pad Prism to establish curves and test for normal distributions. Normality 
was tested using the Kolmogorov Smirnov test (with Dallal-Wilkinson-Lillefor p-value). The data 
(BSA vehicle vs. Se nanoparticle groups and H2O vehicle vs. selenite groups) were then evaluated 
again by ANOVA or by Kruskal-Wallis depending on the presence or absence of normal 
distribution. Dunnett’s and Dunn’s post tests were applied to determine the effects of single 
treatment groups compared to their respective control groups. All data on the graphs are presented 
as the mean, and the error bars represent SEM. A false discovery rate-corrected p-value of less than 
0.05 was considered significant. 
        The metabolites were subjected to identification to provide a level of certainty that 
chromatographic peaks represented metabolites and to provide a picture of the nature of the effects 
induced by the selenium congeners. For the identification of metabolites, The Human Metabolome 
Database (Wishart et al., 2013) was searched using the accurate masses of the metabolites. The 
presence of adducts or fragments (e.g., plus Na+ or minus H2O) at identical HPLC retention times 





The three-dimensional graphical presentation of the results of the PLS analyses provides a picture 
of the overall differences among the treatment groups (Fig. 2). In the positive mode, there were 
clear differences in the spatial locations of all groups, reflecting dose-response effects as indicated 
by the position of the 0.05 mg Se group between the vehicle and the 0.5 mg Se groups. There was a 
clear vehicle-induced difference in the spacing of samples in the PLS analyses as indicated by the 
different position of the BSA-vehicle samples compared to the H2O-vehicle samples (Fig. 2). In the 
negative mode, the picture was similar to that seen for the positive mode, although less clear (Fig. 
2).  
Concomitant analyses of all groups using the MetaboAnalyst online tool indicated statistically 
significant changes in eight peaks in the negative mode and 11 in the positive mode (Tables 1 and 
2). Some of these were adducts of others (see Tables 1 and 2), and after accounting for these, six 
metabolites were significantly changed in the negative mode and seven in the positive mode (Figure 
3). Several metabolites showed dose-response relationships as suggested by the graphs. However, 
application of the post-test identified statistically significant effects only for the 0.5 mg Se/kg 
bw/day groups. Overall, the Se nanoparticles and sodium selenite induced similar patterns of 
regulation. Exceptions were metabolites 316.1229 Da, 233.9 s in negative mode and 367.2448 Da, 
236.8 s in positive mode (see Tables 1 and 2 for the possible identities of these metabolites). The 
levels of the effects (intensity counts) likewise seemed similar, although the number of enhanced 
metabolites in the urine of the sodium selenite-administered animals was larger than in the Se 
nanoparticle-administered animals. The exact mass of discriminatory metabolites (± 5 mDa) was 
used as a search parameter in The Human Metabolome Database (Wishart et al., 2013). The 





The purpose of this investigation was to evaluate the utility of metabolite pattern determination in 
the comparison of chemical congeners with respect to similarities in the biological effect profiles. 
For this study, we utilized urine from rats administered two chemical forms of Se, specifically 
elemental Se nanoparticles or sodium selenite. The PLS analyses indicated effects of both 
formulations at the low (0.05) and the higher (0.5 mg/kg bw/day) Se doses (Figure 2). Among the 
13 metabolites found to be significantly changed, 11 displayed similar patterns of metabolite 
regulation for both Se formulations (Figure 3). Assuming that urine reflects the excreted end 
products of a high proportion of the body’s metabolic processes, there is a strong indication of 
similar biological effects of the two different formulations. However, to providing details on 
whether these similarities were due to equal (toxicological) mechanisms of action it would be 
necessary to know if the altered metabolites reflected the toxicological mechanisms of selenium. It 
has previously been shown that selenium induces liver and bone toxicities (HASEGAWA, ZHANG 
2005, ISHIKAWA, TURAN 2000, YAMAGUCHI 2000). But information on differences in 
metabolite patterns are lacking.  
 
 
The putative identification of the metabolites was attempted by searching The Human Metabolome 
Database using the exact mass of the ions. However, more than one candidate identity was often 
possible for each single metabolite. This was due to similar elemental composition; e.g., for one ion, 
we found 12 different possible isoforms of diacylglycerol with exactly the same molecular mass. 
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This hampered the determination of specific mechanisms of action for Se. However, overall, there 
were changes in fatty acids and amino acids, suggesting that there is a general response on 
metabolism following the administration of Se in the doses employed.  
Thus the metabolite differences could not be tied directly to a mechanism of action of selenium. 
However, such information may very well be the case for other chemical congeners e.g. when a 
leading pharmaceutical structure has already been profiled for its mechanism of action. And when 
this is the case a difference in some metabolites (e.g. those associated with adverse effects of the 
leading structure) but not others (e.g. those associated with the wanted pharmaceutical effect) can 
provide picture on advantages and disadavantages of inducing a certain chemical change or 
formulation change to a leading structure. 
Rather than giving us a specific knowledge on equal mechanisms of action of the similarity of the 
two selenium formulations give an indication of a similar general response in terms of a 
combination of such effects in the body as mechanism of action both on the intended target, 
different metabolism pathways, different distribution, differences in excretion. We suggest that the 
data could be used to estimate the biovaialbility of the two Se formulations to be in a similar range, 
with a tendency to a bioavailability of selenite compared to Se nanoparticles. This tendency is given 
by eight metabolites for which there was a significant effect of sodium selenite but only a non-
significant tendency for Se nanoparticles (Fig. 3). This finding could be due to a high degree of 
dissolution of the Se nanoparticles into ions, probably occurring in the gastro-intestinal tract.  
Others have found that for some toxicity endpoints, selenite was more potent than Se nanoparticles 
in mice and rats (Benko et al., 2012; Jia et al., 2005; J. S. Zhang et al., 2001; J. Zhang et al., 2005). 
However, in spite of this tendency, our previous finding that the high doses of both forms of Se 
were equally available for incorporation into selenoprotein P supports the hypothesis that the 
bioavailability was in a similar range (Loeschner et al., 2014). Moreover, Kojouri and co-workers 
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found similar effects of Se nanoparticles and sodium selenite on iron, transferrin and on neutrophils 
in sheep (Kojouri, Jahanabadi, Shakibaie, Ahadi, & Shahverdi, 2012; Kojouri, Sadeghian, Mohebbi, 
& Mokhber Dezfouli, 2012).  
       Pattern recognition approaches in chemometrics and metabolite profiling have been described 
and employed previously by others (el-Deredy, 1997; Robertson et al., 2011; Robertson, 2005). 
These approaches have, for example, been used to identify specific metabolite patterns for specific 
toxicities without knowing the identity of the specific metabolites (Anthony, Rose, Nicholson, & 
Lindon, 1995; Holmes et al., 1994, 1998; Lenz, Bright, Knight, Wilson, & Major, 2004). However, 
there are arguments against this approach. As reviewed by Robertson (Robertson et al., 2011; 
Robertson, 2005), for example, effects from the primary toxicity of a compound and concomitant 
indirect toxicities may overlay and obscure the picture of specific organ toxicities. In addition, the 
metabolite profile may reflect a minor toxicological target, and therefore, concomitantly activated 
major targets may be missed. Robertson noted that it could therefore be advisable to focus on 
determining the exact identities of metabolites, to establish biomarkers that are understood in terms 
of whether they reflect either effects or mechanisms (Robertson et al., 2011). However, in the use 
proposed here, metabolite patterns are highly useful for assessing differences in biological effects 
between different chemical congeners, even in the absence of confirmed identification of the 
metabolites. Other potential uses are the determination of differences between a novel substance 
and a known standard or the determination of whether impurities have biological effects. For these 
applications, different treatment groups are tested simultaneously to minimize the influence of 
environmental factors such as different stress levels between different animal facilities or 
differences in feed batches, etc., on the results of the study.  
      In conclusion, we used a metabolite pattern determination approach to compare the biological 
effect profiles of Se nanoparticles and sodium selenite. Based on our findings of similar patterns of 
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metabolites in the urine, we conclude that it is highly likely that the two formulations of Se have 
similar biological effects. Moreover, comparisons of the intensities of the effects indicated that the 
formulations exhibited similar bioavailability. This suggests that the effects of nanoparticulate Se 
can be attributed to ions released from its surface. We propose that determination of metabolite 
patterns is a promising approach in pharmacological and toxicological studies in which different 
chemical congeners are compared to determine differences in their effect profiles, including 







Figure 1.  
 














Figure 2.  PLS analyses of urine from rats administered Se nanoparticles or sodium selenite. SeNP 
designates Se nanoparticles, and NaSe designates sodium selenite. The components designate 





Figure 3.  
A) Negative mode: 


































































































































































































































































B) Positive mode 






































































































































































































































































































Figure 3.  Bar graphs of individual metabolites determined by LC-MS in A) negative ion mode or 
B) positive ion mode and indicated by their accurate masses. SeNP designates Se nanoparticles, and 
NaSe designates sodium selenite. The data are the mean values, and the bars indicate SEM. The 
data were statistically tested as BSA-vehicle vs. Se nanoparticles at 0.05 and 0.5 mg Se/kg bw/day 
and as H2O-vehicle vs. sodium selenite at 0.05 and 0.5 mg Se/kg bw/day. The tests were one-way 
ANOVA with Dunnett’s post-test for normally distributed data (* designates p <0.05, **p<0.01 and 
***p<0.001), or with Kruskal-Wallis with Dunn’s post-test for data that were not normally 




Table 1. Possible identities of metabolites measured in negative mode 
Metabolite m/z (Da) HMDB m/z (Da) m/z error (Da)  Ret. Time (s)   Possible identity  
217.1071  217.1082  0.0011  211.5  2-Hydroxydecanedioic acid / 3-Hydroxydecanedioic acid [M-H] 
199.0972  199.0976  0.0004  223.7  cis-4-Decenedioic acid / cis-5-Decenedioic acid [M-H] 
316.1229  316.1303  0.0074  233.9  Tryptophyl-Hydroxyproline / Hydroxyprolyl-Tryptophan [M-H] 
204.0657  204.0666  0.0009  197.9  Cinnamoylglycine / Indolelactic acid / 3-Indolehydracrylic acid / 5- 
Methoxyindoleacetate [M-H] 
201.1129  201.1132  0.0003  233.1  Sebacic acid / Heptylmalonic acid / 3-Methylazelaic acid [M-H] 
160.0757   161.0688  0.0141  197.9  Possible fragment of 204.0657 [M-CH2O2]  
181.0873  n/a   n/a  223.7  cis-4-Decenedioic acid / cis-5-Decenedioic acid [M-H2O] 
243.1234  243.1167  0.0067  214.1  Isoleucyl-Methionine / Methionyl-Isoleucine [M-H20-H] 
 
Legend: Potential metabolites identified by comparing m/z ratios of metabolites with m/z ratios obtained from the human metabolome (HMDB) 




Table 2. Possible identities of metabolites measured in positive mode 
Metabolite (m/z) HMDB MW (m/z) Error (m/z)    Ret. Time (s)   Possible identity  
175.0796  175.0713  0.0083  153.9  N-Acetylasparagine / Formiminoglutamic acid [M+H]+ 
192.1042  192.0979  0.0063  153.9  N-Acetylasparagine / Formiminoglutamic acid [+NH4+] 
172.0960  n/a   n/a  167.3  No candidates 
137.0958  137.0921  0.0037  222.7  L-Threonine / L-Allothreonine [M+NH4+] 
201.1098  201.1121  0.0023  219.3  cis-4-Decenedioic acid / cis-5-Decenedioic acid [M+H]+ 
203.1268  203.1277  0.0009  233.8  Sebacic acid / Heptylmalonic acid / 3-Methylazelaic acid [M+H]+ 
367.2448  367.2426  0.0022  236.8   12 different diacylglycerols [M+Na]+ 
165.0912  n/a   n/a  222.1  No candidates but fits with 137.0958 plus CO [M+H]+ 
376.1124  n/a   n/a  128.7 s   No candidates 
131.0506  131.0503  0.0002  207.3  N-a-Acetyl-L-arginine [M+2Na] 
   131.0514  0.0008    Glutamyl-Asparagine / Asparaginyl-Glutamate [+2H] 
213.1424  213.1485  0.006  212.0  Six different bile acids  [M+H]+ 
Legend: Potential metabolites identified by comparing m/z ratios of metabolites with m/z ratios obtained from the human metabolome (HMDB) 
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